Prescription Drug List

2025 Express Scripts High Performance Formulary for Cigna Healthcare + Oscar*

All Cigna Healthcare [®] + Oscar plans include the Express Scripts Network, so you can fill your prescriptions at retail pharmacies, national pharmacy chains, and independent pharmacies.

Visit <u>cignaoscar.com/search</u> to see if your pharmacy is in-network. Check the cost of any medications before and after your deductible by logging into your member account at cignaoscar.com/member.

For the most updated list of the drugs in our formulary visit hioscar.com/drug-formularies.

Any questions? Message with your Care Team or call 855-672-2789.

For California: Cigna Healthcare + Oscar LocalPlus®, Cigna Healthcare + Oscar Open Access Plus

Last updated: 8/1/2025. This drug list is subject to change and all prior versions are no longer in effect.

* Cigna + Oscar coverage is insured by Cigna Health and Life Insurance Company. CA: benefits administered by Oscar Health Administrators. Other states: benefits administered by Oscar Management Corporation. Pharmacy benefits are provided by Express Scripts, Inc.



Table of Contents

| Information about your drug list | 3 |
|----------------------------------|-----|
| Exclusions and limitations | |
| Words you may need to know | 9 |
| Your prescription drug list | |
| How to read this drug list | |
| Coverage requirements and limits | 11 |
| How to read this drug list | 12 |
| How to find your medication | 13 |
| High Performance Formulary | 14 |
| Index | 133 |

Information about your drug list

Frequently asked questions (FAQs)

Understanding your prescription medication coverage can be confusing. Here are answers to some commonly asked questions.

Q. How often is my drug list updated? How do I know if my medication coverage changed?

- A. Express Scripts reviews and updates the prescription drug list regulary. We make changes for many reasons like when new medications become available or are no longer available, or when medication prices change. We try to give you many options to choose from to treat your health condition. These changes may include:
 - Moving a medication to a lower cost tier. This can happen at any time during the year.
 - > Moving a brand medication to a higher cost tier when a generic becomes available. This can happen at any time during the year.
 - Moving a medication to a higher cost tier and/or no longer covering a medication. This typically happens twice a year on January 1st and July 1st.
 - Adding coverage requirements to a medication. For example, requiring approval from Express Scripts before a medication may be covered or adding a quantity limit to a medication.

When a medication changes tiers or is no longer covered, you may pay a different amount to fill that medication. It's important to know that when we make a change that affects the coverage of a medication you're taking, we let you know before it begins so you have time to talk with your doctor.

Q. Why doesn't my plan cover certain medications?

A. To help lower your overall health care costs, your plan doesn't cover certain high-cost brand medications because they have lower-cost, covered alternatives which are used to treat the same condition. Meaning, the alternative works the same or similar to the non-covered medication. If you're taking a medication that your plan doesn't cover and your doctor feels an alternative isn't right for you, he or she can ask Express Scripts to consider approving coverage of your medication.

Q. How do you decide which medications are covered?

A. The Express Scripts Drug List is developed with the help of Express Scripts Pharmacy and Therapeutics (P&T) Committee, which is a group of practicing doctors and pharmacists. The group meets regularly to review medical evidence and information provided by federal agencies, drug manufacturers, medical professional associations, national organizations and peer-reviewed journals medications about the safety and effectiveness

of medications that are newly approved by the FDA and medications already on the market. The Express Scripts P&T Team looks at clinical review, as well as the medication's overall value and other factors before adding it to, or removing it from, the drug list.

Q. Are medications newly approved by the FDA covered on my drug list?

A. Newly approved medications may not be covered on your drug list for the first six months after they receive FDA approval. These include, but are not limited to, medications, medical supplies or devices covered under standard pharmacy benefit plans. We review all newly approved medications to determine if they should be covered – and if so, at what tier level. If your doctor feels a currently covered medication isn't right for you, he or she can ask Express Scripts to consider approving coverage of the newly approved medication.

Q. I see several medications on this drug list that can be used to treat my condition. Will my doctor write me a prescription for all of them?

A. No. Just because a medication is listed on your plan's drug list doesn't mean your doctor will write you a prescription for it. Your doctor will work with you to find the medication he or she feels is best for your specific treatment.

Q. My medication needs approval before my plan will cover it (also known as prior authorization). What do I need to do to get it covered?

A. Ask your doctor's office to contact Express Scripts so we can start the coverage review process. They know how the review process works and will take care of everything for you. In case the office asks, they can request authorization directly from Express Script's website at

www.express-scripts.com/corporate/ healthcare-providers

Express Scripts will review information your doctor provides to make sure you meet coverage guidelines for the medication. If you do, you'll be approved for coverage of the medication. If you don't meet guidelines, you and your doctor can appeal the decision. We'll send you information either way.

For non-urgent requests, Express Scripts will let you and your doctor know within 72 hours of receiving the request. For urgent requests based on exigent circumstances, Express Scripts will let you and your doctor know within 24 hours of

receiving the request was received. If Express Scripts doesn't respond to a completed prior authorization exception request within 72 hours of receiving a non-urgent request and 24 hours of receiving a request based on exigent circumstances, the request will be considered approved and we can't deny coverage of the medication. Also, if you've already received approval from Express Scripts to cover your medication, Express Scripts can't limit or exclude coverage for that medication if your doctor continues to prescribe it to treat your condition (as long as the medication is appropriately prescribed and is safe and effective in treating your condition).

- Q. My plan doesn't cover my medication. I need to take it because it's medically necessary for my treatment. What do I need to do to get my plan to cover it?
- A. If your doctor feels that your medication is necessary for your treatment and an alternative isn't right for you, he or she can ask Express Scripts to consider approving coverage of your medication. Ask your doctor's office to contact Express Scripts so we can start the coverage review process. They know how the review process works and will take care of everything for you. In case the doctor asks, they can request authorization directly from Express Script's website at

www.express-scripts.com/corporate/ healthcare-providers

Express Scripts will review information your doctor provides to make sure you meet coverage guidelines for the medication. If you do, you'll be approved for coverage of your medication. If you don't meet guidelines, you and your doctor can appeal the decision. We'll send you information either way.

For non-urgent requests, Express Scripts will let you and your doctor know within 72 hours of receiving the request. If approved, coverage will be provided until the prescription runs out (including refills). For urgent requests based on exigent circumstances, Express Scripts will let you and your doctor know within 24 hours of receiving the request. If approved, coverage will be provided for the duration of the exigency.

If Express Scripts doesn't respond to a completed prior authorization exception request within 72 hours of receiving a non-urgent request and 24 hours of receiving a request based on exigent circumstances, the request will be considered approved and your plan can't deny coverage of the medication. Also, if you've already received approval from Express Scripts to cover your medication, Express Scripts can't limit or exclude coverage for that medication if your doctor continues to prescribe it to treat your condition (as long as the medication is appropriately prescribed and is safe and effective in treating your condition).

It's important to know that when medications are approved, it's typically for one year of coverage. If your medication is approved for less time, it's because there's a clinical reason based on Express Script's coverage guidelines for the medication and/or the reviewing doctor.

- Q. My medication is part of the Step Therapy program. I don't want to try an alternative. What do I need to do to get my medication covered?
- A. If you and your doctor feel an alternative medication won't work for you, your doctor can ask Express Scripts to consider approving coverage of your medication. Ask your doctor's office to contact Express Scripts so we can start the coverage review process. They know how the review process works and will take care of everything for you. In case the office asks, they can request authorization directly from Express Script's website at

www.express-scripts.com/corporate/ healthcare-providers

Express Scripts will review information your doctor provides to make sure you meet coverage guidelines for the medication. If you do, you'll be approved for coverage of your medication. If you don't meet guidelines, you and your doctor can appeal the decision. We'll send you information either way.

For non-urgent requests, Express Scripts will let you and your doctor know within 72 hours of receiving the request. For urgent requests based on exigent circumstances, Express Scripts will let you and your doctor know within 24 hours of receiving the request. If Express Scripts doesn't respond to a completed prior authorization exception request within 72 hours of receiving a non-urgent request and 24 hours of receiving a request based on exigent circumstances, the request will be considered approved and your plan can't deny coverage of the medication.

Your Step Therapy rights under California State law:

- Express Scripts may impose prior authorization requirements on prescription drug benefits.
- 2. If there is more than one drug that is clinically appropriate for the treatment of a medical condition, Express Scripts may require step therapy.
 - a. Express Scripts must expeditiously grant a step therapy exception request if the doctor submits necessary justification and supporting clinical documentation supporting the doctor's determination that the required prescription drug is inconsistent with good professional practice for provision of medically necessary covered services. The basis

of the doctor's determination may include, but is not limited to, any of the following criteria:

- The required prescription drug is contraindicated or is likely, or expected, to cause an adverse reaction or harm to you in comparison to the requested prescription drug.
- ii. The required prescription drug is expected to be ineffective.
- iii. You have tried the required prescription drug, and that prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse reaction. Express Scripts may require documentation demonstrating that you tried the required prescription drug before it was discontinued.
- iv. The required prescription drug is not clinically appropriate for you because the required drug is expected to do any of the following, as determined by your doctor: (I) worsen a comorbid condition; (II) decrease the capacity to maintain a reasonable functional ability in performing daily activities; (III) pose a significant barrier to adherence to, or compliance with, your drug regimen or plan of care.
- v. You are stable on a prescription drug selected by your doctor for the medical condition under consideration.
- b. Step therapy exception requests will be deemed approved if Express Scripts fails to send an approval or denial within 72 hours for nonurgent requests, or within 24 hours if exigent circumstances exist.
- c. Your doctor may appeal a denial of an exception request for coverage of a nonformulary drug, prior authorization request, or step therapy exception request consistent with the Express Scripts current utilization management processes. You may appeal a denial of an exception request for coverage of a nonformulary drug, prior authorization request, or step therapy exception request by filing a grievance.
- d. Express Scripts may require you to try an AB-rated generic equivalent or interchangeable biological product before providing coverage for the equivalent branded prescription drug. A health care provider is not prohibited from prescribing a prescription drug that is clinically appropriate.
- Express Scripts shall provide coverage for the medically necessary dosage and quantity of the drug prescribed for the treatment of a medical condition consistent with professionally recognized standards of practice.

Q. How can I find out how much I'll pay for a specific medication?

A. Prescription prices can vary by pharmacy. Before you fill your prescription, compare your costs online. Log in to the Oscar app or hioscar.com and click on hioscar.com/search to see how much your medication may cost you at the different pharmacies in your plan's network. You can also see if there are lower-cost alternatives available.

Q. How can I save money on my prescription medications?

A. You may be able to save money by switching to a medication that's on a lower tier (ex. generic or preferred brand) or by filling a 90-day supply, if your plan allows. You should talk with your doctor to find out if one of these options may work for you.

Q. What's the difference between brand name and generic medications?

- **A.** The FDA requires generic medications to provide the same clinical benefit as its brand name versions. The FDA also requires generic makers to prove that the generic works in the same way as the brand name medication. This means that generic equivalent medications must:²
 - Have the same active ingredient, strength and dosage form as the brand name medication
 - Deliver the same amount of active ingredients into the bloodstream in the same amount of time as the brand name medication
 - Be used in the same way as the brand name medication

Generics typically cost much less than brand name medications – in some cases, up to 85% less.² Just because generics cost less than brands, it doesn't mean they're lower-quality medications.

Q. How do I know which pharmacies are in my network?

A. There are thousands of retail pharmacies in your plan's network. They include local pharmacies, grocery stores, retail chains and wholesale warehouse stores – all places where you may already shop. And some stores are open 24-hours. To find an in-network pharmacy near you, log in to the Oscar app or hioscar.com then click on hioscar.com/search to start searching. Or call 855.672.2789

Q. Can I fill my prescriptions by mail?

- **A.** Yes, as long as your plan offers home delivery.
 - > If you're taking a medication every day to treat an ongoing health condition like diabetes, high blood pressure, high cholesterol or asthma, you can order up to a 90-day supply through our home delivery pharmacy. To get started, log in to the Oscar app or hioscar.com and click on hioscar.com/search

If you're taking a specialty medication to treat a complex medical condition like multiple sclerosis, hepatitis C, or rheumatoid arthritis, you can fill your prescription through Accredo, a specialty pharmacy. Accredo will ship your medication to your home (or location of your choice). To get started, call Accredo at 877.842.9788. They're available Monday–Friday, 7:00 am–10:00 pm CST and on Saturdays, 7:00 am–4:00 pm CST. Be sure to call Accredo about two weeks before your next refill so they have time to get a new prescription from your doctor's office. You can also talk with an Accredo pharmacist at any time, 24/7.

Q. I take a medication every day to treat diabetes. My plan has the option to fill my medication through home delivery. What do I need to do to get started?

A. Some plans encourage you to fill maintenance medications through home delivery. "Maintenance medications" are the medications you take every day to treat an ongoing health condition like diabetes, high blood pressure, high cholesterol or asthma.

To get started using home delivery, log in to the Oscar app or hioscar.com and click on hioscar.com/search or call 855.672.2789.

Our home delivery pharmacy will deliver your medications right to your door (or location of your choice) and you can get up to a 90-day supply of your medication at one time. And you can manage your orders online or through the Oscar mobile app.

Q. I take a specialty medication that can only be filled at certain pharmacies in the United States. How do I fill my prescription?

A. You may be able to use Accredo, an Express Scripts specialty pharmacy, to fill your prescription. Accredo has access to most specialty medications. Ask your doctor to send them your prescription.

To get started using Accredo, call **877.842.9788** for more information. Representatives are available Monday–Friday, 7:00 am–10:00 pm CST and on Saturdays, 7:00 am–4:00 pm CST.

Q. How can I fill my prescription?

- **A.** First, you'll need to get a prescription from your doctor. Then, your doctor can either:
 - 1. Send it electronically to the in-network pharmacy of your choice.
 - 2. Give you a paper prescription. You can bring it to the in-network pharmacy of your choice, or you can mail it to home delivery.

Q. How can I get help with my specialty medication?

A. Managing a complex condition isn't easy. As part of your Express Scripts pharmacy benefits,

you have access to Accredo, a Express Scripts specialty pharmacy. Accredo's team of specialty-trained pharmacists and nurses will provide you with the personalized care and support you need to manage your complex medical condition. They'll help you work through side effects, check in with you and your doctor to see how your therapy's going, help you get your medications approved for coverage, and more.

To get started using Accredo, call **877.842.9788**. Representatives are available Monday–Friday, 7:00 am–10:00 pm CST and on Saturdays, 7:00 am–4:00 pm CST.

Q. Where can I find more information about my prescription medication plan?

A. You can use the online tools and resources on the Oscar app or hioscar.com to help you better understand your pharmacy coverage. You can find out how much your medication costs, see which medications your plan covers, find an in-network pharmacy, and see your pharmacy claims and coverage details. You can also manage your home delivery prescription orders.

Q. How can I find out my cost-share for each tier on my drug list?

- A. Covered medications are divided into tiers (or cost-share levels). Typically, the higher the tier, the higher the price you'll pay to fill the prescription. Here are several places you can go to find out how much you'll pay for your medication based on the tier it's listed in, including the maximum cost-share amount allowed:
 - Log in to the Oscar app or hioscar.com to view your pharmacy coverage information. You can also use the on hioscar.com/search feature to find out how much your medication may cost you at the different pharmacies in your plan's network.¹
 - 2. Check your Summary of Benefits coverage document.

Q. What's the difference between medications covered under the pharmacy benefit and medical benefit?

A. Some medications are covered under the pharmacy benefit, some are covered under the medical benefit, and others are covered under both benefits. Typically, medications that are injected or infused are covered under the medical benefit. These are administered at a doctor's office, an infusion center or at home. Typically, medications that are self-administered and can be filled at a retail pharmacy or through home delivery are covered under the pharmacy benefit. The medications in this drug list are covered under the pharmacy benefit. Check your medical summary of benefits coverage to learn more about how your plan covers medications under the medical benefit.

Q. I take an oral cancer medication. How much will I pay for my medication?

- **A.** On January 1, 2015, California passed a bill limiting the cost-share for oral chemotherapy medications to \$250 per 30 day supply.
 - > For copay plans: If your copay is less than \$250 you will pay the lesser amount.
 - > For high deductible health plans (HDHPs) that include a Health Savings Account (HSA) or qualified HDHPs: You'll pay your plan deductible first. After that, your coinsurance will be no more than \$250 per 30 day supply. If your coinsurance is less than \$250 you will pay the lesser amount.

Q. Which medications are covered under the health care reform law?

A. The Affordable Care Act (ACA), commonly referred to as "health care reform," was signed into law on March 23, 2010. Under this law, certain preventive medications (including some over-the-counter medicines) are available to you at no cost-share (\$0). Log in to the Oscar app, hioscar.com or call 855.672.2789 or check your plan materials, to learn more about how your plan covers preventive medications.

- Q. How are medications, devices and FDA-approved diabetic, contraceptive and federally-mandated products covered under the pharmacy benefit?
- **A.** Here is how these products are covered under the pharmacy benefit:
 - Preventive care medications and products covered under the Affordable Care Act (ACA), also known as "health care reform:"
 - Contraceptives: Covered at 100%, or no cost-share (\$0) to you. Certain prescription contraceptives are available at their applicable cost-share.
 - Tobacco cessation products: All FDA approved prescription tobacco cessation products are covered at 100%, or no costshare (\$0) to you.
 - Certain vitamins: Covered at 100%, or no cost-share (\$0) to you. All other prescription vitamins are available at their applicable cost-share and deductible (if applicable).
 - > Certain over-the-counter (OTC) medicines: Covered at 100%, or no cost-share (\$0) to you, if you have a prescription from a doctor. All other OTC medicines are excluded from coverage.
 - Vaccines: These are currently covered under the pharmacy and medical benefits. Not all plans will cover vaccines in the same way.
 - > Compounded medications: All medications within the compound will need to be covered. If any of the medications are excluded, you'll need approval from Express Scripts before your plan will cover them (prior authorization).

Exclusions and limitations

Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and be medically necessary. Your plan provides coverage for certain preventive prescription drugs with no cost-share. When you use a pharmacy that does not participate in your plan's network, the dollar amount that you pay for the prescription could be higher and could even be the full cost of the prescription.

Certain drugs may require prior authorization, or be subject to step therapy, quantity limits or other utilization management requirements.

Plans do not provide coverage for the following under the pharmacy benefit:

- over-the-counter (OTC) medicines (those that do not require a prescription) except certain preventive prescription drugs or items, contraceptives and insulin unless state or federal law requires coverage of such medicines;
- > doctor-administered injectable medications covered under the Plan's medical benefit, unless otherwise covered under the Plan's prescription drug list or approved by Express Scripts;
- > implantable contraceptive devices covered under the Plan's medical benefit;
- medications that are not medically necessary;
- experimental or investigational medications, including FDA-approved medications used for purposes other than those approved by the FDA unless the medication is recognized for the treatment of the particular indication:
- medications that must be FDA approved and that are not approved by the Food & Drug Administration (FDA);
- > medications used for fertility, sexual dysfunction, cosmetic purposes, or athletic enhancement;
- > prescription vitamins (other than prenatal vitamins) or dietary supplements unless state or federal law requires coverage of such products;
- > immunization agents, biological products for allergy immunization, biological sera, blood, blood plasma and other blood products or fractions as these items are covered under the medical benefit;
- > replacement of prescription medications and related supplies due to loss or theft, unless You are displaced by a declared state of emergency or drug is lost, stolen or destroyed prior to you taking possession, such as mail order drugs that are lost or stolen in transit;
- > medications which are to be taken by or administered to a covered person while they are a patient in a licensed hospital, skilled nursing facility, rest home or similar institution which operates on its premises or allows to be operated on its premises a facility for dispensing pharmaceuticals;
- > coverage for prescription medication products for the amount dispensed (days' supply) which is more than the applicable quantity limit(s) or dosage limit(s) set by the P&T Committee, unless such limits is allowed by an approved exception request;
- > more than one prescription order or refill for a given prescription supply period for the same prescription medication product prescribed by one or more doctors and dispensed by one or more pharmacies;
- prescription medication products dispensed outside the jurisdiction of the United States, except as required for emergency or urgent care treatment. In addition to the plan's standard pharmacy exclusions, certain new FDA-approved medication products (including, but not limited to, medications, medical supplies or devices that are covered under standard pharmacy benefit plans) may not be covered for the first six months of market availability unless approved by Express Scripts as medically necessary.

Words you may need to know

- > Brand name drug: A drug that is marketed under a proprietary, trademark-protected name. Brand name drugs are listed in all CAPITAL letters.
- > Coinsurance: A percentage of the cost of a covered health care benefit that you pay after you have paid the deductible, if one applies to the benefit.
- Copayment: A fixed dollar amount that you pay for a covered health care benefit after you have paid the deductible, if a deductible applies to the benefit.
- Deductible: The amount you pay for covered health care benefits that are subject to the deductible before your health insurer begins to pay. If your health insurance policy has a deductible, it may have either one deductible or separate deductibles for medical benefits and prescription drug benefits. After you pay your deductible, you usually pay only a copayment or coinsurance for covered health care benefits. Your insurance company pays the rest.
- > **Drug tier:** A group of prescription drugs that correspond to a specified cost sharing tier in your health insurance policy. The drug tier in which a prescription drug is placed determines your portion of the cost for the drug.
- > Exception request: A request for coverage of a non-formulary drug. If you, your designee, or your prescribing health care provider submits a request for coverage of a non-formulary drug, your insurer must cover the non-formulary drug when it is medically necessary for you to take the drug.
- > Exigent circumstances: When you suffer from a medical condition that may seriously jeopardize your life, health, or ability to regain maximum function, or when you are undergoing a current course of treatment using a non-formulary drug.
- > Formulary or prescription drug list: The list of drugs that is covered by your health insurance policy under the prescription drug benefit of the policy.
- Generic drug: A drug that is the same as its brand name drug equivalent in dosage, strength, effect, how it is taken, quality, safety, and intended use. A generic drug is listed in this formulary in italicized lowercase letters.
- Medically Necessary: Health care benefits needed to diagnose, treat, or prevent a medical condition or its symptoms and that meet accepted standards of medicine. Health insurance usually does not cover health care benefits that are not medically necessary.

- > Non-formulary drug: A prescription drug that is not listed on this formulary.
- > Out-of-pocket costs: Your expenses for health care benefits that aren't reimbursed by your health insurance. Out-of-pocket costs include deductibles, copayments, and coinsurance for covered health care benefits, plus all costs for health care benefits that are not covered.
- > **Prescribing provider:** A health care provider who can write a prescription for a drug to diagnose, treat, or prevent a medical condition.
- Prescription: An oral, written, or electronic order from a prescribing provider authorizing a prescription drug to be provided to a specific individual.
- > **Prescription drug:** A drug that by law requires a prescription.
- > **Prior Authorization:** A decision by your health insurer that a health care benefit is medically necessary for you. If a prescription drug is subject to prior authorization in this formulary, your prescribing provider must request approval from your health insurer to cover the drug before you fill your prescription. Your health insurer must grant a prior authorization request when it is medically necessary for you to take the drug.
- > Step Therapy: A specific sequence in which prescription drugs for a particular medical condition must be tried. If a drug is subject to step therapy in this formulary, you may have to try one or more other drugs before your health insurance policy will cover that drug for your medical condition. If your prescribing provider submits a request for an exception to the step therapy requirement, your health insurer must grant the request when it is medically necessary for you to take the drug.
- Quantity Limits: For some medications, your plan will only cover up to a certain amount over a certain length of time. For example, 30mg per day for 30 days. Quantity limits help to make sure you're receiving coverage for the right medication, in the right amount, and for the right situation. Your plan will only cover a larger amount if your doctor requests and receives approval.
- Age Requirements: For certain medications, you must be within a specific age range for your plan to cover them. This is because some medications aren't considered clinically appropriate for individuals who aren't within that age range.

Your prescription drug list

This document shows the medications covered on the High Performance Drug List as of January 1, 2025. All of these medications are approved by the U.S. Food and Drug Administration (FDA). Log in to the **Oscar** app, **hioscar.com** or call **855.672.2789**, or check your plan materials, to learn more about the medications your plan covers.

How to read this drug list

Medications are listed alphabetically by their brand and generic names within their therapeutic category and class.* You can also find your medication using the index at the end of this drug list.

- > The generic version of a brand name medication is listed in parentheses and all *lowercase italicized* letters next to the brand name medication; the brand name drugs appear in all capital letters.
- > If a generic equivalent for a brand name medication is both available and covered, the generic will be listed separately from the brand name medication in all lowercase italicized letters.
- > If a generic equivalent for a brand name medication isn't available on the market or isn't covered, the medication won't be listed separately by its generic version.
- > If a generic medication is marketed under a proprietary, trademark-protected brand name, the brand name medication will be listed after the generic version in parentheses and regular typeface with the first letter of each word capitalized.

For example:

- > PRIFTIN ORAL TABLET 150 MG (rifapentine) is an example of generic version listed in parentheses and all lowercase italicized letters ("rifapentine") next to the brand name in all capital letters ("PRIFTIN")
- > cidofovir intravenous solution 75 mg/ml is an example a generic equivalent for a brand name medication that is both available and covered
- > butalbital/acetaminophen (Tencon Oral Tablet 50-325 Mg) Is an example of a generic medication ("butalbital/acetaminophen") marketed under a proprietary, trademark-protected brand name ("Tencon")

Tiers

Covered medications are divided into tiers or cost-share levels. Typically, the higher the tier, the higher the price you'll pay to fill the prescription.

| Tier 1 | Consists of preferred generic drugs which have the same active ingredients, safety, dosage, quality and strength, as their brand name counterparts | \$ |
|-----------|--|----------|
| Tier 2 | Consists of preferred brand-name drugs (with no generic equivalent). | \$\$ |
| Tier 3 | Consists of non-preferred brand name drugs and other drugs that usually have generic versions and/or one or more preferred brand alternative on a lower tier, as well as non-formulary, non-specialty drugs approved for pre-authorization through a Medically Necessary review. | \$\$\$ |
| Tier 4 | Consists of specialty drugs that are biologics, FDA requires distribution through a specialty pharmacy, require special training or clinical monitoring, or drugs that cost more than six hundred dollars (\$600) for a one-month supply, as well as non-formulary, specialty drugs approved for pre-authorization through a Medically Necessary review. | \$\$\$\$ |

Please see your Schedule of Benefits for your cost for each drug tier.

^{*} Medications are listed in the therapeutic category and class provided by First Databank.

Coverage requirements and limits

Some medications on your drug list have extra requirements before your plan will cover them.* This helps to make sure you're receiving coverage for the right medication, at the right cost, in the right amount and for the right situation. These medications will have an abbreviation next to them in the drug list. Here's what each of the abbreviations mean.

- PA **Prior Authorization.*** Express Scripts requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval before you fill your prescriptions. If you don't get approval, Express Scripts may not cover the drug.
- QL **Quantity Limit:*** For some medications, Express Scripts will only cover up to a certain amount over a certain length of time. For example, 30mg per day for 30 days. Express Scripts will only cover a larger amount if your doctor requests and receives approval.
- ST Step Therapy:* In some cases, Express Scripts requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. An exception to Step Therapy requirement that factors in medical necessity may be requested.
- OTC Over the Counter: An OTC drug is a non-prescription drug.
- ACA **No cost-share preventive medications:** Health care reform under the Affordable Care Act (ACA) requires that most plans cover certain categories of medications and other products as preventive care services. These medications may be available to you at no cost-share (copay, coinsurance and/or deductible) and includes contraceptives and certain over the counter items. A prescription is required for over-the-counter preventive medications to be covered at no cost-share. Log in to the **Oscar** app or **hioscar.com**, call **855.672.2789** or check your plan materials to learn more about how your plan covers preventive medications.
- CSL **Oral cancer medications subject to cost-share limits:** The maximum for oral cancer drugs is \$250 for a 30-day supply.
- LA **Limited Access:** Some drugs may be subject to limited access or restricted access. This means that a drug may only be available at select pharmacies. Limited access may be due to the following reasons:
 - > The FDA or the manufacturer has restricted distribution of a drug to certain facilities, pharmacies or prescribers, or
 - > Certain drugs require special handling, coordination of care, or patient education that cannot be provided at a retail pharmacy. If the drug is approved, we will let you know how to get limited access drugs.

How to read this drug list

Use the sample chart to help you understand how to read this drug list. This chart is just an example. It may not show how these medications are actually covered on the High Performance Drug List.

| GASTROENTEROLOGY | | | Therapeutic drug category and |
|---|-----|-----------------------------|---|
| MISCELLANEOUS GASTROINTESTINAL AGENTS | | | class describes the condition the |
| Drug Name | | Requirements / Limits | medication is |
| alophen (bisacodyl) ozal tablet, delayed release (dr/ec) 5 mg | \$0 | ACA; OTC | used to treat |
| alosetron oral tablet 0.5 mg. 1 mg | 1 | | |
| anucort-hc rectal suppository 25 mg | 1 | | Coverage requirements |
| aprepitant oral capsule 125 mg, 40 mg | 1 | QL (1 per 30 days) | and limits lets |
| aprepitant oral capsule 80 mg | 1 | QL (2 per 30 days) | you know if your |
| aprepi ant oral capsule,dose pack 125 mg (1)- 80 mg (2) | 1 | QL (3 per 30 days) | plan has extra |
| balsalazide oral capsule 750 mg | 1 | | requirements before it will cover |
| bisacodyl oral tablet, delayed release (dr/ec) 5 mg | \$0 | ACA; OTC | the medication |
| bisa-lax (biscodyl) oral tablet, delayed release (dr/ec) 5 mg | \$0 | ACA; OTC | |
| budesonide oral capsule,delayed,extend.release 3 mg | 1 | | Drug tier gives |
| budesonide oral tablet,delayed and ext.release 9 mg | 1 | | you an idea of how much you |
| calcium acetate(phosphat bind) oral capsule 667 mg | 1 | | may pay for a |
| calcium acetate(phosphat bind) oral tablet 667 mg | 1 | | medication |
| chenodiol (Chenodal Oral Tablet 250 Mg) | 4 | PA; LA | Drocerinties drug |
| CHOLBAM ORAL CAPSULE 250 MG (cholic acid) | 4 | PA; | Prescription drug name is the name |
| CHOLBAM ORAL CAPSULE 50 MG (cholic acid) | 4 | PA; QL (120 per 30 days) | of the medication |
| citrate of magnesia oral solution | \$0 | ACA; OTC | NA - di ti |
| citroma oral solution | \$0 | ACA; OTC | Medications are listed in |
| clearlax oral powder 17 gram/dose | \$0 | ACA; OTC | alphabetical |
| clearlax oral powder in packet 17 gram | \$0 | ACA; OTC | order within each |
| milk of magnesia concentrated oral suspension 2,400 mg/10 ml | \$0 | ACA; OTC | column |
| milk of magnesia oral suspension 400 mg/5 ml | \$0 | ACA; OTC | Generic |
| miralax oral powder in packet 17 gram | \$0 | ACA; OTC | medications are |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG (naloxegol oxalate) | 2 | QL (30 per 30 days) | in lowercase |
| natura-lax oral powder 17 gram/dose | \$0 | ACA; OTC | italics |
| OCALIVA ORAL TABLET 10 MG, 5 MG (obeticholic acid) | 4 | PA; LA; QL (30 per 30 days) | Brand name |
| | | | medications are in all CAPITAL letters |

This chart is just a sample. It may not show how these medications are actually covered on the High Performance Drug List.

How to find your medication

Find your condition in the alphabetical list below. Then go to that page to see the covered medications available to treat the condition

Table of Contents

| ANTI - INFECTIVES | 14 |
|--|-----|
| ANTINEOPLASTIC & IMMUNOSUPPRESSANT DRUGS | 24 |
| AUTONOMIC & CNS DRUGS, NEUROLOGY & PSYCH | 37 |
| AUTONOMIC & CNS DRUGS, NEUROLOGY | 55 |
| CARDIOVASCULAR, HYPERTENSION & LIPIDS | 57 |
| DERMATOLOGICALS/TOPICAL THERAPY | 68 |
| DIAGNOSTICS & MISCELLANEOUS AGENTS | |
| EAR, NOSE & THROAT MEDICATIONS | |
| ENDOCRINE/DIABETES | 8 |
| GASTROENTEROLOGY | 93 |
| IMMUNOLOGY, VACCINES & BIOTECHNOLOGY | 99 |
| MUSCULOSKELETAL & RHEUMATOLOGY | 105 |
| OBSTETRICS & GYNECOLOGY | 108 |
| OPHTHALMOLOGY | |
| RESPIRATORY, ALLERGY, COUGH & COLD | |
| UROLOGICALS | 128 |
| VITAMINS, HEMATINICS & ELECTROLYTES | 129 |
| Index | 133 |

| Drug Name | Drug Tier | Requirements / Limits | |
|--|-----------|-----------------------|--|
| ANTI - INFECTIVES | | | |
| ANTIFUNGAL AGENTS | | | |
| clotrimazole mucous membrane troche 10 mg | 1 | | |
| CRESEMBA ORAL CAPSULE 186 MG, 74.5 MG (isavuconazonium sulfate) | 2 | PA | |
| fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/ml | 1 | | |
| fluconazole oral tablet 100 mg, 200 mg, 50 mg | 1 | | |
| fluconazole oral tablet 150 mg | 1 | QL (2 per 30 days) | |
| flucytosine oral capsule 250 mg, 500 mg | 1 | PA | |
| griseofulvin microsize oral suspension 125 mg/5 ml | 1 | | |
| griseofulvin microsize oral tablet 500 mg | 1 | | |
| griseofulvin ultramicrosize oral tablet 125 mg, 165 mg, 250 mg | 1 | | |
| itraconazole oral capsule 100 mg | 1 | QL (30 per 30 days) | |
| itraconazole oral solution 10 mg/ml | 1 | QL (300 per 30 days) | |
| ketoconazole oral tablet 200 mg | 1 | | |
| NOXAFIL ORAL SUSP, DELAYED RELEASE FOR RECON 300 MG (posaconazole) | 2 | PA | |
| nystatin oral suspension 100,000 unit/ml | 1 | | |
| nystatin oral tablet 500,000 unit | 1 | | |
| posaconazole oral suspension 200 mg/5 ml (40 mg/ml) | 1 | PA | |
| posaconazole oral tablet,delayed release (dr/ec) 100 mg | 1 | PA | |
| terbinafine hcl oral tablet 250 mg | 1 | | |
| voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml) | 1 | PA | |
| voriconazole oral tablet 200 mg, 50 mg | 1 | PA | |
| ANTIVIRALS | | | |
| abacavir oral solution 20 mg/ml | 1 | | |
| abacavir oral tablet 300 mg | 1 | | |
| abacavir-lamivudine oral tablet 600-300 mg | 1 | | |
| acyclovir oral capsule 200 mg | 1 | | |
| acyclovir oral suspension 200 mg/5 ml | 1 | | |
| acyclovir oral tablet 400 mg, 800 mg | 1 | | |
| adefovir oral tablet 10 mg | 1 | | |
| amantadine hcl oral capsule 100 mg | 1 | | |
| amantadine hcl oral solution 50 mg/5 ml | 1 | | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|------------------------|
| amantadine hcl oral tablet 100 mg | 1 | |
| APRETUDE INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE 600 MG/3 ML (200 MG/ML) (cabotegravir) | \$0 | ACA |
| APTIVUS ORAL CAPSULE 250 MG (tipranavir) | 2 | |
| atazanavir oral capsule 150 mg, 200 mg, 300 mg | 1 | |
| BARACLUDE ORAL SOLUTION 0.05 MG/ML (entecavir) | 4 | |
| BEYFORTUS INTRAMUSCULAR SYRINGE 100 MG/ML, 50 MG/0.5 ML (nirsevimab-alip) | \$0 | ACA |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar) | 2 | |
| CABENUVA INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE 400 MG/2 ML- 600 MG/2 ML (cabotegravir/rilpiv-irine) | 2 | PA; QL (1 per 23 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE 600 MG/3 ML- 900 MG/3 ML (cabotegravir/rilpiv-irine) | 2 | PA; QL (1 per 45 days) |
| cidofovir intravenous solution 75 mg/ml | 4 | |
| CIMDUO ORAL TABLET 300-300 MG (lamivudine/tenofovir disoproxil fumarate) | 2 | |
| darunavir oral tablet 600 mg, 800 mg | 1 | |
| DELSTRIGO ORAL TABLET 100-300-300 MG (doravirine/lamivudine/tenofovir disoproxil fumarate) | 3 | |
| DESCOVY ORAL TABLET 120-15 MG (emtricitabine/tenofovir alafenamide fumarate) | 2 | |
| DESCOVY ORAL TABLET 200-25 MG (emtricitabine/tenofovir alafenamide fumarate) | 2 | ACA |
| DOVATO ORAL TABLET 50-300 MG (dolutegravir sodium/lamivudine) | 2 | |
| EDURANT ORAL TABLET 25 MG (rilpivirine hcl) | 2 | |
| efavirenz oral tablet 600 mg | 1 | |
| efavirenz-emtricitabin-tenofov oral tablet 600-200-300 mg | 1 | |
| efavirenz-lamivu-tenofov disop oral tablet 400-300-300 mg, 600-300-300 mg | 1 | |
| emtricitabine oral capsule 200 mg | 1 | |
| emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg | 1 | |
| emtricitabine-tenofovir (tdf) oral tablet 200-300 mg | 1 | ACA |
| emtricita-rilpivirine-tenof df oral tablet 200-25-300 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--|
| EMTRIVA ORAL SOLUTION 10 MG/ML (emtricitabine) | 2 | |
| entecavir oral tablet 0.5 mg, 1 mg | 1 | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG, 200-50 MG (sofosbuvir/velpatasvir) | 2 | PA; QL (84 per 365 days; 28 per dispense) |
| EPCLUSA ORAL TABLET 200-50 MG, 400-100 MG (sofosbu-vir/velpatasvir) | 2 | PA; QL (84 per 365 days; 28 per dispense) |
| etravirine oral tablet 100 mg, 200 mg | 1 | |
| EVOTAZ ORAL TABLET 300-150 MG (atazanavir sulfate/cobicistat) | 3 | |
| famciclovir oral tablet 125 mg, 500 mg | 1 | QL (21 per 30 days) |
| famciclovir oral tablet 250 mg | 1 | QL (60 per 30 days) |
| fosamprenavir oral tablet 700 mg | 1 | |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG (enfu-virtide) | 2 | QL (60 per 30 days) |
| ganciclovir sodium intravenous recon soln 500 mg | 4 | |
| ganciclovir sodium intravenous solution 50 mg/ml | 4 | |
| GENVOYA ORAL TABLET 150-150-200-10 MG (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) | 2 | |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG (ledipasvir/sofosbuvir) | 2 | PA; QL (56 per 365 days; 28 per dispense) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG (ledipas-vir/sofosbuvir) | 2 | PA; QL (112 per 365 days; 56 per dispense) |
| HARVONI ORAL TABLET 45-200 MG (ledipasvir/sofosbuvir) | 2 | PA; QL (112 per 365 days; 56 per dispense) |
| HARVONI ORAL TABLET 90-400 MG (ledipasvir/sofosbuvir) | 2 | PA; QL (56 per 365 days; 28 per dispense) |
| INTELENCE ORAL TABLET 25 MG (etravirine) | 2 | |
| ISENTRESS HD ORAL TABLET 600 MG (raltegravir potassium) | 2 | |
| ISENTRESS ORAL POWDER IN PACKET 100 MG (raltegravir potassium) | 2 | |
| ISENTRESS ORAL TABLET 400 MG (raltegravir potassium) | 2 | |
| ISENTRESS ORAL TABLET, CHEWABLE 100 MG, 25 MG (raltegravir potassium) | 2 | |
| JULUCA ORAL TABLET 50-25 MG (dolutegravir sodium/rilpi-virine hcl) | 2 | |
| LAGEVRIO (EUA) ORAL CAPSULE 200 MG (molnupiravir) | \$0 | ACA; QL (40 per 180 days) |
| lamivudine oral solution 10 mg/ml | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--|
| lamivudine oral tablet 100 mg, 150 mg, 300 mg | 1 | |
| lamivudine-zidovudine oral tablet 150-300 mg | 1 | |
| lopinavir-ritonavir oral tablet 100-25 mg, 200-50 mg | 1 | |
| maraviroc oral tablet 150 mg, 300 mg | 1 | |
| nevirapine oral suspension 50 mg/5 ml | 1 | |
| nevirapine oral tablet 200 mg | 1 | |
| nevirapine oral tablet extended release 24 hr 100 mg, 400 mg | 1 | |
| NORVIR ORAL POWDER IN PACKET 100 MG (ritonavir) | 2 | |
| ODEFSEY ORAL TABLET 200-25-25 MG (emtricitabine/rilpivirine hcl/tenofovir alafenamide fumarate) | 2 | |
| oseltamivir oral capsule 30 mg | 1 | QL (20 per 30 days) |
| oseltamivir oral capsule 45 mg, 75 mg | 1 | QL (10 per 30 days) |
| oseltamivir oral suspension for reconstitution 6 mg/ml | 1 | QL (180 per 30 days) |
| PAXLOVID ORAL TABLETS, DOSE PACK 150 MG (10)- 100 MG (10), 150 MG (6)- 100 MG (5) (nirmatrelvir/ritonavir) | \$0 | QL (20 per 180 days) |
| PAXLOVID ORAL TABLETS, DOSE PACK 300 MG (150 MG X 2)-100 MG (nirmatrelvir/ritonavir) | \$0 | QL (30 per 180 days) |
| PIFELTRO ORAL TABLET 100 MG (doravirine) | 3 | |
| PREVYMIS INTRAVENOUS SOLUTION 240 MG/12 ML, 480 MG/24 ML (<i>letermovir</i>) | 4 | |
| PREVYMIS ORAL PELLETS IN PACKET 120 MG, 20 MG (letermovir) | 4 | |
| PREVYMIS ORAL TABLET 240 MG, 480 MG (letermovir) | 4 | QL (112 per 365 days; 30 per dispense) |
| PREZCOBIX ORAL TABLET 800-150 MG-MG (darunavir ethanolate/cobicistat) | 2 | |
| PREZISTA ORAL SUSPENSION 100 MG/ML (darunavir) | 2 | |
| PREZISTA ORAL TABLET 150 MG, 75 MG (darunavir) | 2 | |
| RELENZA DISKHALER INHALATION BLISTER WITH DE- VICE 5 MG/ACTUATION (zanamivir) | 3 | QL (1 per 30 days) |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML (zidovudine) | 2 | |
| REYATAZ ORAL POWDER IN PACKET 50 MG (atazanavir sulfate) | 2 | |
| ribavirin inhalation recon soln 6 gram | 1 | PA |
| ribavirin oral capsule 200 mg | 1 | PA |
| ribavirin oral tablet 200 mg | 1 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| rimantadine oral tablet 100 mg | 1 | |
| ritonavir oral tablet 100 mg | 1 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG (fostemsavir tromethamine) | 3 | PA |
| SELZENTRY ORAL SOLUTION 20 MG/ML (maraviroc) | 2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil) | 3 | |
| SUNLENCA ORAL TABLET 300 MG (lenacapavir sodium) | 3 | PA |
| SYMFI ORAL TABLET 600-300-300 MG (efavirenz/lamivudine/tenofovir disoproxil fumarate) | 2 | |
| SYMTUZA ORAL TABLET 800-150-200-10 MG (darunavir eth/cobicistat/emtricitabine/tenofovir alafenamide) | 3 | |
| SYNAGIS INTRAMUSCULAR SOLUTION 100 MG/ML, 50 MG/0.5 ML (palivizumab) | 4 | PA; LA |
| tenofovir disoproxil fumarate oral tablet 300 mg | 1 | |
| TIVICAY ORAL TABLET 50 MG (dolutegravir sodium) | 2 | |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG (do-lutegravir sodium) | 2 | |
| TRIUMEQ ORAL TABLET 600-50-300 MG (abacavir sulfate/dolutegravir sodium/lamivudine) | 2 | |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG (abacavir sulfate/dolutegravir sodium/lamivudine) | 2 | |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) (ibalizumab-uiyk) | 2 | PA |
| TYBOST ORAL TABLET 150 MG (cobicistat) | 3 | |
| valacyclovir oral tablet 1 gram, 500 mg | 1 | QL (30 per 30 days) |
| valganciclovir oral recon soln 50 mg/ml | 1 | |
| valganciclovir oral tablet 450 mg | 1 | |
| VEKLURY INTRAVENOUS RECON SOLN 100 MG (remdesivir) | \$0 | |
| VEMLIDY ORAL TABLET 25 MG (tenofovir alafenamide) | 4 | |
| VIRACEPT ORAL TABLET 250 MG, 625 MG (nelfinavir mesylate) | 2 | |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) (tenofovir disoproxil fumarate) | 2 | |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG (tenofovir disoproxil fumarate) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|---|
| ZEPATIER ORAL TABLET 50-100 MG (elbasvir/grazoprevir) | 2 | PA; QL (84 per 365 days; 28 per dispense) |
| zidovudine oral capsule 100 mg | 1 | |
| zidovudine oral syrup 10 mg/ml | 1 | |
| zidovudine oral tablet 300 mg | 1 | |
| CEPHALOSPORINS | | |
| cefaclor oral capsule 250 mg, 500 mg | 1 | |
| cefaclor oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml | 1 | |
| cefaclor oral tablet extended release 12 hr 500 mg | 1 | |
| cefadroxil oral capsule 500 mg | 1 | |
| cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml | 1 | |
| cefadroxil oral tablet 1 gram | 1 | |
| cefdinir oral capsule 300 mg | 1 | |
| cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml | 1 | |
| cefixime oral capsule 400 mg | 1 | |
| cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml | 1 | |
| cefpodoxime oral suspension for reconstitution 100 mg/5 ml, 50 mg/5 ml | 1 | |
| cefpodoxime oral tablet 100 mg, 200 mg | 1 | |
| cefprozil oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml | 1 | |
| cefprozil oral tablet 250 mg, 500 mg | 1 | |
| cefuroxime axetil oral tablet 250 mg, 500 mg | 1 | |
| cephalexin oral capsule 250 mg, 500 mg, 750 mg | 1 | |
| cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml | 1 | |
| cephalexin oral tablet 250 mg, 500 mg | 1 | |
| ERYTHROMYCINS & OTHER MACROLIDES | | |
| azithromycin oral packet 1 gram | 1 | |
| azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml | 1 | |
| azithromycin oral tablet 250 mg, 500 mg, 600 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|---|
| clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml | 1 | |
| clarithromycin oral tablet 250 mg, 500 mg | 1 | |
| clarithromycin oral tablet extended release 24 hr 500 mg | 1 | |
| e.e.s. 400 oral tablet 400 mg | 1 | |
| ery-tab oral tablet,delayed release (dr/ec) 250 mg, 333 mg | 1 | |
| erythrocin (as stearate) oral tablet 250 mg | 1 | |
| erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml, 400 mg/5 ml | 1 | |
| erythromycin ethylsuccinate oral tablet 400 mg | 1 | |
| erythromycin oral capsule,delayed release(dr/ec) 250 mg | 1 | |
| erythromycin oral tablet 250 mg, 500 mg | 1 | |
| erythromycin oral tablet,delayed release (dr/ec) 250 mg, 333 mg, 500 mg | 1 | |
| MISCELLANEOUS ANTIINFECTIVES | | |
| albendazole oral tablet 200 mg | 1 | QL (120 per 23 days) |
| ALINIA ORAL SUSPENSION FOR RECONSTITUTION 100 MG/5 ML (nitazoxanide) | 2 | QL (180 per 23 days) |
| ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML (amikacin sulfate liposomal with nebulizer accessories) | 4 | PA; LA |
| atovaquone oral suspension 750 mg/5 ml | 1 | |
| atovaquone-proguanil oral tablet 250-100 mg | 1 | QL (60 per 180 days) |
| atovaquone-proguanil oral tablet 62.5-25 mg | 1 | QL (180 per 180 days) |
| BENZNIDAZOLE ORAL TABLET 100 MG, 12.5 MG (benznidazole) | 2 | QL (720 per 365 days; 360 per dispense) |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML (aztreonam lysine) | 4 | PA; LA; QL (84 per 30 days) |
| chloroquine phosphate oral tablet 250 mg | 1 | |
| chloroquine phosphate oral tablet 500 mg | 1 | |
| clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg | 1 | |
| clindamycin pediatric oral recon soln 75 mg/5 ml | 1 | |
| COARTEM ORAL TABLET 20-120 MG (artemether/lumefantrine) | 2 | QL (24 per 23 days) |
| cycloserine oral capsule 250 mg | 1 | |
| dapsone oral tablet 100 mg, 25 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--------------------------|
| EMVERM ORAL TABLET, CHEWABLE 100 MG (mebendazole) | 2 | QL (6 per 23 days) |
| ethambutol oral tablet 100 mg, 400 mg | 1 | |
| hydroxychloroquine oral tablet 100 mg, 400 mg | 1 | |
| hydroxychloroquine oral tablet 200 mg, 300 mg | 1 | |
| imipenem-cilastatin intravenous recon soln 250 mg | 1 | PA |
| IMPAVIDO ORAL CAPSULE 50 MG (miltefosine) | 2 | PA; QL (84 per 23 days) |
| isoniazid oral solution 50 mg/5 ml | 1 | |
| isoniazid oral tablet 100 mg, 300 mg | 1 | |
| ivermectin oral tablet 3 mg | 1 | PA; QL (14 per 23 days) |
| ivermectin oral tablet 6 mg | 1 | PA; QL (8 per 23 days) |
| KITABIS PAK INHALATION SOLUTION FOR NEBULIZA- TION 300 MG/5 ML (tobramycin/nebulizer) | 4 | PA; QL (280 per 30 days) |
| linezolid oral suspension for reconstitution 100 mg/5 ml | 1 | PA |
| linezolid oral tablet 600 mg | 1 | PA |
| mefloquine oral tablet 250 mg | 1 | QL (13 per 180 days) |
| metronidazole oral capsule 375 mg | 1 | |
| metronidazole oral tablet 250 mg, 500 mg | 1 | |
| neomycin oral tablet 500 mg | 1 | |
| nitazoxanide oral tablet 500 mg | 1 | QL (12 per 23 days) |
| PASER ORAL GRANULES DR FOR SUSP IN PACKET 4 GRAM (aminosalicylic acid) | 3 | |
| pentamidine inhalation recon soln 300 mg | 1 | QL (1 per 21 days) |
| praziquantel oral tablet 600 mg | 1 | |
| PRIFTIN ORAL TABLET 150 MG (rifapentine) | 2 | |
| primaquine oral tablet 26.3 mg (15 mg base) | 1 | QL (120 per 180 days) |
| pyrazinamide oral tablet 500 mg | 1 | |
| pyrimethamine oral tablet 25 mg | 1 | PA |
| quinine sulfate oral capsule 324 mg | 1 | QL (42 per 23 days) |
| rifabutin oral capsule 150 mg | 1 | |
| rifampin oral capsule 150 mg, 300 mg | 1 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG (bedaquiline fumarate) | 4 | PA; LA |
| tinidazole oral tablet 250 mg | 1 | QL (40 per 23 days) |
| tinidazole oral tablet 500 mg | 1 | QL (20 per 23 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--------------------------|
| tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml | 1 | PA; QL (280 per 30 days) |
| tobramycin inhalation solution for nebulization 300 mg/4 ml | 1 | PA; QL (224 per 30 days) |
| XIFAXAN ORAL TABLET 200 MG (rifaximin) | 2 | PA; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG (rifaximin) | 2 | PA; QL (60 per 30 days) |
| PENICILLINS | | |
| amoxicillin oral capsule 250 mg, 500 mg | 1 | |
| amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml | 1 | |
| amoxicillin oral tablet 500 mg, 875 mg | 1 | |
| amoxicillin oral tablet,chewable 125 mg, 250 mg | 1 | |
| amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml | 1 | |
| amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg | 1 | |
| amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg | 1 | |
| amoxicillin-pot clavulanate oral tablet,chewable 200-28.5 mg, 400-57 mg | 1 | |
| ampicillin oral capsule 500 mg | 1 | |
| AUGMENTIN ORAL SUSPENSION FOR RECONSTITUTION 125-31.25 MG/5 ML (amoxicillin/potassium clavulanate) | 2 | |
| dicloxacillin oral capsule 250 mg, 500 mg | 1 | |
| penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml | 1 | |
| penicillin v potassium oral tablet 250 mg, 500 mg | 1 | |
| QUINOLONES | | |
| ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg | 1 | |
| ciprofloxacin oral suspension,microcapsule recon 250 mg/5 ml, 500 mg/5 ml | 1 | |
| levofloxacin oral solution 250 mg/10 ml | 1 | |
| levofloxacin oral tablet 250 mg, 500 mg, 750 mg | 1 | |
| moxifloxacin oral tablet 400 mg | 1 | |
| ofloxacin oral tablet 300 mg, 400 mg | 1 | |
| SULFA'S & RELATED AGENTS | | |
| sulfadiazine oral tablet 500 mg | 1 | |
| sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg | 1 | |
| sulfatrim oral suspension 200-40 mg/5 ml | 1 | |
| TETRACYCLINES | | |
| avidoxy oral tablet 100 mg | 1 | |
| demeclocycline oral tablet 150 mg, 300 mg | 1 | |
| doxycycline hyclate oral capsule 100 mg, 50 mg | 1 | |
| doxycycline hyclate oral tablet 100 mg, 20 mg | 1 | |
| doxycycline hyclate oral tablet 150 mg, 50 mg, 75 mg | 1 | ST |
| doxycycline hyclate oral tablet,delayed release (dr/ec) 100 mg, 150 mg, 200 mg, 50 mg, 75 mg | 1 | ST |
| doxycycline monohydrate oral capsule 100 mg, 50 mg | 1 | |
| doxycycline monohydrate oral capsule 150 mg, 75 mg | 1 | ST |
| doxycycline monohydrate oral capsule,ir - delay rel,biphase 40 mg | 1 | ST |
| doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml | 1 | |
| doxycycline monohydrate oral tablet 100 mg, 150 mg, 50 mg, 75 mg | 1 | |
| minocycline oral capsule 100 mg, 50 mg, 75 mg | 1 | |
| minocycline oral tablet 100 mg, 50 mg, 75 mg | 1 | ST |
| minocycline oral tablet extended release 24 hr 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg | 1 | ST |
| mondoxyne nl oral capsule 100 mg | 1 | |
| mondoxyne nl oral capsule 75 mg | 1 | ST |
| tetracycline oral capsule 250 mg, 500 mg | 1 | |
| tetracycline oral tablet 250 mg, 500 mg | 1 | ST |
| URINARY TRACT AGENTS | | |
| fosfomycin tromethamine oral packet 3 gram | 1 | |
| methenamine hippurate oral tablet 1 gram | 1 | |
| methenamine mandelate oral tablet 0.5 gram, 1 gram | 1 | |
| nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg | 1 | |
| nitrofurantoin monohyd/m-cryst oral capsule 100 mg | 1 | |
| nitrofurantoin oral suspension 25 mg/5 ml | 1 | |
| trimethoprim oral tablet 100 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------------|
| VANCOMYCIN | | 1 |
| vancomycin oral capsule 125 mg | 1 | PA; QL (40 per 30 days) |
| vancomycin oral capsule 250 mg | 1 | PA; QL (80 per 30 days) |
| vancomycin oral recon soln 25 mg/ml | 1 | QL (300 per 30 days) |
| vancomycin oral recon soln 50 mg/ml | 1 | QL (450 per 30 days) |
| ANTINEOPLASTIC & IMMUNOSUPPRESSAN | T DRUGS | |
| ADJUNCTIVE AGENTS | | |
| dexrazoxane hcl intravenous recon soln 250 mg, 500 mg | 4 | |
| ELITEK INTRAVENOUS RECON SOLN 1.5 MG, 7.5 MG (rasburicase) | 4 | |
| KEPIVANCE INTRAVENOUS RECON SOLN 5.16 MG (palifermin) | 4 | |
| leucovorin calcium oral tablet 10 mg, 15 mg | 1 | |
| leucovorin calcium oral tablet 25 mg, 5 mg | 1 | |
| mesna intravenous solution 100 mg/ml | 4 | |
| MESNEX ORAL TABLET 400 MG (mesna) | 4 | |
| VISTOGARD ORAL GRANULES IN PACKET 10 GRAM (uridine triacetate) | 4 | PA; QL (20 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) (denosumab) | 4 | PA; QL (1 per 30 days) |
| ANTINEOPLASTIC & IMMUNOSUPPRESSANT DRUG | GS | <u></u> |
| abiraterone oral tablet 250 mg | 1 | PA; CSL; QL (120 per 30 days) |
| abiraterone oral tablet 500 mg | 1 | PA; CSL; QL (60 per 30 days) |
| abirtega oral tablet 250 mg | 1 | PA; CSL; QL (120 per 30 days) |
| ADAKVEO INTRAVENOUS SOLUTION 10 MG/ML (crizanli-zumab-tmca) | 4 | PA |
| ADCETRIS INTRAVENOUS RECON SOLN 50 MG (brentux-imab vedotin) | 4 | PA |
| adrucil intravenous solution 2.5 gram/50 ml | 4 | |
| ALECENSA ORAL CAPSULE 150 MG (alectinib hcl) | 4 | PA; CSL; QL (240 per 30 days) |
| ALIQOPA INTRAVENOUS RECON SOLN 60 MG (copanlisib di-hcl) | 4 | PA; LA |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG (brigatinib) | 4 | PA; CSL; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG (brigatinib) | 4 | PA; CSL; QL (60 per 30 days) |
| ALUNBRIG ORAL TABLETS, DOSE PACK 90 MG (7)- 180 MG (23) (brigatinib) | 4 | PA; CSL; QL (30 per 30 days) |
| AMTAGVI INTRAVENOUS SUSPENSION 7.5 X 10EXP9 TO 72X 10EXP9 CELL (<i>lifileucel</i>) PA - Prior Authorization • OL - Quantity Limit • ST - Step Therapy • OTC – Over the | 4 | PA |

PA - Prior Authorization • QL - Quantity Limit • ST - Step Therapy • OTC - Over the counter • ACA - No cost-share preventive medications

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|----------------------------------|
| anastrozole oral tablet 1 mg | 1 | CSL; ACA |
| arsenic trioxide intravenous solution 1 mg/ml, 2 mg/ml | 4 | PA |
| azacitidine injection recon soln 100 mg | 4 | |
| azathioprine oral tablet 100 mg, 50 mg, 75 mg | 1 | |
| BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG (erdafitinib) | 4 | PA; CSL; LA |
| BAVENCIO INTRAVENOUS SOLUTION 20 MG/ML (avelumab) | 4 | PA; LA |
| bendamustine intravenous recon soln 100 mg, 25 mg | 4 | PA |
| BENDEKA INTRAVENOUS SOLUTION 25 MG/ML (bendamustine hcl) | 4 | PA |
| BESPONSA INTRAVENOUS RECON SOLN 0.9 MG (0.25 MG/ML INITIAL) (inotuzumab ozogamicin) | 4 | PA |
| bevacizumab intravitreal syringe 1.25 mg/0.05 ml | 4 | |
| bexarotene oral capsule 75 mg | 1 | PA; CSL |
| bexarotene topical gel 1 % | 4 | PA |
| bicalutamide oral tablet 50 mg | 1 | CSL |
| BIZENGRI INTRAVENOUS SOLUTION 375 MG/18.75 ML (20 MG/ML) (zenocutuzumab-zbco) | 4 | PA |
| bleomycin injection recon soln 15 unit, 30 unit | 4 | |
| BLINCYTO INTRAVENOUS KIT 35 MCG (blinatumomab) | 4 | PA |
| BORTEZOMIB INJECTION RECON SOLN 1 MG, 2.5 MG (bortezomib) | 4 | PA |
| bortezomib injection recon soln 3.5 mg | 4 | PA |
| BORTEZOMIB INTRAVENOUS SOLUTION 2.5 MG/ML (bort-ezomib) | 4 | PA |
| BOSULIF ORAL CAPSULE 100 MG (bosutinib) | 4 | PA; CSL; QL (90 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG (bosutinib) | 4 | PA; CSL; QL (30 per 30 days) |
| BOSULIF ORAL TABLET 100 MG (bosutinib) | 4 | PA; CSL; QL (90 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG (bosutinib) | 4 | PA; CSL; QL (30 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG (zanubrutinib) | 4 | PA; CSL; LA |
| busulfan intravenous solution 60 mg/10 ml | 4 | |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG (cabozantinib s-malate) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG (acalabrutinib maleate) | 4 | PA; CSL; LA; QL (60 per 30 days) |
| capecitabine oral tablet 150 mg | 1 | PA; CSL; QL (56 per 30 days) |
| capecitabine oral tablet 500 mg | 1 | PA; CSL; QL (140 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|----------------------------------|
| CAPRELSA ORAL TABLET 100 MG (vandetanib) | 4 | PA; CSL; LA; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 MG (vandetanib) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| carboplatin intravenous recon soln 150 mg | 4 | |
| carboplatin intravenous solution 10 mg/ml | 4 | |
| carmustine intravenous recon soln 100 mg | 4 | PA |
| CARVYKTI INTRAVENOUS SUSPENSION 0.5 X 10EXP6 TO 1 X 10EXP8 CELL (ciltacabtagene autoleucel) | 4 | PA |
| cisplatin intravenous solution 1 mg/ml | 4 | |
| cladribine intravenous solution 10 mg/10 ml | 4 | |
| clofarabine intravenous solution 1 mg/ml | 4 | |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1) (cabozantinib s-malate) | 4 | PA; CSL; QL (56 per 30 days) |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) (cabozantinib s-malate) | 4 | PA; CSL; QL (112 per 30 days) |
| COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY) (cabozantinib s-malate) | 4 | PA; CSL; QL (84 per 30 days) |
| COTELLIC ORAL TABLET 20 MG (cobimetinib fumarate) | 4 | PA; CSL; LA; QL (63 per 30 days) |
| cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg | 4 | |
| cyclophosphamide oral capsule 25 mg, 50 mg | 1 | CSL |
| cyclosporine intravenous solution 250 mg/5 ml | 1 | |
| cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg | 1 | |
| cyclosporine modified oral solution 100 mg/ml | 1 | |
| cyclosporine oral capsule 100 mg, 25 mg | 1 | |
| CYRAMZA INTRAVENOUS SOLUTION 10 MG/ML (ramucirumab) | 4 | PA |
| cytarabine (pf) injection solution 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml | 4 | |
| cytarabine injection solution 20 mg/ml | 4 | |
| dacarbazine intravenous recon soln 100 mg, 200 mg | 4 | |
| dactinomycin intravenous recon soln 0.5 mg | 4 | |
| DANZITEN ORAL TABLET 71 MG, 95 MG (nilotinib tartrate) | 4 | PA; CSL |
| DARZALEX INTRAVENOUS SOLUTION 20 MG/ML (daratumumab) | 4 | PA; LA |
| dasatinib oral tablet 100 mg, 140 mg, 50 mg, 80 mg | 1 | PA; CSL; QL (30 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------------|
| dasatinib oral tablet 20 mg | 1 | PA; CSL; QL (90 per 30 days) |
| dasatinib oral tablet 70 mg | 1 | PA; CSL; QL (60 per 30 days) |
| daunorubicin intravenous solution 5 mg/ml | 4 | |
| decitabine intravenous recon soln 50 mg | 4 | PA |
| docetaxel intravenous solution 160 mg/16 ml (10 mg/ml), 20 mg/2 ml (10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml) | 4 | |
| docetaxel intravenous solution 160 mg/8 ml (20 mg/ml) | 4 | |
| doxorubicin intravenous recon soln 10 mg, 50 mg | 4 | |
| doxorubicin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml | 4 | |
| doxorubicin, peg-liposomal intravenous suspension 2 mg/ml | 4 | |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG (hydroxyurea) | 2 | |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG (leuprolide acetate) | 4 | PA |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG (leuprolide acetate) | 4 | PA |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG (leuprolide acetate) | 4 | PA |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) (leuprolide acetate) | 4 | PA |
| ELZONRIS INTRAVENOUS SOLUTION 1,000 MCG/ML (tagraxofusp-erzs) | 4 | PA |
| ENSPRYNG SUBCUTANEOUS SYRINGE 120 MG/ML (satralizumab-mwge) | 2 | PA |
| ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 0.75 MG, 1 MG, 4 MG (tacrolimus) | 3 | ST |
| epirubicin intravenous solution 200 mg/100 ml | 4 | |
| ERBITUX INTRAVENOUS SOLUTION 100 MG/50 ML, 200 MG/100 ML (cetuximab) | 4 | PA |
| eribulin intravenous solution 1 mg/2 ml (0.5 mg/ml) | 4 | PA |
| ERIVEDGE ORAL CAPSULE 150 MG (vismodegib) | 4 | PA; CSL; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 240 MG (apalutamide) | 4 | PA; CSL; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG (apalutamide) | 4 | PA; CSL; QL (120 per 30 days) |
| erlotinib oral tablet 100 mg, 150 mg | 1 | PA; CSL; QL (30 per 30 days) |
| erlotinib oral tablet 25 mg | 1 | PA; CSL; QL (60 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------------------|
| ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG (etoposide phosphate) | 4 | |
| etoposide intravenous solution 20 mg/ml | 4 | |
| etoposide oral capsule 50 mg | 1 | CSL |
| everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg | 1 | PA; CSL; QL (30 per 30 days) |
| everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg | 1 | PA; CSL; QL (30 per 30 days) |
| everolimus (immunosuppressive) oral tablet $0.25~\mathrm{mg},~0.5~\mathrm{mg},~0.75~\mathrm{mg},~1~\mathrm{mg}$ | 1 | |
| exemestane oral tablet 25 mg | 1 | CSL; ACA |
| FENSOLVI SUBCUTANEOUS SYRINGE 45 MG (leuprolide acetate) | 4 | PA |
| floxuridine injection recon soln 0.5 gram | 4 | |
| fludarabine intravenous recon soln 50 mg | 4 | |
| fludarabine intravenous solution 50 mg/2 ml | 4 | |
| fluorouracil intravenous solution 1 gram/20 ml | 4 | |
| fluorouracil intravenous solution 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml | 4 | |
| FOLOTYN INTRAVENOUS SOLUTION 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) (<i>pralatrexate</i>) | 4 | PA |
| fulvestrant intramuscular syringe 250 mg/5 ml | 4 | PA |
| GAMIFANT INTRAVENOUS SOLUTION 5 MG/ML (emapalumab-lzsg) | 2 | PA |
| GAVRETO ORAL CAPSULE 100 MG (pralsetinib) | 4 | PA; CSL; LA; QL (120 per 30 days) |
| GAZYVA INTRAVENOUS SOLUTION 1,000 MG/40 ML (obinutuzumab) | 4 | PA |
| gefitinib oral tablet 250 mg | 1 | PA; CSL; QL (30 per 30 days) |
| gemcitabine intravenous recon soln 1 gram, 200 mg | 4 | |
| gemcitabine intravenous recon soln 2 gram | 4 | |
| gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml) | 4 | |
| gengraf oral capsule 100 mg, 25 mg | 1 | |
| gengraf oral solution 100 mg/ml | 1 | |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG (afatinib dimaleate) | 4 | PA; CSL; QL (30 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|----------------------------------|
| GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG (lomustine) | 2 | CSL |
| GOMEKLI ORAL CAPSULE 1 MG, 2 MG (mirdametinib) | 4 | PA; CSL |
| GOMEKLI ORAL TABLET FOR SUSPENSION 1 MG (mirdametinib) | 4 | PA; CSL |
| HALAVEN INTRAVENOUS SOLUTION 1 MG/2 ML (0.5 MG/ML) (eribulin mesylate) | 4 | PA |
| HYCAMTIN ORAL CAPSULE 0.25 MG, 1 MG (topotecan hcl) | 4 | PA; CSL |
| hydroxyurea oral capsule 500 mg | 1 | CSL |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG (ponatinib hcl) | 4 | PA; CSL; QL (30 per 30 days) |
| idarubicin intravenous solution 1 mg/ml | 4 | |
| IDHIFA ORAL TABLET 100 MG, 50 MG (enasidenib mesylate) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| ifosfamide intravenous recon soln 1 gram, 3 gram | 4 | |
| ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml | 4 | |
| imatinib oral tablet 100 mg | 1 | PA; CSL; QL (180 per 30 days) |
| imatinib oral tablet 400 mg | 1 | PA; CSL; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG (ibrutinib) | 4 | PA; CSL; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG (ibrutinib) | 4 | PA; CSL; QL (30 per 30 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML (ibrutinib) | 4 | PA; CSL; QL (324 per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG (<i>ibrutinib</i>) | 4 | PA; CSL; QL (30 per 30 days) |
| IMFINZI INTRAVENOUS SOLUTION 50 MG/ML (durvalum-ab) | 4 | PA; LA |
| IMKELDI ORAL SOLUTION 80 MG/ML (imatinib mesylate) | 4 | PA; CSL |
| INLYTA ORAL TABLET 1 MG (axitinib) | 4 | PA; CSL; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG (axitinib) | 4 | PA; CSL; QL (120 per 30 days) |
| irinotecan intravenous solution 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml | 4 | |
| irinotecan intravenous solution 500 mg/25 ml | 4 | |
| ISTODAX INTRAVENOUS RECON SOLN 10 MG/2 ML (ro-midepsin) | 4 | PA |
| IWILFIN ORAL TABLET 192 MG (eflornithine hcl) | 4 | PA; CSL; LA |
| IXEMPRA INTRAVENOUS RECON SOLN 15 MG, 45 MG (ixabepilone) | 4 | PA |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG (ruxolitinib phosphate) | 4 | PA; CSL; QL (60 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------------|
| KADCYLA INTRAVENOUS RECON SOLN 100 MG, 160 MG (ado-trastuzumab emtansine) | 4 | PA |
| KANJINTI INTRAVENOUS RECON SOLN 150 MG, 420 MG (trastuzumab-anns) | 4 | PA |
| kemoplat intravenous solution 1 mg/ml | 4 | |
| KEYTRUDA INTRAVENOUS SOLUTION 25 MG/ML (pembrolizumab) | 4 | PA |
| KIMMTRAK INTRAVENOUS SOLUTION 100 MCG/0.5 ML (tebentafusp-tebn) | 4 | PA |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) (ribociclib succinate) | 4 | PA; CSL; QL (21 per 30 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) (ribociclib succinate) | 4 | PA; CSL; QL (42 per 30 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) (ribociclib succinate) | 4 | PA; CSL; QL (63 per 30 days) |
| KYMRIAH INTRAVENOUS SUSPENSION 0.2X10EXP6 TO 2.5X10EXP8 CELL, 0.6 TO 6 X 10EXP8 CELL (tisagenlecleucel) | 4 | PA |
| KYPROLIS INTRAVENOUS RECON SOLN 10 MG, 30 MG, 60 MG (carfilzomib) | 4 | PA |
| lanreotide subcutaneous syringe 120 mg/0.5 ml | 1 | PA; QL (1 per 21 days) |
| lapatinib oral tablet 250 mg | 1 | PA; CSL; QL (180 per 30 days) |
| lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg | 1 | PA; CSL; QL (30 per 30 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 4 MG (lenvatinib mesylate) | 4 | PA; CSL; QL (30 per 30 days) |
| LENVIMA ORAL CAPSULE 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X2), 24 MG/DAY(10 MG X 2-4 MG X 1) (lenvatinib mesylate) | 4 | PA; CSL; QL (90 per 30 days) |
| LENVIMA ORAL CAPSULE 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) (lenvatinib mesylate) | 4 | PA; CSL; QL (60 per 30 days) |
| letrozole oral tablet 2.5 mg | 1 | CSL |
| LEUKERAN ORAL TABLET 2 MG (chlorambucil) | 2 | CSL |
| leuprolide subcutaneous kit 1 mg/0.2 ml | 1 | |
| LIBTAYO INTRAVENOUS SOLUTION 50 MG/ML (cemiplim-ab-rwlc) | 4 | PA |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG (trifluridine/tipiracil hcl) | 4 | PA; CSL |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--------------------------------|
| LOQTORZI INTRAVENOUS SOLUTION 240 MG/6 ML (40 MG/ML) (toripalimab-tpzi) | 4 | PA |
| LORBRENA ORAL TABLET 100 MG (lorlatinib) | 4 | PA; CSL; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG (lorlatinib) | 4 | PA; CSL; QL (90 per 30 days) |
| LUNSUMIO INTRAVENOUS SOLUTION 1 MG/ML (mosunetuzumab-axgb) | 4 | PA |
| LUPKYNIS ORAL CAPSULE 7.9 MG (voclosporin) | 2 | PA; QL (180 per 30 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG, 22.5 MG (leuprolide acetate) | 4 | PA |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG (<i>leuprolide acetate</i>) | 4 | PA |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG (leuprolide acetate) | 4 | PA |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG, 7.5 MG (leuprolide acetate) | 4 | PA |
| LYNPARZA ORAL TABLET 100 MG, 150 MG (olaparib) | 4 | PA; CSL; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG (mitotane) | 2 | CSL |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) (futibatinib) | 4 | PA; CSL; LA |
| MATULANE ORAL CAPSULE 50 MG (procarbazine hcl) | 4 | CSL |
| megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml) | 1 | |
| megestrol oral tablet 20 mg, 40 mg | 1 | CSL |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML (trametinib dimethyl sulfoxide) | 4 | PA; CSL; QL (1080 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG (trametinib dimethyl sulfoxide) | 4 | PA; CSL; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG (trametinib dimethyl sulfoxide) | 4 | PA; CSL; QL (30 per 30 days) |
| melphalan hcl intravenous recon soln 50 mg | 4 | |
| mercaptopurine oral suspension 20 mg/ml | 1 | CSL |
| mercaptopurine oral tablet 50 mg | 1 | CSL |
| methotrexate sodium (pf) injection recon soln 1 gram | 1 | |
| methotrexate sodium (pf) injection solution 25 mg/ml | 1 | |
| methotrexate sodium injection solution 25 mg/ml | 1 | |
| methotrexate sodium oral tablet 2.5 mg | 1 | CSL |
| mitomycin intravenous recon soln 20 mg, 40 mg, 5 mg | 4 | |
| mitoxantrone intravenous concentrate 2 mg/ml | 4 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------------------|
| mycophenolate mofetil (hcl) intravenous recon soln 500 mg | 1 | |
| mycophenolate mofetil oral capsule 250 mg | 1 | |
| mycophenolate mofetil oral suspension for reconstitution 200 mg/ml | 1 | |
| mycophenolate mofetil oral tablet 500 mg | 1 | |
| mycophenolate sodium oral tablet,delayed release (dr/ec) 180 mg, 360 mg | 1 | |
| MYHIBBIN ORAL SUSPENSION 200 MG/ML (mycophenolate mofetil) | 2 | |
| MYLERAN ORAL TABLET 2 MG (busulfan) | 2 | CSL |
| MYLOTARG INTRAVENOUS RECON SOLN 4.5 MG (1 MG/ML INITIAL CONC) (gemtuzumab ozogamicin) | 4 | PA; LA |
| nelarabine intravenous solution 250 mg/50 ml | 4 | |
| NEMLUVIO SUBCUTANEOUS PEN INJECTOR 30 MG (nemolizumab-ilto) | 4 | PA; QL (2 per 21 days) |
| NERLYNX ORAL TABLET 40 MG (neratinib maleate) | 4 | PA; CSL; LA |
| nilotinib hcl oral capsule 50 mg | 1 | PA; CSL; QL (120 per 30 days) |
| nilutamide oral tablet 150 mg | 1 | PA; CSL |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG (ixazomib citrate) | 4 | PA; CSL; QL (3 per 30 days) |
| NUBEQA ORAL TABLET 300 MG (darolutamide) | 4 | PA; CSL; LA; QL (120 per 30 days) |
| NULOJIX INTRAVENOUS RECON SOLN 250 MG (belatacept) | 2 | |
| octreotide acetate injection solution 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml | 4 | PA |
| octreotide acetate injection syringe 100 mcg/ml (1 ml), 50 mcg/ml (1 ml), 500 mcg/ml (1 ml) | 4 | PA |
| octreotide,microspheres intramuscular suspension,extended rel recon 10 mg, 30 mg | 4 | PA; QL (1 per 21 days) |
| octreotide,microspheres intramuscular suspension,extended rel recon 20 mg | 4 | PA; QL (2 per 21 days) |
| ODOMZO ORAL CAPSULE 200 MG (sonidegib phosphate) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML (tovorafenib) | 4 | PA; CSL |
| OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) (tovo-rafenib) | 4 | PA; CSL |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|----------------------------------|
| ONCASPAR INJECTION SOLUTION 750 UNIT/ML (pegaspargase) | 4 | PA |
| ONIVYDE INTRAVENOUS DISPERSION 4.3 MG/ML (irinote-can liposomal) | 4 | PA |
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10 ML, 120 MG/12 ML, 240 MG/24 ML, 40 MG/4 ML (nivolumab) | 4 | PA |
| OPDIVO QVANTIG SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML (nivolumab-hyaluronidase-nvhy) | 4 | PA |
| OPDUALAG INTRAVENOUS SOLUTION 240-80 MG/20 ML (nivolumab-relatlimab-rmbw) | 4 | PA |
| ORSERDU ORAL TABLET 345 MG (elacestrant hcl) | 4 | PA; CSL; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG (elacestrant hcl) | 4 | PA; CSL; QL (90 per 30 days) |
| oxaliplatin intravenous recon soln 100 mg, 50 mg | 4 | |
| oxaliplatin intravenous solution 100 mg/20 ml, 200 mg/40 ml, 50 mg/10 ml (5 mg/ml) | 4 | |
| paclitaxel intravenous concentrate 6 mg/ml | 4 | |
| paclitaxel protein-bound intravenous suspension for reconstitution 100 mg | 4 | |
| paraplatin intravenous solution 10 mg/ml | 4 | |
| pazopanib oral tablet 200 mg | 1 | PA; CSL; QL (120 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG (pemigatinib) | 4 | PA; CSL; LA; QL (28 per 30 days) |
| pemetrexed disodium intravenous recon soln 1,000 mg, 750 mg | 4 | |
| pemetrexed disodium intravenous recon soln 100 mg, 500 mg | 4 | |
| PERJETA INTRAVENOUS SOLUTION 420 MG/14 ML (30 MG/ML) (pertuzumab) | 4 | PA |
| PHESGO SUBCUTANEOUS SOLUTION 1,200 MG-600MG-30000 UNIT/15ML, 600 MG-600 MG- 20000 UNIT/10ML (pertuzumab-trastuzumab-hyaluronidase-zzxf) | 4 | PA |
| PHOTOFRIN INTRAVENOUS RECON SOLN 75 MG (porfimer sodium) | 4 | |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) (alpelisib) | 4 | PA; CSL |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG (pomalidomide) | 4 | PA; CSL; LA |
| POTELIGEO INTRAVENOUS SOLUTION 4 MG/ML (mogamu-lizumab-kpkc) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|----------------------------------|
| PRALATREXATE INTRAVENOUS SOLUTION 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) | 4 | PA |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML (tacrolimus) | 2 | |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG (tacrolimus) | 2 | |
| PURIXAN ORAL SUSPENSION 20 MG/ML (mercaptopurine) | 4 | CSL |
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG (lenalidomide) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG (revumenib citrate) | 4 | PA; CSL |
| romidepsin intravenous recon soln 10 mg/2 ml | 4 | PA |
| ROZLYTREK ORAL CAPSULE 100 MG (entrectinib) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG (entrectinib) | 4 | PA; CSL; LA; QL (90 per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG (entrectinib) | 4 | PA; CSL; LA; QL (42 per 30 days) |
| RUXIENCE INTRAVENOUS SOLUTION 10 MG/ML (ritux-imab-pvvr) | 4 | PA |
| RYDAPT ORAL CAPSULE 25 MG (midostaurin) | 4 | PA; CSL; QL (224 per 30 days) |
| SCEMBLIX ORAL TABLET 100 MG (asciminib hydrochloride) | 4 | PA; CSL; QL (120 per 30 days) |
| SCEMBLIX ORAL TABLET 20 MG, 40 MG (asciminib hydrochloride) | 4 | PA; CSL; QL (60 per 30 days) |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) (pasireotide diaspartate) | 4 | PA |
| SIMULECT INTRAVENOUS RECON SOLN 10 MG, 20 MG (basiliximab) | 2 | |
| sirolimus oral solution 1 mg/ml | 1 | |
| sirolimus oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |
| SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML (lanreotide acetate) | 4 | PA; QL (1 per 21 days) |
| sorafenib oral tablet 200 mg | 1 | PA; CSL; QL (120 per 30 days) |
| STIVARGA ORAL TABLET 40 MG (regorafenib) | 4 | PA; CSL; QL (84 per 30 days) |
| sunitinib malate oral capsule 12.5 mg | 1 | PA; CSL; QL (90 per 30 days) |
| sunitinib malate oral capsule 25 mg, 37.5 mg, 50 mg | 1 | PA; CSL; QL (30 per 30 days) |
| SYLVANT INTRAVENOUS RECON SOLN 100 MG, 400 MG (siltuximab) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|----------------------------------|
| TABLOID ORAL TABLET 40 MG (thioguanine) | 3 | CSL |
| TABRECTA ORAL TABLET 150 MG, 200 MG (capmatinib hydrochloride) | 4 | PA; CSL |
| tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg | 1 | |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG (dabrafenib mesylate) | 4 | PA; CSL; QL (120 per 30 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG (dab-rafenib mesylate) | 4 | PA; CSL; QL (840 per 30 days) |
| TAGRISSO ORAL TABLET 40 MG, 80 MG (osimertinib mesylate) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG (talazoparib tosylate) | 4 | PA; CSL; QL (30 per 30 days) |
| tamoxifen oral tablet 10 mg, 20 mg | 1 | CSL; ACA |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG (nilotinib hcl) | 4 | PA; CSL; QL (112 per 30 days) |
| TASIGNA ORAL CAPSULE 50 MG (nilotinib hcl) | 4 | PA; CSL; QL (120 per 30 days) |
| TECELRA INTRAVENOUS SUSPENSION 2.68X10EXP9 TO 10X10EXP9 CELL (afamitresgene autoleucel) | 4 | PA |
| TECENTRIQ HYBREZA SUBCUTANEOUS SOLUTION 1,875 MG-30,000 UNIT/15 ML (atezolizumab-hyaluronidase-tqjs) | 4 | PA |
| TECENTRIQ INTRAVENOUS SOLUTION 1,200 MG/20 ML (60 MG/ML), 840 MG/14 ML (60 MG/ML) (atezolizumab) | 4 | PA; LA |
| TEMODAR INTRAVENOUS RECON SOLN 100 MG (temozolo-mide) | 4 | |
| temozolomide oral capsule 100 mg, 140 mg, 180 mg, 20 mg, 250 mg, 5 mg | 1 | PA; CSL |
| temsirolimus intravenous recon soln 30 mg/3 ml (10 mg/ml) (first) | 4 | PA |
| TEVIMBRA INTRAVENOUS SOLUTION 10 MG/ML (tisleli-zumab-jsgr) | 4 | PA |
| THALOMID ORAL CAPSULE 100 MG (thalidomide) | 4 | PA; CSL; QL (112 per 30 days) |
| THALOMID ORAL CAPSULE 50 MG (thalidomide) | 4 | PA; CSL; QL (28 per 30 days) |
| thiotepa injection recon soln 100 mg, 15 mg | 4 | PA |
| TIBSOVO ORAL TABLET 250 MG (ivosidenib) | 4 | PA; CSL |
| topotecan intravenous recon soln 4 mg | 4 | PA |
| topotecan intravenous solution 4 mg/4 ml (1 mg/ml) | 4 | PA |
| toremifene oral tablet 60 mg | 1 | CSL |
| torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg | 1 | PA; CSL; QL (30 per 30 days) |
| TRAZIMERA INTRAVENOUS RECON SOLN 150 MG, 420 MG (trastuzumab-qyyp) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------------------|
| tretinoin (antineoplastic) oral capsule 10 mg | 1 | CSL |
| TRIPTODUR INTRAMUSCULAR SUSPENSION FOR RE- CONSTITUTION 22.5 MG (triptorelin pamoate) | 4 | PA |
| UNITUXIN INTRAVENOUS SOLUTION 3.5 MG/ML (dinutux-imab) | 4 | PA |
| VECTIBIX INTRAVENOUS SOLUTION 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) (panitumumab) | 4 | PA |
| VENCLEXTA ORAL TABLET 10 MG (venetoclax) | 4 | PA; CSL; LA; QL (56 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG (venetoclax) | 4 | PA; CSL; LA; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG (venetoclax) | 4 | PA; CSL; LA; QL (28 per 30 days) |
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG (venetoclax) | 4 | PA; CSL; QL (42 per 30 days) |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG (abemaciclib) | 4 | PA; CSL; LA; QL (60 per 30 days) |
| VIJOICE ORAL GRANULES IN PACKET 50 MG (alpelisib) | 4 | PA; QL (28 per 21 days) |
| VIJOICE ORAL TABLET 125 MG, 50 MG (alpelisib) | 4 | PA; QL (28 per 21 days) |
| VIJOICE ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1) (alpelisib) | 4 | PA; QL (56 per 21 days) |
| vinblastine intravenous solution 1 mg/ml | 4 | |
| vincasar pfs intravenous solution 1 mg/ml, 2 mg/2 ml | 4 | |
| vincristine intravenous solution 1 mg/ml, 2 mg/2 ml | 4 | |
| vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml | 4 | |
| VITRAKVI ORAL CAPSULE 100 MG (larotrectinib sulfate) | 4 | PA; CSL; LA; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG (larotrectinib sulfate) | 4 | PA; CSL; LA; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML (larotrectinib sulfate) | 4 | PA; CSL; LA; QL (300 per 30 days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG (dacomitinib) | 4 | PA; CSL; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG (pacritinib citrate) | 4 | PA; CSL; QL (120 per 30 days) |
| VYLOY INTRAVENOUS RECON SOLN 100 MG, 300 MG (zolbetuximab-clzb) | 4 | PA |
| VYXEOS INTRAVENOUS RECON SOLN 44-100 MG (dauno-rubicin/cytarabine liposomal) | 4 | PA |
| XALKORI ORAL CAPSULE 200 MG, 250 MG (crizotinib) | 4 | PA; CSL; QL (60 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|--------------|----------------------------------|
| XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG (crizotinib) | 4 | PA; CSL; QL (120 per 30 days) |
| XERMELO ORAL TABLET 250 MG (telotristat etiprate) | 4 | PA; LA; QL (84 per 30 days) |
| XOSPATA ORAL TABLET 40 MG (gilteritinib fumarate) | 4 | PA; CSL; LA; QL (90 per 30 days) |
| XTANDI ORAL CAPSULE 40 MG (enzalutamide) | 4 | PA; CSL; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG (enzalutamide) | 4 | PA; CSL; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG (enzalutamide) | 4 | PA; CSL; QL (60 per 30 days) |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) (<i>ipilimumab</i>) | 4 | PA |
| YESCARTA INTRAVENOUS SUSPENSION (axicabtagene ciloleucel) | 4 | PA |
| YONDELIS INTRAVENOUS RECON SOLN 1 MG (trabectedin) | 4 | |
| ZEJULA ORAL TABLET 100 MG (niraparib tosylate) | 4 | PA; CSL; LA; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 200 MG, 300 MG (niraparib tosylate) | 4 | PA; CSL; LA; QL (30 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG (vemurafenib) | 4 | PA; CSL; QL (240 per 30 days) |
| ZEVALIN (Y-90) INTRAVENOUS KIT 3.2 MG/2 ML (kit for prep yttrium-90/ibritumomab tiuxetan/albumin human) | 4 | |
| ZIRABEV INTRAVENOUS SOLUTION 25 MG/ML (bevaci-zumab-bvzr) | 4 | PA |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG (goserelin acetate) | 4 | PA |
| ZOLINZA ORAL CAPSULE 100 MG (vorinostat) | 4 | PA; CSL; QL (120 per 30 days) |
| ZYDELIG ORAL TABLET 100 MG, 150 MG (idelalisib) | 4 | PA; CSL; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG (ceritinib) | 4 | PA; CSL; QL (90 per 30 days) |
| ZYNYZ INTRAVENOUS SOLUTION 500 MG/20 ML (retifan-limab-dlwr) | 4 | PA |
| AUTONOMIC & CNS DRUGS, NEUROLOGY & | PSYCH | |
| ANTICONVULSANTS | | |
| carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg | 1 | |
| carbamazepine oral suspension 100 mg/5 ml, 200 mg/10 ml | 1 | |
| carbamazepine oral tablet 200 mg | 1 | |
| carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg | 1 | |
| carbamazepine oral tablet,chewable 100 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|------------------------------|
| clobazam oral suspension 2.5 mg/ml | 1 | PA |
| clobazam oral tablet 10 mg, 20 mg | 1 | PA |
| clonazepam oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |
| clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg | 1 | |
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG (stiripentol) | 4 | PA |
| DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG (stiripentol) | 4 | PA |
| diazepam rectal kit 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg | 1 | |
| DILANTIN ORAL CAPSULE 30 MG (phenytoin sodium extended) | 2 | |
| divalproex oral capsule, delayed rel sprinkle 125 mg | 1 | |
| divalproex oral tablet extended release 24 hr 250 mg, 500 mg | 1 | |
| divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg | 1 | |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML (cannabidiol (cbd)) | 4 | PA; LA |
| epitol oral tablet 200 mg | 1 | |
| eslicarbazepine oral tablet 200 mg, 400 mg, 600 mg, 800 mg | 1 | |
| ethosuximide oral capsule 250 mg | 1 | |
| ethosuximide oral solution 250 mg/5 ml | 1 | |
| felbamate oral suspension 600 mg/5 ml | 1 | |
| felbamate oral tablet 400 mg, 600 mg | 1 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML (fenfluramine hcl) | 4 | PA; LA; QL (360 per 30 days) |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML (perampanel) | 3 | |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG (perampanel) | 3 | |
| gabapentin oral capsule 100 mg, 300 mg, 400 mg | 1 | |
| gabapentin oral solution 250 mg/5 ml | 1 | |
| gabapentin oral solution 300 mg/6 ml (6 ml) | 1 | |
| gabapentin oral tablet 600 mg, 800 mg | 1 | |
| gabapentin oral tablet extended release 24 hr 300 mg, 600 mg | 1 | ST |
| lacosamide oral solution 10 mg/ml | 1 | |
| lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg | 1 | |
| lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg | 1 | |
| lamotrigine oral tablet disintegrating, dose pk 25 mg (21) -50 mg (7), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg (42) -100 mg (14) | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|------------------------|
| lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg | 1 | |
| lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg | 1 | |
| lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg | 1 | |
| lamotrigine oral tablets,dose pack 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14) | 1 | |
| levetiracetam oral solution 100 mg/ml | 1 | |
| levetiracetam oral solution 500 mg/5 ml (5 ml) | 1 | |
| levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg | 1 | |
| levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg | 1 | |
| methsuximide oral capsule 300 mg | 1 | |
| NAYZILAM NASAL SPRAY,NON-AEROSOL 5 MG/SPRAY (0.1 ML) (midazolam) | 2 | PA; QL (2 per 30 days) |
| oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml) | 1 | |
| oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg | 1 | |
| oxcarbazepine oral tablet extended release 24 hr 150 mg, 300 mg, 600 mg | 1 | |
| perampanel oral tablet 10 mg, 12 mg, 2 mg, 4 mg, 6 mg, 8 mg | 1 | |
| phenobarbital oral elixir 20 mg/5 ml (4 mg/ml) | 1 | |
| phenobarbital oral tablet 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg | 1 | |
| phenobarbital oral tablet 15 mg, 30 mg, 60 mg | 1 | |
| phenytoin oral suspension 125 mg/5 ml | 1 | |
| phenytoin oral tablet,chewable 50 mg | 1 | |
| phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg | 1 | |
| pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg | 1 | |
| pregabalin oral solution 20 mg/ml | 1 | |
| pregabalin oral tablet extended release 24 hr 165 mg, 330 mg, 82.5 mg | 1 | ST |
| primidone oral tablet 250 mg, 50 mg | 1 | |
| roweepra oral tablet 500 mg | 1 | |
| rufinamide oral suspension 40 mg/ml | 1 | PA |
| rufinamide oral tablet 200 mg, 400 mg | 1 | PA |
| subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg | 1 | |
| subvenite starter (blue) kit oral tablets,dose pack 25 mg (35) | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|------------------------------|
| subvenite starter (green) kit oral tablets,dose pack 25 mg (84) -100 mg (14) | 1 | |
| subvenite starter (orange) kit oral tablets,dose pack 25 mg (42) -100 mg (7) | 1 | |
| tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg | 1 | |
| topiramate oral capsule, sprinkle 15 mg, 25 mg | 1 | |
| topiramate oral capsule, extended release 24hr 100 mg, 200 mg, 25 mg, 50 mg | 1 | ST |
| topiramate oral capsule,sprinkle,er 24hr 100 mg, 150 mg, 200 mg, 25 mg, 50 mg | 1 | ST |
| topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg | 1 | |
| valproic acid (as sodium salt) oral solution 250 mg/5 ml | 1 | |
| valproic acid (as sodium salt) oral solution 500 mg/10 ml (10 ml) | 1 | |
| valproic acid oral capsule 250 mg | 1 | |
| vigabatrin oral powder in packet 500 mg | 1 | PA; LA; QL (150 per 30 days) |
| vigabatrin oral tablet 500 mg | 1 | PA; LA; QL (180 per 30 days) |
| vigadrone oral powder in packet 500 mg | 1 | PA; QL (150 per 30 days) |
| vigadrone oral tablet 500 mg | 1 | PA; QL (180 per 30 days) |
| zonisamide oral capsule 100 mg, 25 mg, 50 mg | 1 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML (ganaxolone) | 4 | PA; LA |
| ANTIPARKINSONISM AGENTS | | |
| apomorphine subcutaneous cartridge 10 mg/ml | 1 | PA; QL (30 per 23 days) |
| benztropine oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |
| bromocriptine oral capsule 5 mg | 1 | |
| bromocriptine oral tablet 2.5 mg | 1 | |
| carbidopa oral tablet 25 mg | 1 | PA |
| carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg | 1 | |
| carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg | 1 | |
| carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg | 1 | |
| carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg | 1 | |
| DUOPA J-TUBE INTESTINAL PUMP SUSPENSION 4.63-20 MG/ML (carbidopa/levodopa) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------------|
| entacapone oral tablet 200 mg | 1 | |
| INBRIJA INHALATION CAPSULE, W/INHALATION DE- VICE 42 MG (<i>levodopa</i>) | 4 | PA; QL (300 per 30 days) |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR (rotigotine) | 3 | |
| NOURIANZ ORAL TABLET 20 MG, 40 MG (istradefylline) | 4 | PA; LA; QL (30 per 30 days) |
| pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg | 1 | |
| pramipexole oral tablet extended release 24 hr 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg | 1 | |
| rasagiline oral tablet 0.5 mg, 1 mg | 1 | |
| ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg | 1 | |
| ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg | 1 | |
| selegiline hcl oral capsule 5 mg | 1 | |
| selegiline hcl oral tablet 5 mg | 1 | |
| tolcapone oral tablet 100 mg | 1 | PA |
| trihexyphenidyl oral elixir 0.4 mg/ml | 1 | |
| trihexyphenidyl oral tablet 2 mg, 5 mg | 1 | |
| MIGRAINE & CLUSTER HEADACHE THERAPY | | |
| AJOVY AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 225 MG/1.5 ML (fremanezumab-vfrm) | 2 | PA; QL (1 per 23 days) |
| AJOVY SYRINGE SUBCUTANEOUS SYRINGE 225 MG/1.5 ML (fremanezumab-vfrm) | 2 | PA; QL (1 per 23 days) |
| almotriptan malate oral tablet 12.5 mg | 1 | ST; QL (12 per 30 days) |
| almotriptan malate oral tablet 6.25 mg | 1 | ST; QL (6 per 30 days) |
| dihydroergotamine injection solution 1 mg/ml | 1 | |
| dihydroergotamine nasal spray,non-aerosol 0.5 mg/pump act. (4 mg/ml) | 1 | ST; QL (8 per 30 days) |
| eletriptan oral tablet 20 mg, 40 mg | 1 | QL (6 per 30 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML (galcanezumab-gnlm) | 2 | PA; QL (1 per 23 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML (galcanezumab-gnlm) | 2 | PA; QL (1 per 23 days) |
| ergotamine-caffeine oral tablet 1-100 mg | 1 | |
| frovatriptan oral tablet 2.5 mg | 1 | ST; QL (9 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|------------------------------|
| migergot rectal suppository 2-100 mg | 1 | |
| naratriptan oral tablet 1 mg, 2.5 mg | 1 | QL (9 per 30 days) |
| NURTEC ODT ORAL TABLET, DISINTEGRATING 75 MG (rimegepant sulfate) | 3 | PA; QL (16 per 30 days) |
| REYVOW ORAL TABLET 100 MG, 50 MG (lasmiditan succinate) | 2 | PA; QL (8 per 30 days) |
| rizatriptan oral tablet 10 mg, 5 mg | 1 | QL (18 per 30 days) |
| rizatriptan oral tablet,disintegrating 10 mg, 5 mg | 1 | QL (18 per 30 days) |
| sumatriptan nasal spray,non-aerosol 20 mg/actuation, 5 mg/actuation | 1 | QL (6 per 30 days) |
| sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg | 1 | QL (9 per 30 days) |
| sumatriptan succinate subcutaneous cartridge 4 mg/0.5 ml, 6 mg/0.5 ml | 1 | QL (1 per 30 days) |
| sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml, 6 mg/0.5 ml | 1 | QL (1 per 30 days) |
| sumatriptan succinate subcutaneous solution 6 mg/0.5 ml | 1 | QL (1 per 30 days) |
| zolmitriptan nasal spray,non-aerosol 5 mg | 1 | ST; QL (6 per 30 days) |
| zolmitriptan oral tablet 2.5 mg, 5 mg | 1 | QL (6 per 30 days) |
| zolmitriptan oral tablet,disintegrating 2.5 mg, 5 mg | 1 | QL (6 per 30 days) |
| MISCELLANEOUS NEUROLOGICAL THERAPY | | |
| AUSTEDO ORAL TABLET 12 MG, 9 MG (deutetrabenazine) | 4 | PA; LA; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG (deutetrabenazine) | 4 | PA; LA; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG (deutetrabenazine) | 4 | PA; QL (30 per 30 days) |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG (deutetrabenazine) | 4 | PA; QL (28 per 30 days) |
| dalfampridine oral tablet extended release 12 hr 10 mg | 1 | PA; QL (60 per 30 days) |
| dichlorphenamide oral tablet 50 mg | 1 | PA |
| donepezil oral tablet 10 mg, 5 mg | 1 | |
| donepezil oral tablet 23 mg | 1 | ST |
| donepezil oral tablet, disintegrating 10 mg, 5 mg | 1 | |
| edaravone intravenous solution 30 mg/100 ml | 4 | PA |
| edaravone intravenous solution 60 mg/100 ml | 4 | PA |
| FIRDAPSE ORAL TABLET 10 MG (amifampridine phosphate) | 4 | PA; LA |
| galantamine oral capsule,ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg | 1 | |
| galantamine oral solution 4 mg/ml | 1 | |

PA - Prior Authorization • QL - Quantity Limit • ST - Step Therapy • OTC – Over the counter • ACA - No cost-share preventive medications • CSL - Oral cancer medications subject to cost-share limits • LA – Limited Access

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------------|
| galantamine oral tablet 12 mg, 4 mg, 8 mg | 1 | |
| memantine oral capsule,sprinkle,er 24hr 14 mg, 21 mg, 28 mg, 7 mg | 1 | |
| memantine oral solution 2 mg/ml | 1 | |
| memantine oral tablet 10 mg, 5 mg | 1 | |
| memantine-donepezil oral capsule,sprinkle,er 24hr 14-10 mg, 21-10 mg, 28-10 mg | 1 | ST |
| NUEDEXTA ORAL CAPSULE 20-10 MG (dextromethorphan hbr/quinidine sulfate) | 2 | PA |
| ormalvi oral tablet 50 mg | 1 | PA |
| RADICAVA INTRAVENOUS SOLUTION 30 MG/100 ML (edaravone) | 4 | PA |
| RADICAVA ORS STARTER KIT SUSP ORAL SUSPENSION 105 MG/5 ML (edaravone) | 4 | PA |
| rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg | 1 | |
| rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour | 1 | |
| SKYSONA INTRAVENOUS SUSPENSION 4 X TO 30 X 10EXP6 CELL/ML (elivaldogene autotemcel) | 4 | PA |
| SPINRAZA (PF) INTRATHECAL SOLUTION 12 MG/5 ML (nusinersen sodium/pf) | 4 | PA; QL (1 per 90 days) |
| tetrabenazine oral tablet 12.5 mg | 1 | PA; QL (120 per 30 days) |
| tetrabenazine oral tablet 25 mg | 1 | PA; QL (60 per 30 days) |
| TYSABRI INTRAVENOUS SOLUTION 300 MG/15 ML (natalizumab) | 4 | PA; LA; QL (15 per 30 days) |
| ZEPOSIA ORAL CAPSULE 0.92 MG (ozanimod hydrochloride) | 4 | PA; QL (30 per 30 days) |
| ZEPOSIA STARTER KIT (28-DAY) ORAL CAPSULE, DOSE PACK 0.23 MG-0.46 MG -0.92 MG (21) (ozanimod hydrochloride) | 4 | PA; QL (28 per 30 days) |
| ZEPOSIA STARTER PACK (7-DAY) ORAL CAPSULE, DOSE PACK 0.23 MG (4)- 0.46 MG (3) (ozanimod hydrochloride) | 4 | PA; QL (7 per 30 days) |
| MUSCLE RELAXANTS & ANTISPASMODIC THERAPY | | |
| baclofen oral solution 5 mg/5 ml | 1 | |
| baclofen oral suspension 25 mg/5 ml (5 mg/ml) | 1 | |
| baclofen oral tablet 10 mg, 20 mg | 1 | |
| baclofen oral tablet 15 mg, 5 mg | 1 | |
| chlorzoxazone oral tablet 250 mg, 375 mg, 500 mg, 750 mg | 1 | |
| cyclobenzaprine oral capsule,extended release 24hr 15 mg, 30 mg | 1 | ST |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| cyclobenzaprine oral tablet 10 mg, 5 mg, 7.5 mg | 1 | |
| dantrolene oral capsule 100 mg, 25 mg, 50 mg | 1 | |
| metaxalone oral tablet 400 mg, 800 mg | 1 | |
| methocarbamol oral tablet 1,000 mg, 500 mg, 750 mg | 1 | |
| neostigmine methylsulfate intravenous syringe 3 mg/3 ml (1 mg/ml) | 1 | |
| orphenadrine citrate oral tablet extended release 100 mg | 1 | |
| orphenadrine-asa-caffeine oral tablet 25-385-30 mg | 1 | |
| orphengesic forte oral tablet 50-770-60 mg | 1 | |
| pyridostigmine bromide oral syrup 60 mg/5 ml | 1 | |
| pyridostigmine bromide oral tablet 60 mg | 1 | |
| pyridostigmine bromide oral tablet extended release 180 mg | 1 | |
| tanlor oral tablet 1,000 mg | 1 | |
| tizanidine oral capsule 2 mg, 4 mg, 6 mg | 1 | |
| tizanidine oral tablet 2 mg, 4 mg | 1 | |
| NARCOTIC ANALGESICS | | |
| acetaminophen-caff-dihydrocod oral capsule 320.5-30-16 mg | 1 | |
| acetaminophen-codeine oral solution 120-12 mg/5 ml | 1 | |
| acetaminophen-codeine oral solution 300 mg-30 mg/12.5 ml | 1 | |
| acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg, 300-60 mg | 1 | |
| ascomp with codeine oral capsule 30-50-325-40 mg | 1 | |
| BRIXADI SUBCUTANEOUS SOLUTION, EXTENDED REL SYRINGE 128 MG/0.36 ML, 16 MG/0.32 ML, 24 MG/0.48 ML, 32 MG/0.64 ML, 64 MG/0.18 ML, 8 MG/0.16 ML, 96 MG/0.27 ML (buprenorphine) | 4 | |
| buprenorphine hcl sublingual tablet 2 mg, 8 mg | 1 | |
| buprenorphine transdermal patch weekly 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour | 1 | |
| butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg | 1 | |
| butalbital-acetaminophen oral capsule 50-300 mg | 1 | |
| butalbital-acetaminophen oral tablet 50-300 mg, 50-325 mg | 1 | |
| butalbital-acetaminophen-caff oral capsule 50-300-40 mg, 50-325-40 mg | 1 | |
| butalbital-acetaminophen-caff oral tablet 50-325-40 mg | 1 | |
| butalbital-aspirin-caffeine oral capsule 50-325-40 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| butalbital-aspirin-caffeine oral tablet 50-325-40 mg | 1 | |
| codeine sulfate oral tablet 15 mg, 30 mg, 60 mg | 1 | |
| codeine-butalbital-asa-caff oral capsule 30-50-325-40 mg | 1 | |
| diskets oral tablet,soluble 40 mg | 1 | |
| endocet oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg | 1 | |
| fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr | 1 | QL (15 per 23 days) |
| fentanyl transdermal patch 72 hour 37.5 mcg/hour, 62.5 mcg/hour, 87.5 mcg/hour | 1 | QL (15 per 23 days) |
| hydrocodone bitartrate oral capsule, oral only, er 12hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg | 1 | QL (90 per 23 days) |
| hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 100 mg, 120 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg | 1 | QL (60 per 23 days) |
| hydrocodone-acetaminophen oral solution 10-300 mg/15 ml, 10-325 mg/15 ml, 7.5-325 mg/15 ml | 1 | |
| hydrocodone-acetaminophen oral solution 10-325 mg/15 ml(15 ml) | 1 | |
| hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg | 1 | |
| hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg | 1 | |
| hydromorphone oral liquid 1 mg/ml | 1 | |
| hydromorphone oral tablet 2 mg, 4 mg, 8 mg | 1 | |
| hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 32 mg, 8 mg | 1 | QL (60 per 23 days) |
| hydromorphone rectal suppository 3 mg | 1 | |
| meperidine oral tablet 50 mg | 1 | |
| methadone oral concentrate 10 mg/ml | 1 | |
| methadone oral solution 10 mg/5 ml, 5 mg/5 ml | 1 | |
| methadone oral tablet 10 mg, 5 mg | 1 | |
| methadone oral tablet,soluble 40 mg | 1 | |
| methadose oral concentrate 10 mg/ml | 1 | |
| methadose oral tablet,soluble 40 mg | 1 | |
| morphine concentrate oral solution 100 mg/5 ml (20 mg/ml) | 1 | |
| morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg | 1 | QL (60 per 23 days) |
| morphine oral capsule,extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg | 1 | QL (90 per 23 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|------------------------|
| morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml) | 1 | |
| morphine oral tablet 15 mg, 30 mg | 1 | |
| morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg | 1 | QL (120 per 23 days) |
| morphine rectal suppository 10 mg, 20 mg, 30 mg, 5 mg | 1 | |
| oxycodone oral capsule 5 mg | 1 | |
| oxycodone oral concentrate 20 mg/ml | 1 | |
| oxycodone oral solution 5 mg/5 ml | 1 | |
| oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg | 1 | |
| oxycodone-acetaminophen oral solution 10-300 mg/5 ml, 5-325 mg/5 ml | 1 | |
| oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-300 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg | 1 | |
| oxymorphone oral tablet 10 mg, 5 mg | 1 | |
| oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg | 1 | QL (90 per 23 days) |
| prolate oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg | 1 | |
| SUBLOCADE SUBCUTANEOUS SOLUTION, EXTENDED REL SYRINGE 100 MG/0.5 ML, 300 MG/1.5 ML (buprenorphine) | 4 | |
| tencon oral tablet 50-325 mg | 1 | |
| NON-NARCOTIC ANALGESICS | | |
| aspirin childrens oral tablet,chewable 81 mg | 1 | ACA; OTC |
| aspirin oral tablet 81 mg | 1 | ACA; OTC |
| aspirin oral tablet,chewable 81 mg | 1 | ACA; OTC |
| aspirin oral tablet,delayed release (dr/ec) 81 mg | 1 | ACA; OTC |
| bayer low dose aspirin oral tablet,delayed release (dr/ec) 81 mg | 1 | ACA; OTC |
| buprenorphine-naloxone sublingual film 12-3 mg, 2-0.5 mg, 4-1 mg, 8-2 mg | 1 | |
| buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg | 1 | |
| butorphanol injection solution 1 mg/ml, 2 mg/ml | 1 | |
| butorphanol nasal spray,non-aerosol 10 mg/ml | 1 | QL (5 per 30 days) |
| celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg | 1 | |
| diclofenac potassium oral capsule 25 mg | 1 | ST |
| diclofenac potassium oral powder in packet 50 mg | 1 | ST; QL (9 per 30 days) |
| diclofenac potassium oral tablet 25 mg | 1 | ST |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--------------------------|
| diclofenac potassium oral tablet 50 mg | 1 | |
| diclofenac sodium oral tablet extended release 24 hr 100 mg | 1 | |
| diclofenac sodium oral tablet,delayed release (dr/ec) 25 mg, 50 mg, 75 mg | 1 | |
| diclofenac sodium topical drops 1.5 % | 1 | QL (150 per 21 days) |
| diclofenac sodium topical solution in metered-dose pump 20 mg/gram /actuation(2 %) | 1 | ST; QL (112 per 21 days) |
| diclofenac-misoprostol oral tablet,ir,delayed rel,biphasic 50-200 mg-mcg, 75-200 mg-mcg | 1 | |
| diflunisal oral tablet 500 mg | 1 | |
| ecotrin low strength oral tablet,delayed release (dr/ec) 81 mg | 1 | ACA; OTC |
| etodolac oral capsule 200 mg, 300 mg | 1 | |
| etodolac oral tablet 400 mg, 500 mg | 1 | |
| etodolac oral tablet extended release 24 hr 400 mg, 500 mg, 600 mg | 1 | |
| fenoprofen oral capsule 400 mg | 1 | ST |
| fenoprofen oral tablet 600 mg | 1 | ST |
| flurbiprofen oral tablet 100 mg | 1 | |
| ibu oral tablet 400 mg, 600 mg, 800 mg | 1 | |
| ibuprofen oral suspension 100 mg/5 ml | 1 | |
| ibuprofen oral tablet 400 mg, 600 mg, 800 mg | 1 | |
| indomethacin oral capsule 25 mg, 50 mg | 1 | |
| indomethacin oral capsule, extended release 75 mg | 1 | |
| indomethacin oral suspension 25 mg/5 ml | 1 | ST |
| indomethacin rectal suppository 50 mg | 1 | |
| ketoprofen oral capsule 25 mg | 1 | ST |
| ketoprofen oral capsule 50 mg, 75 mg | 1 | |
| ketoprofen oral capsule,ext rel. pellets 24 hr 200 mg | 1 | ST |
| ketorolac oral tablet 10 mg | 1 | QL (20 per 30 days) |
| kiprofen oral capsule 25 mg | 1 | ST |
| lofena oral tablet 25 mg | 1 | ST |
| lofexidine oral tablet 0.18 mg | 1 | QL (224 per 30 days) |
| meclofenamate oral capsule 100 mg, 50 mg | 1 | |
| mefenamic acid oral capsule 250 mg | 1 | |
| meloxicam oral tablet 15 mg, 7.5 mg | 1 | QL (30 per 30 days) |
| meloxicam submicronized oral capsule 10 mg, 5 mg | 1 | ST; QL (30 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| nabumetone oral tablet 500 mg, 750 mg | 1 | |
| naloxone injection solution 0.4 mg/ml | 1 | |
| naloxone injection syringe 0.4 mg/ml, 1 mg/ml | 1 | |
| naltrexone oral tablet 50 mg | 1 | |
| naproxen oral suspension 125 mg/5 ml | 1 | ST |
| naproxen oral tablet 250 mg, 375 mg, 500 mg | 1 | |
| naproxen oral tablet,delayed release (dr/ec) 375 mg | 1 | |
| naproxen oral tablet,delayed release (dr/ec) 500 mg | 1 | ST |
| naproxen sodium oral tablet 275 mg, 550 mg | 1 | |
| naproxen sodium oral tablet, er multiphase 24 hr 375 mg, 500 mg, 750 mg | 1 | ST |
| oxaprozin oral tablet 600 mg | 1 | |
| piroxicam oral capsule 10 mg, 20 mg | 1 | |
| REXTOVY NASAL SPRAY,NON-AEROSOL 4 MG/ACTUA-TION (naloxone hcl) | 2 | QL (2 per 30 days) |
| salsalate oral tablet 500 mg, 750 mg | 1 | |
| st joseph aspirin oral tablet,chewable 81 mg | 1 | ACA; OTC |
| sulindac oral tablet 150 mg, 200 mg | 1 | |
| tolmetin oral capsule 400 mg | 1 | ST |
| tolmetin oral tablet 600 mg | 1 | ST |
| tramadol oral tablet 100 mg | 1 | QL (120 per 30 days) |
| tramadol oral tablet 50 mg | 1 | QL (240 per 30 days) |
| tramadol oral tablet extended release 24 hr 100 mg, 200 mg, 300 mg | 1 | PA; QL (30 per 30 days) |
| tramadol oral tablet, er multiphase 24 hr 100 mg, 200 mg, 300 mg | 1 | PA; QL (30 per 30 days) |
| tramadol-acetaminophen oral tablet 37.5-325 mg | 1 | QL (240 per 30 days) |
| VISCO-3 INTRA-ARTICULAR SYRINGE 10 MG/ML (hyaluro-nate sodium) | 4 | PA |
| VIVITROL INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 380 MG (naltrexone microspheres) | 4 | |
| ZUBSOLV SUBLINGUAL TABLET 0.7-0.18 MG, 1.4-0.36 MG, 11.4-2.9 MG, 2.9-0.71 MG, 5.7-1.4 MG, 8.6-2.1 MG (buprenorphine hcl/naloxone hcl) | 2 | |
| PSYCHOTHERAPEUTIC DRUGS | | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG (aripiprazole) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG (aripiprazole) | 2 | |
| alprazolam intensol oral concentrate 1 mg/ml | 1 | |
| alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg | 1 | |
| alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg | 1 | |
| alprazolam oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg | 1 | |
| amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 1 | |
| amitriptyline-chlordiazepoxide oral tablet 12.5-5 mg, 25-10 mg | 1 | |
| amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg | 1 | |
| amphetamine sulfate oral tablet 10 mg, 5 mg | 1 | |
| aripiprazole oral solution 1 mg/ml | 1 | |
| aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg | 1 | QL (30 per 30 days) |
| aripiprazole oral tablet,disintegrating 10 mg, 15 mg | 1 | QL (60 per 30 days) |
| armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg | 1 | ST; QL (30 per 30 days) |
| asenapine maleate sublingual tablet 10 mg, 2.5 mg, 5 mg | 1 | QL (60 per 30 days) |
| atomoxetine oral capsule 10 mg, 100 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg | 1 | |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG (dextromethorphan hbr/bupropion hcl) | 3 | ST; QL (60 per 30 days) |
| bupropion hcl oral tablet 100 mg, 75 mg | 1 | |
| bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg | 1 | QL (30 per 30 days) |
| bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg | 1 | QL (60 per 30 days) |
| buspirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg | 1 | |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG (lumateperone tosylate) | 3 | QL (30 per 30 days) |
| chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg | 1 | |
| chlorpromazine injection solution 25 mg/ml | 1 | |
| chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml | 1 | |
| chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg | 1 | |
| citalopram oral solution 10 mg/5 ml | 1 | |
| citalopram oral tablet 10 mg, 20 mg, 40 mg | 1 | QL (30 per 30 days) |
| clomipramine oral capsule 25 mg, 50 mg, 75 mg | 1 | |
| clonidine hcl oral tablet extended release 12 hr 0.1 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg | 1 | |
| clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg | 1 | |
| clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg | 1 | |
| desipramine oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 1 | |
| desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg | 1 | ST; QL (30 per 30 days) |
| dexmethylphenidate oral capsule,er biphasic 50-50 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg | 1 | |
| dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg | 1 | |
| dextroamphetamine sulfate oral capsule, extended release 10 mg, 15 mg, 5 mg | 1 | |
| dextroamphetamine sulfate oral solution 5 mg/5 ml | 1 | |
| dextroamphetamine sulfate oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 30 mg, 5 mg, 7.5 mg | 1 | |
| dextroamphetamine-amphetamine oral capsule, er triphasic 24 hr 12.5 mg, 25 mg, 37.5 mg, 50 mg | 1 | |
| dextroamphetamine-amphetamine oral capsule,extended release 24hr 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 5 mg | 1 | |
| dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg | 1 | |
| diazepam intensol oral concentrate 5 mg/ml | 1 | |
| diazepam oral solution 5 mg/5 ml (1 mg/ml) | 1 | |
| diazepam oral tablet 10 mg, 2 mg, 5 mg | 1 | |
| doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 1 | |
| doxepin oral concentrate 10 mg/ml | 1 | |
| doxepin oral tablet 3 mg, 6 mg | 1 | ST; QL (30 per 30 days) |
| duloxetine oral capsule,delayed release(dr/ec) 20 mg, 60 mg | 1 | QL (60 per 30 days) |
| duloxetine oral capsule,delayed release(dr/ec) 30 mg | 1 | QL (30 per 30 days) |
| duloxetine oral capsule,delayed release(dr/ec) 40 mg | 1 | ST; QL (30 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR (selegiline) | 3 | |
| ergoloid oral tablet 1 mg | 1 | |
| escitalopram oxalate oral solution 5 mg/5 ml | 1 | ST |
| escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg | 1 | QL (30 per 30 days) |
| estazolam oral tablet 1 mg, 2 mg | 1 | QL (15 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| eszopiclone oral tablet 1 mg, 2 mg, 3 mg | 1 | QL (30 per 30 days) |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG (iloperidone) | 3 | QL (60 per 30 days) |
| FANAPT TITRATION PACK A ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)-4MG(2)-6MG(2) (iloperidone) | 3 | QL (8 per 30 days) |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) (levomilnacipran hcl) | 3 | ST; QL (28 per 30 days) |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG (levomilnacipran hcl) | 3 | ST; QL (30 per 30 days) |
| fluoxetine oral capsule 10 mg | 1 | QL (30 per 30 days) |
| fluoxetine oral capsule 20 mg | 1 | |
| fluoxetine oral capsule 40 mg | 1 | QL (60 per 30 days) |
| fluoxetine oral capsule,delayed release(dr/ec) 90 mg | 1 | ST; QL (4 per 30 days) |
| fluoxetine oral solution 20 mg/5 ml (4 mg/ml) | 1 | |
| fluoxetine oral tablet 10 mg | 1 | ST; QL (30 per 30 days) |
| fluoxetine oral tablet 20 mg | 1 | ST |
| fluoxetine oral tablet 60 mg | 1 | ST |
| fluphenazine decanoate injection solution 25 mg/ml | 1 | |
| fluphenazine hcl injection solution 2.5 mg/ml | 1 | |
| fluphenazine hcl oral concentrate 5 mg/ml | 1 | |
| fluphenazine hcl oral elixir 2.5 mg/5 ml | 1 | |
| fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg | 1 | |
| flurazepam oral capsule 15 mg, 30 mg | 1 | QL (15 per 30 days) |
| fluvoxamine oral capsule,extended release 24hr 100 mg, 150 mg | 1 | ST; QL (60 per 30 days) |
| fluvoxamine oral tablet 100 mg | 1 | QL (90 per 30 days) |
| fluvoxamine oral tablet 25 mg | 1 | QL (30 per 30 days) |
| fluvoxamine oral tablet 50 mg | 1 | QL (60 per 30 days) |
| guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg | 1 | |
| haloperidol decanoate intramuscular solution 100 mg/ml, 50 mg/ml | 1 | |
| haloperidol lactate injection solution 5 mg/ml | 1 | |
| haloperidol lactate intramuscular syringe 5 mg/ml | 1 | |
| haloperidol lactate oral concentrate 2 mg/ml | 1 | |
| haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg | 1 | |
| imipramine hcl oral tablet 10 mg, 25 mg, 50 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg | 1 | |
| lisdexamfetamine oral capsule 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg | 1 | |
| lisdexamfetamine oral tablet,chewable 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg | 1 | ST |
| lithium carbonate oral capsule 150 mg, 600 mg | 1 | |
| lithium carbonate oral capsule 300 mg | 1 | |
| lithium carbonate oral tablet 300 mg | 1 | |
| lithium carbonate oral tablet extended release 300 mg, 450 mg | 1 | |
| lithium citrate oral solution 8 meq/5 ml | 1 | |
| lorazepam intensol oral concentrate 2 mg/ml | 1 | |
| lorazepam oral concentrate 2 mg/ml | 1 | |
| lorazepam oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |
| loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg | 1 | |
| LUMRYZ ORAL EXTEND RELEASE GRANULES,PACKET 4.5 GRAM, 6 GRAM, 7.5 GRAM, 9 GRAM (sodium oxybate) | 4 | PA; QL (30 per 30 days) |
| LUMRYZ STARTER PACK ORAL GRANULES ER PACKET, DOSE PACK 4.5-6-7.5 GRAM (sodium oxybate) | 4 | PA |
| lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg | 1 | QL (30 per 30 days) |
| lurasidone oral tablet 80 mg | 1 | QL (60 per 30 days) |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG (olanzapine/samidorphan malate) | 3 | QL (30 per 30 days) |
| MARPLAN ORAL TABLET 10 MG (isocarboxazid) | 3 | |
| methamphetamine oral tablet 5 mg | 1 | |
| methylphenidate hcl oral cap,er sprinkle,biphasic 40-60 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg | 1 | ST |
| methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg | 1 | |
| methylphenidate hcl oral capsule,er biphasic 50-50 10 mg, 20 mg, 30 mg, 40 mg, 60 mg | 1 | |
| methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml | 1 | |
| methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg | 1 | |
| methylphenidate hcl oral tablet extended release 10 mg, 20 mg | 1 | |
| methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 36 mg, 54 mg, 72 mg | 1 | |
| methylphenidate hcl oral tablet,chewable 10 mg, 2.5 mg, 5 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| methylphenidate transdermal patch 24 hour 10 mg/9 hr, 15 mg/9 hr, 20 mg/9 hr, 30 mg/9 hr | 1 | ST |
| midazolam oral syrup 2 mg/ml | 1 | |
| mirtazapine oral tablet 15 mg, 30 mg, 45 mg | 1 | |
| mirtazapine oral tablet 7.5 mg | 1 | |
| mirtazapine oral tablet, disintegrating 15 mg, 30 mg, 45 mg | 1 | |
| modafinil oral tablet 100 mg | 1 | ST; QL (30 per 30 days) |
| modafinil oral tablet 200 mg | 1 | ST; QL (60 per 30 days) |
| molindone oral tablet 10 mg, 25 mg, 5 mg | 1 | |
| nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg | 1 | |
| nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg | 1 | |
| nortriptyline oral solution 10 mg/5 ml | 1 | |
| olanzapine intramuscular recon soln 10 mg | 1 | |
| olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg | 1 | QL (30 per 30 days) |
| olanzapine oral tablet, disintegrating 10 mg, 15 mg, 20 mg, 5 mg | 1 | QL (30 per 30 days) |
| olanzapine-fluoxetine oral capsule 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg | 1 | |
| paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg | 1 | QL (30 per 30 days) |
| paliperidone oral tablet extended release 24hr 6 mg | 1 | QL (60 per 30 days) |
| paroxetine hcl oral suspension 10 mg/5 ml | 1 | ST |
| paroxetine hcl oral tablet 10 mg, 40 mg | 1 | QL (30 per 30 days) |
| paroxetine hcl oral tablet 20 mg, 30 mg | 1 | QL (60 per 30 days) |
| paroxetine hcl oral tablet extended release 24 hr 12.5 mg, 25 mg, 37.5 mg | 1 | ST; QL (60 per 30 days) |
| paroxetine mesylate(menop.sym) oral capsule 7.5 mg | 1 | ST; QL (30 per 30 days) |
| perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg | 1 | |
| perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg | 1 | |
| phenelzine oral tablet 15 mg | 1 | |
| pimozide oral tablet 1 mg, 2 mg | 1 | |
| procentra oral solution 5 mg/5 ml | 1 | |
| protriptyline oral tablet 10 mg, 5 mg | 1 | |
| quetiapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg | 1 | QL (90 per 30 days) |
| quetiapine oral tablet 300 mg, 400 mg | 1 | QL (60 per 30 days) |
| quetiapine oral tablet extended release 24 hr 150 mg, 200 mg | 1 | QL (30 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|------------------------------|
| quetiapine oral tablet extended release 24 hr 300 mg, 400 mg, 50 mg | 1 | QL (60 per 30 days) |
| ramelteon oral tablet 8 mg | 1 | QL (30 per 30 days) |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG (brexpiprazole) | 3 | QL (30 per 30 days) |
| risperidone microspheres intramuscular suspension,extended rel recon 12.5 mg/2 ml, 25 mg/2 ml, 37.5 mg/2 ml, 50 mg/2 ml | 1 | |
| risperidone oral solution 1 mg/ml | 1 | |
| risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg | 1 | QL (60 per 30 days) |
| risperidone oral tablet,disintegrating 0.25 mg | 1 | QL (60 per 30 days) |
| risperidone oral tablet, disintegrating 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg | 1 | QL (60 per 30 days) |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR (asenapine) | 3 | QL (30 per 30 days) |
| sertraline oral concentrate 20 mg/ml | 1 | |
| sertraline oral tablet 100 mg, 50 mg | 1 | QL (60 per 30 days) |
| sertraline oral tablet 25 mg | 1 | QL (45 per 30 days) |
| SODIUM OXYBATE ORAL SOLUTION 500 MG/ML | 4 | PA; LA; QL (540 per 30 days) |
| SPRAVATO NASAL SPRAY,NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3) (esketamine hcl) | 4 | PA |
| SUNOSI ORAL TABLET 150 MG, 75 MG (solriamfetol hcl) | 2 | ST; QL (30 per 30 days) |
| thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg | 1 | |
| thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg | 1 | |
| tranylcypromine oral tablet 10 mg | 1 | |
| trazodone oral tablet 100 mg, 150 mg, 300 mg, 50 mg | 1 | |
| triazolam oral tablet 0.125 mg, 0.25 mg | 1 | QL (15 per 30 days) |
| trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg | 1 | |
| trimipramine oral capsule 100 mg, 25 mg, 50 mg | 1 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG (vortioxetine hydrobromide) | 3 | ST; QL (30 per 30 days) |
| venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg | 1 | QL (30 per 30 days) |
| venlafaxine oral capsule,extended release 24hr 75 mg | 1 | QL (90 per 30 days) |
| venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg | 1 | QL (90 per 30 days) |
| venlafaxine oral tablet extended release 24hr 150 mg, 225 mg, 37.5 mg, 75 mg | 1 | ST; QL (30 per 30 days) |
| vilazodone oral tablet 10 mg, 20 mg, 40 mg | 1 | ST; QL (30 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|---|
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG (cariprazine hcl) | 3 | QL (30 per 30 days) |
| XYWAV ORAL SOLUTION 0.5 GRAM/ML (sodium oxybate/calcium oxybate/magnesium oxybate/pot oxybate) | 4 | PA; LA; QL (540 per 30 days) |
| zaleplon oral capsule 10 mg, 5 mg | 1 | QL (30 per 30 days) |
| zenzedi oral tablet 10 mg, 5 mg | 1 | |
| ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg | 1 | QL (60 per 30 days) |
| ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.) | 1 | |
| zolpidem oral tablet 10 mg, 5 mg | 1 | QL (30 per 30 days) |
| zolpidem oral tablet,ext release multiphase 12.5 mg, 6.25 mg | 1 | QL (30 per 30 days) |
| zolpidem sublingual tablet 1.75 mg, 3.5 mg | 1 | QL (30 per 30 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG (zuranolone) | 4 | PA; QL (28 per 365 days) |
| ZURZUVAE ORAL CAPSULE 30 MG (zuranolone) | 4 | PA; QL (14 per 365 days) |
| AUTONOMIC & CNS DRUGS, NEUROLOGY | | |
| MULTIPLE SCLEROSIS AGENTS | | |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML (interferon beta-la) | 2 | PA; QL (4 per 21 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML (interferon beta-la) | 2 | PA; QL (4 per 21 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG (interferon beta-lb) | 4 | PA; QL (14 per 23 days) |
| dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg | 1 | PA; QL (60 per 30 days) |
| fingolimod oral capsule 0.5 mg | 1 | PA; QL (30 per 30 days) |
| glatiramer subcutaneous syringe 20 mg/ml | 1 | PA; QL (30 per 23 days) |
| glatiramer subcutaneous syringe 40 mg/ml | 1 | PA; QL (12 per 23 days) |
| glatopa subcutaneous syringe 20 mg/ml | 1 | PA; QL (30 per 23 days) |
| glatopa subcutaneous syringe 40 mg/ml | 1 | PA; QL (12 per 23 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML (ofatumumab) | 4 | PA; QL (1 per 21 days) |
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG (cladribine) | 3 | PA; QL (40 per 720 days; 10 per dispense); LA |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG (cladribine) | 3 | PA; QL (16 per 720 days; 4 per dispense); LA |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG (cladribine) | 3 | PA; QL (20 per 720 days; 5 per dispense); LA |

Drug Name

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--|
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG (cladribine) | 3 | PA; QL (24 per 720 days; 6 per dispense); LA |
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG (cladribine) | 3 | PA; QL (28 per 720 days; 7 per dispense); LA |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG (cladribine) | 3 | PA; QL (32 per 720 days; 8 per dispense); LA |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG (cladribine) | 3 | PA; QL (36 per 720 days; 9 per dispense); LA |
| MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG (siponimod) | 4 | PA; QL (30 per 30 days) |
| MAYZENT STARTER(FOR 1MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (7 TABS) (siponimod) | 4 | PA; QL (7 per 30 days) |
| MAYZENT STARTER(FOR 2MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) (siponimod) | 4 | PA; QL (12 per 30 days) |
| OCREVUS INTRAVENOUS SOLUTION 30 MG/ML (ocrelizumab) | 4 | PA; QL (20 per 135 days) |
| OCREVUS ZUNOVO SUBCUTANEOUS SOLUTION 920 MG-23,000 UNIT/23 ML (ocrelizumab-hyaluronidase-ocsq) | 4 | PA; QL (1 per 135 days) |
| PLEGRIDY INTRAMUSCULAR SYRINGE 125 MCG/0.5 ML (peginterferon beta-1a) | 4 | PA; QL (1 per 21 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML (peginterferon beta-la) | 4 | PA; QL (1 per 21 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 63 MCG/0.5 ML- 94 MCG/0.5 ML (peginterferon beta-la) | 4 | PA; QL (1 per 365 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML (peginterferon beta-1a) | 4 | PA; QL (1 per 21 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 63 MCG/0.5 ML- 94 MCG/0.5 ML (peginterferon beta-la) | 4 | PA; QL (1 per 365 days) |
| REBIF (WITH ALBUMIN) SUBCUTANEOUS SYRINGE 22 MCG/0.5 ML, 44 MCG/0.5 ML (interferon beta-la/albumin human) | 2 | PA; QL (6 per 21 days) |
| REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML (interferon beta-la/albumin human) | 2 | PA; QL (6 per 21 days) |
| REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 8.8MCG/0.2ML-22 MCG/0.5ML (6) (interferon beta-la/albumin human) | 2 | PA; QL (1 per 21 days) |
| REBIF TITRATION PACK SUBCUTANEOUS SYRINGE 8.8MCG/0.2ML-22 MCG/0.5ML (6) (interferon beta-la/albumin human) | 2 | PA; QL (1 per 21 days) |
| teriflunomide oral tablet 14 mg, 7 mg | 1 | PA; QL (30 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--------------------------|
| VUMERITY ORAL CAPSULE, DELAYED RELEASE (DR/EC) 231 MG (diroximel fumarate) | 4 | PA; QL (120 per 30 days) |
| CARDIOVASCULAR, HYPERTENSION & LIPI | DS | |
| ANTIARRHYTHMIC AGENTS | | |
| amiodarone oral tablet 100 mg, 200 mg, 400 mg | 1 | |
| dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg | 1 | |
| flecainide oral tablet 100 mg, 150 mg, 50 mg | 1 | |
| mexiletine oral capsule 150 mg, 200 mg, 250 mg | 1 | |
| pacerone oral tablet 100 mg, 200 mg | 1 | |
| propafenone oral capsule,extended release 12 hr 225 mg, 325 mg, 425 mg | 1 | |
| propafenone oral tablet 150 mg, 225 mg, 300 mg | 1 | |
| quinidine gluconate oral tablet extended release 324 mg | 1 | |
| quinidine sulfate oral tablet 200 mg, 300 mg | 1 | |
| sotalol af oral tablet 120 mg, 160 mg, 80 mg | 1 | |
| sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg | 1 | |
| SOTYLIZE ORAL SOLUTION 5 MG/ML (sotalol hcl) | 2 | |
| ANTIHYPERTENSIVE THERAPY | | |
| acebutolol oral capsule 200 mg, 400 mg | 1 | |
| aliskiren oral tablet 150 mg, 300 mg | 1 | |
| amiloride oral tablet 5 mg | 1 | |
| amiloride-hydrochlorothiazide oral tablet 5-50 mg | 1 | |
| amlodipine oral tablet 10 mg, 2.5 mg, 5 mg | 1 | |
| amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg | 1 | |
| amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg | 1 | |
| amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg | 1 | |
| amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10- 160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg | 1 | |
| atenolol oral tablet 100 mg, 25 mg, 50 mg | 1 | |
| atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg | 1 | |
| benazepril oral tablet 10 mg, 20 mg, 40 mg, 5 mg | 1 | |
| benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| betaxolol oral tablet 10 mg, 20 mg | 1 | |
| bisoprolol fumarate oral tablet 10 mg, 5 mg | 1 | |
| bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg | 1 | |
| bumetanide oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |
| candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg | 1 | |
| candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg | 1 | |
| captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg | 1 | |
| captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg | 1 | |
| cartia xt oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg | 1 | |
| carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg | 1 | |
| carvedilol phosphate oral capsule, er multiphase 24 hr 10 mg, 20 mg, 40 mg, 80 mg | 1 | |
| chlorthalidone oral tablet 25 mg, 50 mg | 1 | |
| clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg | 1 | |
| clonidine transdermal patch weekly 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr | 1 | QL (4 per 21 days) |
| diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg | 1 | |
| diltiazem hcl oral capsule,extended release 12 hr 120 mg, 60 mg, 90 mg | 1 | |
| diltiazem hcl oral capsule,extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | 1 | |
| diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg | 1 | |
| diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg | 1 | |
| diltiazem hcl oral tablet extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | 1 | |
| dilt-xr oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg | 1 | |
| doxazosin oral tablet 1 mg, 2 mg, 4 mg | 1 | QL (30 per 30 days) |
| doxazosin oral tablet 8 mg | 1 | QL (60 per 30 days) |
| enalapril maleate oral solution 1 mg/ml | 1 | |
| enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg | 1 | |
| enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| eplerenone oral tablet 25 mg, 50 mg | 1 | |
| epoprostenol intravenous recon soln 0.5 mg, 1.5 mg | 4 | PA |
| eprosartan oral tablet 600 mg | 1 | |
| ethacrynic acid oral tablet 25 mg | 1 | |
| felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg | 1 | |
| fosinopril oral tablet 10 mg, 20 mg, 40 mg | 1 | |
| fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg | 1 | |
| furosemide oral solution 10 mg/ml | 1 | |
| furosemide oral solution 40 mg/5 ml (8 mg/ml) | 1 | |
| furosemide oral tablet 20 mg, 40 mg, 80 mg | 1 | |
| guanfacine oral tablet 1 mg, 2 mg | 1 | |
| hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg | 1 | |
| hydrochlorothiazide oral capsule 12.5 mg | 1 | |
| hydrochlorothiazide oral tablet 12.5 mg | 1 | |
| hydrochlorothiazide oral tablet 25 mg, 50 mg | 1 | |
| indapamide oral tablet 1.25 mg, 2.5 mg | 1 | |
| irbesartan oral tablet 150 mg, 300 mg, 75 mg | 1 | |
| irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg | 1 | |
| isosorbide-hydralazine oral tablet 20-37.5 mg | 1 | |
| isradipine oral capsule 2.5 mg, 5 mg | 1 | |
| KERENDIA ORAL TABLET 10 MG, 20 MG (finerenone) | 2 | PA; QL (30 per 30 days) |
| labetalol oral tablet 100 mg, 200 mg, 300 mg | 1 | |
| lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg | 1 | |
| lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg | 1 | |
| losartan oral tablet 100 mg, 25 mg, 50 mg | 1 | |
| losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg | 1 | |
| matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | 1 | |
| methyldopa oral tablet 250 mg, 500 mg | 1 | |
| methyldopa-hydrochlorothiazide oral tablet 250-15 mg, 250-25 mg | 1 | |
| metolazone oral tablet 10 mg, 2.5 mg, 5 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg | 1 | |
| metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg, 50-25 mg | 1 | |
| metoprolol tartrate oral tablet 100 mg, 50 mg | 1 | |
| metoprolol tartrate oral tablet 25 mg, 37.5 mg, 75 mg | 1 | |
| metyrosine oral capsule 250 mg | 1 | PA |
| minoxidil oral tablet 10 mg, 2.5 mg | 1 | |
| moexipril oral tablet 15 mg, 7.5 mg | 1 | |
| nadolol oral tablet 20 mg, 40 mg, 80 mg | 1 | |
| nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg | 1 | |
| nicardipine oral capsule 20 mg, 30 mg | 1 | |
| nifedipine oral tablet extended release 24hr 30 mg, 60 mg, 90 mg | 1 | |
| nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg | 1 | |
| nimodipine oral capsule 30 mg | 1 | |
| nimodipine oral solution 60 mg/20 ml | 1 | |
| nisoldipine oral tablet extended release 24 hr 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg, 8.5 mg | 1 | |
| olmesartan oral tablet 20 mg, 40 mg, 5 mg | 1 | |
| olmesartan-amlodipin-hcthiazid oral tablet 20-5-12.5 mg, 40-10- 12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg | 1 | |
| olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg | 1 | |
| perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg | 1 | |
| phenoxybenzamine oral capsule 10 mg | 1 | PA |
| pindolol oral tablet 10 mg, 5 mg | 1 | |
| prazosin oral capsule 1 mg, 2 mg, 5 mg | 1 | |
| propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg | 1 | |
| propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml) | 1 | |
| propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg | 1 | |
| propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg | 1 | |
| quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg | 1 | |
| quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg | 1 | |
| ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------------|
| spironolactone oral suspension 25 mg/5 ml | 1 | |
| spironolactone oral tablet 100 mg, 25 mg, 50 mg | 1 | |
| spironolacton-hydrochlorothiaz oral tablet 25-25 mg | 1 | |
| telmisartan oral tablet 20 mg, 40 mg, 80 mg | 1 | |
| telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg | 1 | |
| telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg | 1 | |
| terazosin oral capsule 1 mg, 2 mg, 5 mg | 1 | QL (30 per 30 days) |
| terazosin oral capsule 10 mg | 1 | QL (60 per 30 days) |
| tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | 1 | |
| timolol maleate oral tablet 10 mg, 20 mg, 5 mg | 1 | |
| torsemide oral tablet 10 mg, 100 mg, 20 mg, 5 mg | 1 | |
| trandolapril oral tablet 1 mg, 2 mg, 4 mg | 1 | |
| trandolapril-verapamil oral tablet, ir - er, biphasic 24hr 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg | 1 | |
| treprostinil sodium injection solution 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml | 4 | PA |
| triamterene oral capsule 100 mg, 50 mg | 1 | |
| triamterene-hydrochlorothiazid oral capsule 37.5-25 mg | 1 | |
| triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg | 1 | |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG (selexipag) | 4 | PA; LA; QL (60 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) (selexipag) | 4 | PA; LA; QL (200 per 365 days) |
| valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg | 1 | |
| valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg | 1 | |
| veletri intravenous recon soln 0.5 mg, 1.5 mg | 4 | PA |
| verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg | 1 | ST |
| verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg, 360 mg | 1 | |
| verapamil oral tablet 120 mg, 40 mg, 80 mg | 1 | |
| verapamil oral tablet extended release 120 mg, 180 mg, 240 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| CARDIAC GLYCOSIDES | | _ |
| digoxin oral solution 50 mcg/ml (0.05 mg/ml) | 1 | |
| digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg), 62.5 mcg (0.0625 mg) | 1 | |
| COAGULATION THERAPY | | |
| ADVATE INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 1,500 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 3,000 (+/-) UNIT, 4,000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor (fviii) recombinant, full length) | 4 | PA |
| ADYNOVATE INTRAVENOUS SOLUTION 1,000 (+/-) UNIT, 1,500 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 3,000 (+/-) UNIT, 500 (+/-) UNIT, 750 (+/-) UNIT (antihemophilic factor (fviii) recombinant, full length, peg) | 4 | PA |
| AFSTYLA INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT RANGE, 1,500 (+/-) UNIT RANGE, 2,000 (+/-) UNIT RANGE, 2,500 (+/-) UNIT RANGE, 250 (+/-) UNIT RANGE, 3,000 (+/-) UNIT RANGE, 500 (+/-) UNIT RANGE (antihemophilic factor viii recomb, single-chn, b-dom truncated) | 4 | PA |
| ALPHANATE INTRAVENOUS RECON SOLN 1,000 (400 VWF) UNIT/10 ML, 1,500 (600 VWF) UNIT/10 ML, 2,000 (800 VWF) UNIT/10 ML, 250 (100 VWF) UNIT/5 ML, 500 (200 VWF) UNIT/5 ML (antihemophilic factor, human/von willebrand factor,human) | 4 | PA |
| ALTUVIIIO INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 3,000 (+/-) UNIT, 4000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor rfviii fc-vwf-xten,bdd-ehtl) | 4 | PA |
| aminocaproic acid intravenous solution 250 mg/ml | 4 | |
| aminocaproic acid oral solution 250 mg/ml (25 %) | 1 | |
| aminocaproic acid oral tablet 1,000 mg, 500 mg | 1 | |
| argatroban in 0.9 % sod chlor intravenous solution 1 mg/ml | 4 | |
| aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg | 1 | |
| BENEFIX INTRAVENOUS RECON SOLN 1,000 UNIT, 2,000 UNIT, 250 UNIT, 3,000 UNIT, 500 UNIT (factor ix human recombinant) | 4 | PA |
| CABLIVI INJECTION KIT 11 MG (caplacizumab-yhdp) | 4 | PA; LA |
| CEPROTIN (BLUE BAR) INTRAVENOUS RECON SOLN 500 UNIT (protein c, human) | 4 | PA |
| CEPROTIN (GREEN BAR) INTRAVENOUS RECON SOLN 1,000 UNIT (protein c, human) | 4 | PA |
| cilostazol oral tablet 100 mg, 50 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------------|
| clopidogrel oral tablet 300 mg, 75 mg | 1 | |
| COAGADEX INTRAVENOUS RECON SOLN 250 (+/-) UNIT RANGE, 500 (+/-) UNIT RANGE (coagulation factor x) | 4 | PA |
| CORIFACT INTRAVENOUS RECON SOLN 1,000-1,600 UNIT (factor xiii) | 4 | PA |
| dabigatran etexilate oral capsule 110 mg, 150 mg, 75 mg | 1 | PA |
| dipyridamole oral tablet 25 mg, 50 mg, 75 mg | 1 | |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG (avatrombopag maleate) | 4 | PA; LA; QL (15 per 30 days) |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) (apixaban) | 2 | PA |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG (apixaban) | 2 | PA |
| ELOCTATE INTRAVENOUS RECON SOLN 1,000 UNIT, 1,500 UNIT, 2,000 UNIT, 250 UNIT, 3,000 UNIT, 4,000 UNIT, 5,000 UNIT, 500 UNIT, 6,000 UNIT, 750 UNIT (antihemophilic factor (fviii) recombinant, fc fusion protein) | 4 | PA |
| eltrombopag olamine oral powder in packet 12.5 mg, 25 mg | 1 | PA |
| eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg | 1 | PA |
| enoxaparin subcutaneous solution 300 mg/3 ml | 1 | |
| enoxaparin subcutaneous syringe 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml, 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml | 1 | |
| ESPEROCT INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 1,500 (+/-) UNIT, 2,000 (+/-) UNIT, 3,000 (+/-) UNIT, 4,000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor (fviii) rec, b-dom truncated peg-exei) | 4 | PA |
| FEIBA NF INTRAVENOUS RECON SOLN 1,750-3,250 UNIT, 350-650 UNIT, 700-1,300 UNIT (anti-inhibitor coagulant complex) | 4 | PA |
| fondaparinux subcutaneous syringe 10 mg/0.8 ml, 2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml | 1 | |
| HEMGENIX INTRAVENOUS SUSPENSION 1X10EXP13 GC/ ML (etranacogene dezaparvovec-drlb) | 4 | PA |
| HEMLIBRA SUBCUTANEOUS SOLUTION 105 MG/0.7 ML, 12 MG/0.4 ML, 150 MG/ML, 30 MG/ML, 300 MG/2 ML (150 MG/ML), 60 MG/0.4 ML (emicizumab-kxwh) | 4 | PA |
| HEMOFIL M HIGH INTRAVENOUS RECON SOLN 801-1,500 UNIT (antihemophilic factor, human) | 4 | PA |
| HEMOFIL M LOW INTRAVENOUS RECON SOLN 220-400 UNIT (antihemophilic factor, human) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| HEMOFIL M MID INTRAVENOUS RECON SOLN 401-800 UNIT (antihemophilic factor, human) | 4 | PA |
| HEMOFIL M SUPER HIGH INTRAVENOUS RECON SOLN 1,501-2,000 UNIT (antihemophilic factor, human) | 4 | PA |
| hep flush-10 (pf) intravenous solution 10 unit/ml | 1 | |
| heparin (porcine) in 0.9% nacl intravenous parenteral solution 2,500 unit/500 ml (5 unit/ml) | 1 | |
| heparin (porcine) in 5 % dex intravenous parenteral solution 20,000 unit/500 ml (40 unit/ml), 25,000 unit/250 ml(100 unit/ml), 25,000 unit/500 ml (50 unit/ml) | 1 | |
| heparin (porcine) in nacl (pf) intravenous parenteral solution 1,000 unit/500 ml, 2,000 unit/1,000 ml | 1 | |
| heparin (porcine) injection cartridge 5,000 unit/ml (1 ml) | 1 | |
| heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml | 1 | |
| heparin (porcine) injection syringe 5,000 unit/ml | 1 | |
| heparin lock flush (porcine) intravenous solution 10 unit/ml, 100 unit/ml | 1 | |
| heparin lockflush(porcine)(pf) intravenous syringe 10 unit/ml, 100 unit/ml | 1 | |
| heparin(porcine) in 0.45% nacl intravenous parenteral solution 25,000 unit/250 ml, 25,000 unit/500 ml | 1 | |
| heparin, porcine (pf) injection solution 1,000 unit/ml, 5,000 unit/0.5 ml | 1 | |
| heparin, porcine (pf) injection syringe 5,000 unit/0.5 ml | 1 | |
| heparin, porcine (pf) intravenous solution 100 unit/ml (1 ml) | 1 | |
| heparin, porcine (pf) intravenous syringe 1 unit/ml | 1 | |
| heparin, porcine (pf) intravenous syringe 100 unit/ml | 1 | |
| HUMATE-P INTRAVENOUS RECON SOLN 1,000-2,400 UNIT, 250-600 UNIT, 500-1,200 UNIT (antihemophilic factor, human/von willebrand factor,human) | 4 | PA |
| IDELVION INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 3,500 (+/-) UNIT, 500 (+/-) UNIT (factor ix recombinant, albumin fusion protein) | 4 | PA |
| jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg | 1 | |
| JIVI INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 2,000 (+/-) UNIT, 3,000 (+/-) UNIT, 4,000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor (fviii) rec, b-domain deleted peg-aucl) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------------|
| KOGENATE FS INTRAVENOUS RECON SOLN 250 (+/-) UNIT, 3,000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor (fviii) recombinant, full length) | 4 | PA |
| KOVALTRY INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 3,000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor (fviii) recombinant, full length) | 4 | PA |
| NOVOEIGHT INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 1,500 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 3,000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor viii recombinant, b-domain truncated) | 4 | PA |
| NPLATE SUBCUTANEOUS RECON SOLN 125 MCG, 250 MCG, 500 MCG (romiplostim) | 4 | PA |
| OBIZUR INTRAVENOUS RECON SOLN 500 (+/-) UNIT RANGE (antihemophilic factor viii, recombinant porcine sequence) | 4 | |
| pentoxifylline oral tablet extended release 400 mg | 1 | |
| prasugrel hcl oral tablet 10 mg, 5 mg | 1 | |
| PROFILNINE INTRAVENOUS RECON SOLN 1,000 (+/-) UNIT, 1,500 (+/-) UNIT, 500 (+/-) UNIT (factor ix complex, pro-thrombin complex conc no.4, 3-factor) | 4 | PA |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG (eltrombopag olamine) | 4 | PA; LA |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG (eltrombopag olamine) | 4 | PA; LA |
| RIASTAP INTRAVENOUS RECON SOLN 1 GRAM (900MG-1,300MG) (fibrinogen) | 4 | PA |
| rivaroxaban oral tablet 2.5 mg | 1 | PA |
| ROCTAVIAN INTRAVENOUS SUSPENSION 2 X 10EXP13 VG/ML (valoctocogene roxaparvovec-rvox) | 4 | PA |
| SEVENFACT INTRAVENOUS RECON SOLN 1 MG (1,000 MCG), 2 MG (2,000 MCG), 5 MG (5,000 MCG) (coagulation factor viia recombinant-jncw) | 4 | PA |
| TAVALISSE ORAL TABLET 100 MG, 150 MG (fostamatinib disodium) | 4 | PA; LA; QL (60 per 30 days) |
| ticagrelor oral tablet 60 mg, 90 mg | 1 | |
| tranexamic acid in nacl,iso-os intravenous piggyback 1,000 mg/100 ml (10 mg/ml) | 4 | |
| tranexamic acid intravenous solution 1,000 mg/10 ml (100 mg/ml) | 4 | |
| TRETTEN INTRAVENOUS RECON SOLN 2,500 UNIT (factor xiii a-subunit, recombinant) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--------------------------|
| VONVENDI INTRAVENOUS RECON SOLN 1,300 (+/-) UNIT RANGE, 650 (+/-) UNIT RANGE (von willebrand factor (recombinant)) | 4 | PA |
| warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg | 1 | |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) (rivaroxaban) | 2 | PA |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION 1 MG/ML (rivaroxaban) | 2 | PA |
| XARELTO ORAL TABLET 10 MG, 15 MG, 2.5 MG, 20 MG (rivaroxaban) | 2 | PA |
| XYNTHA INTRAVENOUS SOLUTION 1,000 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor (factor viii) recomb,b-domain deleted) | 4 | PA |
| XYNTHA SOLOFUSE INTRAVENOUS SYRINGE 1,000 (+/-) UNIT, 2,000 (+/-) UNIT, 250 (+/-) UNIT, 3,000 (+/-) UNIT, 500 (+/-) UNIT (antihemophilic factor (factor viii) recomb,b-domain deleted) | 4 | PA |
| LIPID/CHOLESTEROL LOWERING AGENTS | | |
| amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg | 1 | QL (30 per 30 days) |
| atorvastatin oral tablet 10 mg, 20 mg | 1 | ACA; QL (30 per 30 days) |
| atorvastatin oral tablet 40 mg, 80 mg | 1 | QL (30 per 30 days) |
| cholestyramine (with sugar) oral powder 4 gram | 1 | |
| cholestyramine (with sugar) oral powder in packet 4 gram | 1 | |
| cholestyramine light oral powder 4 gram | 1 | |
| cholestyramine light oral powder in packet 4 gram | 1 | |
| colesevelam oral powder in packet 3.75 gram | 1 | |
| colesevelam oral tablet 625 mg | 1 | |
| colestipol oral granules 5 gram | 1 | |
| colestipol oral packet 5 gram | 1 | |
| colestipol oral tablet 1 gram | 1 | |
| ezetimibe oral tablet 10 mg | 1 | |
| ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg | 1 | QL (30 per 30 days) |
| fenofibrate micronized oral capsule 130 mg | 1 | ST |
| fenofibrate micronized oral capsule 134 mg, 200 mg, 43 mg, 67 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--------------------------|
| fenofibrate nanocrystallized oral tablet 145 mg, 48 mg | 1 | |
| fenofibrate oral tablet 120 mg, 40 mg | 1 | ST |
| fenofibrate oral tablet 160 mg, 54 mg | 1 | |
| fenofibric acid (choline) oral capsule,delayed release(dr/ec) 135 mg, 45 mg | 1 | |
| fenofibric acid oral tablet 105 mg, 35 mg | 1 | |
| fluvastatin oral capsule 20 mg | 1 | ACA; QL (30 per 30 days) |
| fluvastatin oral capsule 40 mg | 1 | ACA; QL (60 per 30 days) |
| fluvastatin oral tablet extended release 24 hr 80 mg | 1 | ACA; QL (30 per 30 days) |
| gemfibrozil oral tablet 600 mg | 1 | |
| icosapent ethyl oral capsule 0.5 gram, 1 gram | 1 | PA |
| JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG (lomitapide mesylate) | 4 | PA; LA |
| lovastatin oral tablet 10 mg | 1 | ACA; QL (30 per 30 days) |
| lovastatin oral tablet 20 mg, 40 mg | 1 | ACA; QL (60 per 30 days) |
| niacin oral tablet 500 mg | 1 | |
| niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg | 1 | |
| omega-3 acid ethyl esters oral capsule 1 gram | 1 | PA |
| pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg | 1 | ACA; QL (30 per 30 days) |
| pravastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg | 1 | ACA; QL (30 per 30 days) |
| prevalite oral powder 4 gram | 1 | |
| prevalite oral powder in packet 4 gram | 1 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML (evolocumab) | 2 | PA; QL (1 per 21 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML (evolocumab) | 2 | PA; QL (2 per 21 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ ML (evolocumab) | 2 | PA; QL (2 per 21 days) |
| rosuvastatin oral tablet 10 mg, 5 mg | 1 | ACA; QL (30 per 30 days) |
| rosuvastatin oral tablet 20 mg, 40 mg | 1 | QL (30 per 30 days) |
| simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg | 1 | ACA; QL (30 per 30 days) |
| simvastatin oral tablet 80 mg | 1 | QL (30 per 30 days) |
| VASCEPA ORAL CAPSULE 0.5 GRAM, 1 GRAM (icosapent ethyl) | 2 | PA |
| MISCELLANEOUS CARDIOVASCULAR AGENTS | | |
| ATTRUBY ORAL TABLET 356 MG (acoramidis hcl) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| CAMZYOS ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 5 MG (mavacamten) | 4 | PA; QL (30 per 30 days) |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG (sacubitril/valsartan) | 2 | QL (60 per 30 days) |
| ENTRESTO SPRINKLE ORAL PELLET 15-16 MG, 6-6 MG (sacubitril/valsartan) | 2 | QL (240 per 30 days) |
| ivabradine oral tablet 5 mg, 7.5 mg | 1 | PA |
| ranolazine oral tablet extended release 12 hr 1,000 mg, 500 mg | 1 | |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG (vericiguat) | 2 | QL (30 per 30 days) |
| VYNDAMAX ORAL CAPSULE 61 MG (tafamidis) | 4 | PA |
| VYNDAQEL ORAL CAPSULE 20 MG (tafamidis meglumine) | 4 | PA |
| NITRATES | | |
| isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 40 mg, 5 mg | 1 | |
| isosorbide mononitrate oral tablet 10 mg, 20 mg | 1 | |
| isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg | 1 | |
| nitro-bid transdermal ointment 2 % | 1 | |
| nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg | 1 | |
| nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr | 1 | |
| nitroglycerin translingual spray,non-aerosol 400 mcg/spray | 1 | |
| nitro-time oral capsule, extended release 2.5 mg, 6.5 mg, 9 mg | 1 | |
| DERMATOLOGICALS/TOPICAL THERAPY | | |
| ANTIPSORIATIC / ANTISEBORRHEIC | | |
| acitretin oral capsule 10 mg, 17.5 mg, 25 mg | 1 | |
| calcipotriene scalp solution 0.005 % | 1 | QL (120 per 23 days) |
| calcipotriene topical cream 0.005 % | 1 | QL (120 per 23 days) |
| calcipotriene topical ointment 0.005 % | 1 | QL (120 per 23 days) |
| calcipotriene-betamethasone topical ointment 0.005-0.064 % | 1 | ST; QL (60 per 23 days) |
| calcipotriene-betamethasone topical suspension 0.005-0.064 % | 1 | QL (60 per 23 days) |
| calcitriol topical ointment 3 mcg/gram | 1 | |
| hydrocortisone-pramoxine topical cream 2.5-1 % | 1 | ST |
| SELARSDI INTRAVENOUS SOLUTION 130 MG/26 ML (ustekinumab-aekn) | 2 | PA |
| SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML (ustekinumab-aekn) | 2 | PA; QL (1 per 63 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| SELARSDI SUBCUTANEOUS SYRINGE 90 MG/ML (ustekinumab-aekn) | 2 | PA; QL (1 per 42 days) |
| selenium sulfide topical lotion 2.5 % | 1 | |
| selenium sulfide topical shampoo 2.25 %, 2.3 % | 1 | |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML (risankizumab-rzaa) | 2 | PA; QL (1 per 84 days) |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML (risanki-zumab-rzaa) | 2 | PA; QL (1 per 84 days) |
| SOTYKTU ORAL TABLET 6 MG (deucravacitinib) | 4 | PA; QL (30 per 23 days) |
| SPEVIGO INTRAVENOUS SOLUTION 60 MG/ML (spesolim-ab-sbzo) | 4 | PA |
| STELARA INTRAVENOUS SOLUTION 130 MG/26 ML (ustekinumab) | 4 | PA |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML (ustekinumab) | 2 | PA; QL (1 per 84 days) |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML (ustekinumab) | 2 | PA; QL (1 per 84 days) |
| STELARA SUBCUTANEOUS SYRINGE 90 MG/ML (ustekinumab) | 2 | PA; QL (1 per 56 days) |
| sulfacetamide sodium topical cleanser 10 % | 1 | |
| sulfacetamide sodium topical cleanser, gel 10 % | 1 | |
| sulfacetamide sodium topical shampoo 10 %, 9.8 % | 1 | |
| TALTZ AUTOINJECTOR (2 PACK) SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML (ixekizumab) | 2 | PA; QL (1 per 21 days) |
| TALTZ AUTOINJECTOR (3 PACK) SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML (ixekizumab) | 2 | PA; QL (1 per 21 days) |
| TALTZ AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML (ixekizumab) | 2 | PA; QL (1 per 21 days) |
| TALTZ SYRINGE SUBCUTANEOUS SYRINGE 20 MG/0.25 ML, 40 MG/0.5 ML, 80 MG/ML (ixekizumab) | 2 | PA; QL (1 per 21 days) |
| TREMFYA INTRAVENOUS SOLUTION 200 MG/20 ML (10 MG/ML) (guselkumab) | 2 | PA |
| TREMFYA PEN INDUCTION PK-CROHN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML (guselkumab) | 2 | PA; QL (1 per 21 days) |
| TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 100 MG/ML (guselkumab) | 2 | PA; QL (1 per 42 days) |
| TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML (guselkumab) | 2 | PA; QL (1 per 21 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--------------------------|
| TREMFYA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML (guselkumab) | 2 | PA; QL (1 per 56 days) |
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML (gusel-kumab) | 2 | PA; QL (1 per 56 days) |
| TREMFYA SUBCUTANEOUS SYRINGE 200 MG/2 ML (guselkumab) | 2 | PA; QL (1 per 21 days) |
| USTEKINUMAB-TTWE INTRAVENOUS SOLUTION 130 MG/26 ML | 2 | PA |
| USTEKINUMAB-TTWE SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | 2 | PA; QL (1 per 63 days) |
| USTEKINUMAB-TTWE SUBCUTANEOUS SYRINGE 90 MG/ML | 2 | PA; QL (1 per 42 days) |
| YESINTEK INTRAVENOUS SOLUTION 130 MG/26 ML (ustekinumab-kfce) | 2 | PA |
| YESINTEK SUBCUTANEOUS SOLUTION 45 MG/0.5 ML (ustekinumab-kfce) | 2 | PA; QL (1 per 63 days) |
| YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML (ustekinumab-kfce) | 2 | PA; QL (1 per 63 days) |
| YESINTEK SUBCUTANEOUS SYRINGE 90 MG/ML (ustekinumab-kfce) | 2 | PA; QL (1 per 42 days) |
| BURN THERAPY | | |
| silver sulfadiazine topical cream 1 % | 1 | |
| ssd topical cream 1 % | 1 | |
| MISCELLANEOUS DERMATOLOGICALS | | |
| ADBRY SUBCUTANEOUS AUTO-INJECTOR 300 MG/2 ML (tralokinumab-ldrm) | 4 | PA; QL (2 per 21 days) |
| ADBRY SUBCUTANEOUS SYRINGE 150 MG/ML (tralokinumab-ldrm) | 4 | PA; QL (2 per 21 days) |
| CIBINQO ORAL TABLET 100 MG, 200 MG, 50 MG (abrocitinib) | 4 | PA; QL (30 per 23 days) |
| diclofenac sodium topical gel 3 % | 1 | PA; QL (100 per 21 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML (dupilumab) | 4 | PA; QL (2 per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML (dupilumab) | 4 | PA; QL (2 per 28 days) |
| EBGLYSS PEN SUBCUTANEOUS PEN INJECTOR 250 MG/2 ML (lebrikizumab-lbkz) | 4 | PA; QL (4 per 21 days) |
| EBGLYSS SYRINGE SUBCUTANEOUS SYRINGE 250 MG/2 ML (lebrikizumab-lbkz) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--------------------------|
| EUCRISA TOPICAL OINTMENT 2 % (crisaborole) | 2 | ST; QL (120 per 23 days) |
| fluorouracil topical cream 5 % | 1 | |
| fluorouracil topical solution 2 %, 5 % | 1 | |
| imiquimod topical cream in metered-dose pump 3.75 % | 1 | |
| imiquimod topical cream in packet 3.75 %, 5 % | 1 | |
| methoxsalen oral capsule,liqd-filled,rapid rel 10 mg | 1 | |
| methyl salicylate oil | 1 | |
| methyl salicylate topical liquid | 1 | |
| pimecrolimus topical cream 1 % | 1 | ST; QL (120 per 23 days) |
| podofilox topical gel 0.5 % | 1 | ST; QL (7 per 30 days) |
| podofilox topical solution 0.5 % | 1 | |
| REGRANEX TOPICAL GEL 0.01 % (becaplermin) | 2 | QL (15 per 30 days) |
| tacrolimus topical ointment 0.03 %, 0.1 % | 1 | ST; QL (120 per 23 days) |
| VALCHLOR TOPICAL GEL 0.016 % (mechlorethamine hcl) | 4 | PA |
| wintergreen oil oil | 1 | |
| THERAPY FOR ACNE | | |
| accutane oral capsule 10 mg, 20 mg, 30 mg, 40 mg | 1 | |
| adapalene topical cream 0.1 % | 1 | |
| adapalene topical gel 0.3 % | 1 | |
| adapalene topical gel with pump 0.3 % | 1 | |
| adapalene topical solution 0.1 % | 1 | |
| adapalene topical swab 0.1 % | 1 | ST |
| adapalene-benzoyl peroxide topical gel with pump 0.1-2.5 %, 0.3-2.5 % | 1 | |
| amnesteem oral capsule 10 mg, 20 mg, 30 mg, 40 mg | 1 | |
| avar topical cleanser 10-5 % (w/w) | 1 | ST |
| azelaic acid topical gel 15 % | 1 | |
| benzepro topical towelette 6 % | 1 | |
| benzoyl peroxide topical cleanser 7 % | 1 | |
| benzoyl peroxide topical foam 9.8 % | 1 | |
| bp 10-1 topical cleanser 10-1 % | 1 | ST |
| brimonidine topical gel with pump 0.33 % | 1 | PA |
| claravis oral capsule 10 mg, 20 mg, 30 mg, 40 mg | 1 | |
| clindacin etz topical swab 1 % | 1 | |
| clindacin p topical swab 1 % PA - Prior Authorization • OL - Quantity Limit • ST - Step Therapy • OTC - Over the | 1 | |

PA - Prior Authorization • QL - Quantity Limit • ST - Step Therapy • OTC – Over the counter • ACA - No cost-share preventive medications

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--------------------------|
| clindacin topical foam 1 % | 1 | ST; QL (100 per 23 days) |
| clindamycin phosphate topical foam 1 % | 1 | ST; QL (100 per 23 days) |
| clindamycin phosphate topical gel 1 % | 1 | QL (120 per 23 days) |
| clindamycin phosphate topical gel, once daily 1 % | 1 | ST; QL (150 per 23 days) |
| clindamycin phosphate topical lotion 1 % | 1 | QL (120 per 23 days) |
| clindamycin phosphate topical solution 1 % | 1 | QL (120 per 23 days) |
| clindamycin phosphate topical swab 1 % | 1 | |
| clindamycin-benzoyl peroxide topical gel 1-5 %, 1.2 %(1 % base) -5 % | 1 | |
| clindamycin-benzoyl peroxide topical gel with pump 1-5 %, 1.2 %(1 % base) -3.75 %, 1.2-2.5 % | 1 | |
| clindamycin-tretinoin topical gel 1.2-0.025 % | 1 | |
| dapsone topical gel 5 % | 1 | |
| dapsone topical gel with pump 7.5 % | 1 | |
| ery pads topical swab 2 % | 1 | |
| erygel topical gel 2 % | 1 | |
| erythromycin with ethanol topical gel 2 % | 1 | |
| erythromycin with ethanol topical solution 2 % | 1 | |
| erythromycin-benzoyl peroxide topical gel 3-5 % | 1 | |
| isotretinoin oral capsule 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg | 1 | |
| ivermectin topical cream 1 % | 1 | QL (45 per 23 days) |
| metronidazole topical cream 0.75 % | 1 | |
| metronidazole topical gel 0.75 %, 1 % | 1 | |
| metronidazole topical gel with pump 1 % | 1 | |
| metronidazole topical lotion 0.75 % | 1 | |
| neuac topical gel 1.2 %(1 % base) -5 % | 1 | |
| rosadan topical cream 0.75 % | 1 | |
| rosadan topical gel 0.75 % | 1 | |
| rosula cleansing cloths topical pads, medicated 10-5 % | 1 | |
| sss 10-5 topical cream 10-5 % (w/w) | 1 | |
| sss 10-5 topical foam 10-5 % | 1 | ST |
| sulfacetamide sodium-sulfur topical cleanser 10-2 %, 10-5 % (w/w), 9-4.5 %, 9.8-4.8 % | 1 | ST |
| sulfacetamide sodium-sulfur topical cleanser 9-4 % | 1 | |
| sulfacetamide sodium-sulfur topical cream 10-2 %, 9.8-4.8 % | 1 | ST |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| sulfacetamide sodium-sulfur topical cream 10-5 % (w/w) | 1 | |
| sulfacetamide sodium-sulfur topical lotion 10-5 % (w/v), 10-5 % (w/w), 9.8-4.8 % | 1 | ST |
| sulfacetamide sodium-sulfur topical pads, medicated 10-4 % | 1 | |
| sulfacetamide sodium-sulfur topical suspension 10-5 %, 8-4 % | 1 | ST |
| sulfacetamide-sulfur 9-4% clsr | 1 | ST |
| sulfacleanse 8-4 topical suspension 8-4 % | 1 | ST |
| tazarotene topical cream 0.05 %, 0.1 % | 1 | PA |
| tazarotene topical gel 0.05 %, 0.1 % | 1 | PA |
| tretinoin microspheres topical gel 0.04 %, 0.1 % | 1 | |
| tretinoin microspheres topical gel with pump 0.04 %, 0.08 %, 0.1 % | 1 | |
| tretinoin topical cream 0.025 %, 0.05 %, 0.1 % | 1 | |
| tretinoin topical gel 0.01 %, 0.025 %, 0.05 % | 1 | |
| zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg | 1 | |
| TOPICAL ANESTHETICS | | |
| dermacinrx lidocan topical adhesive patch,medicated 5 % | 1 | PA |
| lidocaine hcl laryngotracheal solution 4 % | 1 | |
| lidocaine hcl mucous membrane solution 4 % (40 mg/ml) | 1 | |
| lidocaine hcl-hydrocortison ac topical cream 3-0.5 % | 1 | |
| lidocaine topical adhesive patch,medicated 5 % | 1 | PA |
| lidocaine topical ointment 5 % | 1 | QL (50 per 23 days) |
| lidocaine viscous mucous membrane solution 2 % | 1 | |
| lidocaine-prilocaine topical cream 2.5-2.5 % | 1 | QL (30 per 23 days) |
| lidocaine-prilocaine topical kit 2.5-2.5 % | 1 | |
| lidocan iii topical adhesive patch,medicated 5 % | 1 | PA |
| lidocan iv topical adhesive patch,medicated 5 % | 1 | PA |
| lidocan v topical adhesive patch,medicated 5 % | 1 | PA |
| lidocort topical cream 3-0.5 % | 1 | |
| ZTLIDO TOPICAL ADHESIVE PATCH, MEDICATED 1.8 % (lidocaine) | 2 | PA |
| TOPICAL ANTIBACTERIALS | | |
| gentamicin topical cream 0.1 % | 1 | QL (60 per 30 days) |
| gentamicin topical ointment 0.1 % | 1 | QL (60 per 30 days) |
| lugols topical solution 5-10 % | 1 | |
| mafenide acetate topical packet 50 gram | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--------------------------|
| mupirocin calcium topical cream 2 % | 1 | ST; QL (30 per 30 days) |
| mupirocin topical ointment 2 % | 1 | QL (44 per 30 days) |
| strong iodine topical solution 5-10 % | 1 | |
| sulfacetamide sodium (acne) topical suspension 10 % | 1 | |
| SULFAMYLON TOPICAL CREAM 85 MG/G (mafenide acetate) | 2 | |
| TOPICAL ANTIFUNGALS | | |
| ciclodan topical cream 0.77 % | 1 | QL (90 per 21 days) |
| ciclodan topical solution 8 % | 1 | |
| ciclopirox topical cream 0.77 % | 1 | QL (90 per 21 days) |
| ciclopirox topical gel 0.77 % | 1 | QL (100 per 21 days) |
| ciclopirox topical shampoo 1 % | 1 | QL (120 per 21 days) |
| ciclopirox topical solution 8 % | 1 | |
| ciclopirox topical suspension 0.77 % | 1 | QL (60 per 21 days) |
| ciclopirox-ure-camph-menth-euc topical solution 8 % | 1 | |
| clotrimazole-betamethasone topical cream 1-0.05 % | 1 | QL (90 per 21 days) |
| clotrimazole-betamethasone topical lotion 1-0.05 % | 1 | QL (60 per 21 days) |
| econazole nitrate topical cream 1 % | 1 | QL (85 per 21 days) |
| ketoconazole topical cream 2 % | 1 | QL (60 per 21 days) |
| ketoconazole topical foam 2 % | 1 | ST; QL (100 per 21 days) |
| ketoconazole topical shampoo 2 % | 1 | QL (120 per 21 days) |
| ketodan kit topical combo pack 2 % | 1 | ST |
| ketodan topical foam 2 % | 1 | ST; QL (100 per 21 days) |
| klayesta topical powder 100,000 unit/gram | 1 | QL (180 per 30 days) |
| naftifine topical cream 1 % | 1 | QL (90 per 21 days) |
| naftifine topical cream 2 % | 1 | QL (60 per 21 days) |
| naftifine topical gel 2 % | 1 | QL (60 per 21 days) |
| nyamyc topical powder 100,000 unit/gram | 1 | QL (180 per 30 days) |
| nystatin topical cream 100,000 unit/gram | 1 | QL (60 per 21 days) |
| nystatin topical ointment 100,000 unit/gram | 1 | QL (60 per 21 days) |
| nystatin topical powder 100,000 unit/gram | 1 | QL (180 per 30 days) |
| nystatin-triamcinolone topical cream 100,000-0.1 unit/g-% | 1 | QL (60 per 21 days) |
| nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-% | 1 | QL (60 per 21 days) |
| nystop topical powder 100,000 unit/gram | 1 | QL (180 per 30 days) |
| oxiconazole topical cream 1 % | 1 | QL (90 per 21 days) |

| tavaborole topical solution with applicator 5 % TOPICAL ANTIVIRALS acyclovir topical cream 5 % | Drug Name | Drug Tier | Requirements / Limits |
|--|--|-----------|--------------------------|
| acyclovir topical cream 5 % 1 PA; QL (5 per 30 days) acyclovir topical ointment 5 % 1 PA; QL (30 per 30 days) penciclovir topical cream 1 % 1 TOPICAL CORTICOSTEROIDS alclometasone topical cream 0.05 % 1 alclometasone topical ointment 0.05 % 1 amcinonide topical ointment 0.01 % 1 ST amcinonide topical ointment 0.1 % 1 ST beser topical lotion 0.05 % 1 ST bestamethasone dipropionate topical cream 0.05 % 1 betamethasone dipropionate topical ointment 0.05 % 1 betamethasone dipropionate topical colina 0.05 % 1 betamethasone dipropionate topical ointment 0.05 % 1 betamethasone dipropionate topical ointment 0.05 % 1 betamethasone valerate topical ointment 0.05 % 1 betamethasone valerate topical ointment 0.05 % 1 betamethasone valerate topical foam 0.12 % 1 betamethasone valerate topical ointment 0.1 % 1 betamethasone valerate topical ointment 0.1 % 1 betamethasone valerate topical ointment 0.1 % 1 betamethasone, augmented topical cream 0.05 % 1 betamethasone, augmented topical cream 0.05 % 1 betamethasone, augmented topical ointment 0.05 % 1 clobetasol scalp solution 0.05 % 1 clobetasol topical polution 0.05 % 1 clobetasol topical polution 0.05 % 1 Clobetasol topical foam 0.05 % 1 Clobetasol topical foam 0.05 % 1 Clobetasol topical foam 0.05 % 1 Clobetasol topical spray, non-aerosol 0.05 % 1 Clobetasol topical spray, non-aerosol 0.05 % 1 Clobetasol topical spray, non-aerosol 0.05 % 1 Clobetasol-emollient topical foam 0.05 % 1 Clobetasol-emollient | tavaborole topical solution with applicator 5 % | 1 | ST |
| acyclovir topical ointment 5 % 1 PA; QL (30 per 30 days) penciclovir topical cream 1 % 1 TOPICAL CORTICOSTEROIDS alclometasone topical cream 0.05 % 1 ancinonide topical ointment 0.05 % 1 smarcinonide topical cream 0.1 % 1 ST amcinonide topical cream 0.1 % 1 ST beser topical toin 0.05 % 1 ST betamethasone dipropionate topical cream 0.05 % 1 betamethasone dipropionate topical ointment 0.05 % 1 betamethasone dipropionate topical ointment 0.05 % 1 betamethasone dipropionate topical ointment 0.05 % 1 betamethasone valerate topical ointment 0.05 % 1 betamethasone valerate topical ointment 0.05 % 1 betamethasone valerate topical foam 0.12 % 1 betamethasone valerate topical ointment 0.1 % 1 betamethasone valerate topical ointment 0.1 % 1 betamethasone, augmented topical ointment 0.1 % 1 betamethasone, augmented topical ointment 0.05 % 1 betamethasone oil propionate topical ointment 0.05 % 1 betamethasone oil propionate topical ointment 0.05 % 1 clobetasol topical cream 0.05 % 1 clobetasol topical foam 0.05 % 1 clobetasol topical foar 0.05 % 1 clobetasol topical foar 0.05 % 1 clobetasol topical foar 0.05 % 1 clobetasol topical shampoo 0.05 % 1 clobetasol-emollient topical foam 0.05 % 1 clobeta | TOPICAL ANTIVIRALS | | |
| penciclovir topical cream 1 % 1 TOPICAL CORTICOSTEROIDS alclometasone topical cream 0.05 % 1 ancinonide topical cream 0.105 % 1 amcinonide topical cintment 0.05 % 1 amcinonide topical cintment 0.15 % 1 bestamethasone dipropionate topical cream 0.05 % 1 betamethasone dipropionate topical cream 0.05 % 1 betamethasone dipropionate topical lotion 0.05 % 1 betamethasone valerate topical cream 0.1 % 1 betamethasone valerate topical cream 0.1 % 1 betamethasone valerate topical foam 0.12 % 1 betamethasone valerate topical foam 0.12 % 1 betamethasone valerate topical lotion 0.1 % 1 betamethasone valerate topical ointment 0.1 % 1 betamethasone valerate topical lotion 0.1 % 1 betamethasone, augmented topical ointment 0.1 % 1 betamethasone, augmented topical ointment 0.05 % 1 betamethasone oil propical cream 0.05 % 1 clobetasol topical foam 0.05 % 1 clobetasol topical foam 0.05 % 1 clobetasol topical solution 0.05 % 1 clobetasol topical foam 0.05 % 1 clobetasol topical solution 0. | acyclovir topical cream 5 % | 1 | PA; QL (5 per 30 days) |
| alclometasone topical cream 0.05 % alclometasone topical cream 0.15 % alclometasone topical cream 0.1 % amcinonide topical cream 0.1 % amcinonide topical cream 0.1 % amcinonide topical cream 0.1 % betamethasone dipropionate topical cream 0.05 % betamethasone dipropionate topical cream 0.05 % betamethasone dipropionate topical cream 0.05 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical cream 0.05 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical ointment 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % clobetasol topical cream 0.05 % clobetasol topical foam 0.05 % clobetasol topical foam 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical ointment 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical shampoo 0.05 % clobetasol-emollient topical foam 0.05 % clobeta | acyclovir topical ointment 5 % | 1 | PA; QL (30 per 30 days) |
| alclometasone topical cream 0.05 % alclometasone topical ointment 0.05 % amcinonide topical cintment 0.1 % amcinonide topical cintment 0.1 % beser topical lotion 0.05 % betamethasone dipropionate topical cream 0.05 % betamethasone dipropionate topical lotion 0.05 % betamethasone dipropionate topical lotion 0.05 % betamethasone valerate topical cream 0.12 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical cream 0.05 % betamethasone valerate topical ointment 0.05 % betamethasone valerate topical ointment 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % clobetasol topical foam 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical ointment 0.05 % clobetasol topical shampoo 0.05 % clobetasol-emollient topical foam 0.05 % clobetasol-emollient top | penciclovir topical cream 1 % | 1 | |
| alclometasone topical ointment 0.05 % amcinonide topical cream 0.1 % amcinonide topical ointment 0.1 % beser topical lotion 0.05 % betamethasone dipropionate topical lotion 0.05 % betamethasone dipropionate topical lotion 0.05 % betamethasone dipropionate topical lotion 0.05 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical lotion 0.05 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % 1 QL (100 per 23 days) clobetasol topical foam 0.05 % 1 ST, QL (100 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical ointment 0.05 % 1 ST, QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 ST, QL (120 per 23 days) clobetasol topical ointment 0.05 % 1 ST, QL (120 per 23 days) clobetasol topical ointment 0.05 % 1 ST, QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST, QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST, QL (120 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST, QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST, QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST, QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST, QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST, QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST, QL (100 per 23 days) | TOPICAL CORTICOSTEROIDS | | |
| alclometasone topical ointment 0.05 % amcinonide topical cream 0.1 % amcinonide topical cream 0.1 % beser topical lotion 0.05 % betamethasone dipropionate topical cream 0.05 % betamethasone dipropionate topical ointment 0.05 % betamethasone dipropionate topical ointment 0.05 % betamethasone dipropionate topical ointment 0.05 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical ointment 0.05 % betamethasone valerate topical ointment 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical ointment 0.05 % betamethasone, augmented topical ointment 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % clobetasol topical foam 0.05 % clobetasol topical foam 0.05 % clobetasol topical ointment 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical shampoo 0.05 % clobetasol-emollient topical cream 0.05 % clobetasol-emollient topical foam 0.05 % clobetasol-emo | alclometasone topical cream 0.05 % | 1 | |
| amcinonide topical ointment 0.1 % beser topical lotion 0.05 % betamethasone dipropionate topical cream 0.05 % betamethasone dipropionate topical lotion 0.05 % betamethasone dipropionate topical ointment 0.05 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical form 0.12 % betamethasone valerate topical form 0.12 % betamethasone valerate topical lotion 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % clobetasol topical form 0.05 % clobetasol topical form 0.05 % clobetasol topical gel 0.05 % clobetasol topical gel 0.05 % clobetasol topical form 0.05 % clobetasol topical solution 0.05 % clobetasol topical ointment 0.05 % clobetasol topical ointment 0.05 % clobetasol topical shampoo 0.05 % clobetasol-topical shampoo 0.05 % clobetasol-topical shampoo 0.05 % clobetasol-topical shampoo 0.05 % clobetasol-topical shampoo 0.05 % clobetasol-emollient topical cream 0.05 % clobetasol-emollient topical form 0.05 % clobetasol-emollient topical shampoo 0.05 % clobetasol-topical shampoo | | 1 | |
| beser topical lotion 0.05 % 1 ST betamethasone dipropionate topical cream 0.05 % 1 betamethasone dipropionate topical lotion 0.05 % 1 betamethasone dipropionate topical ointment 0.05 % 1 betamethasone valerate topical cream 0.1 % 1 betamethasone valerate topical foam 0.12 % 1 betamethasone valerate topical lotion 0.1 % 1 betamethasone valerate topical lotion 0.1 % 1 betamethasone valerate topical ointment 0.1 % 1 betamethasone, augmented topical cream 0.05 % 1 betamethasone, augmented topical gel 0.05 % 1 betamethasone, augmented topical lotion 0.05 % 1 betamethasone, augmented topical lotion 0.05 % 1 betamethasone, augmented topical ointment 0.05 % 1 betamethasone, augmented topical ointment 0.05 % 1 clobetasol topical reram 0.05 % 1 clobetasol topical foam 0.05 % 1 clobetasol topical foam 0.05 % 1 clobetasol topical foam 0.05 % 1 clobetasol topical gel 0.05 % 1 clobetasol topical solution 0.05 % 1 clobetasol topical solution 0.05 % 1 clobetasol topical solution 0.05 % 1 clobetasol topical shampoo 0.05 % 1 clobetasol-emollient topical cream 0.05 % 1 clobetasol-emollient topical cream 0.05 % 1 clobetasol-emollient topical shampoo 0.05 % 1 clobetasol-emollient topical cream 0.05 % 1 clobetasol-emollient topical shampoo 0.05 % 1 clobetasol-emollient topical cream 0.05 % 1 clobetasol- | amcinonide topical cream 0.1 % | 1 | ST |
| betamethasone dipropionate topical cream 0.05 % betamethasone dipropionate topical lotion 0.05 % betamethasone dipropionate topical ointment 0.05 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical lotion 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % clobetasol topical foam 0.05 % clobetasol topical foam 0.05 % clobetasol topical foam 0.05 % clobetasol topical gel 0.05 % clobetasol topical gel 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical shampoo 0.05 % clobetasol topical spray,non-aerosol 0.05 % clobetasol-emollient topical cream 0.05 % clobetasol-emollient topical cream 0.05 % clobetasol-emollient topical foam 0.05 % | amcinonide topical ointment 0.1 % | 1 | ST |
| betamethasone dipropionale topical lotion 0.05 % betamethasone valerate topical cream 0.1 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical lotion 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical ointment 0.05 % 1 betamethasone, augmented topical ointment 0.05 % 1 betamethasone, augmented topical ointment 0.05 % 1 clobetasol scalp solution 0.05 % 1 QL (100 per 23 days) clobetasol topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) | beser topical lotion 0.05 % | 1 | ST |
| betamethasone dipropionate topical ointment 0.05 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical lotion 0.1 % betamethasone valerate topical lotion 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % 1 QL (100 per 23 days) clobetasol topical cream 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 ST; QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) | betamethasone dipropionate topical cream 0.05 % | 1 | |
| betamethasone valerate topical cream 0.1 % betamethasone valerate topical foam 0.12 % betamethasone valerate topical lotion 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % 1 QL (100 per 23 days) clobetasol topical cream 0.05 % 1 QL (120 per 23 days) clobetasol topical foam 0.05 % 1 QL (120 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) | betamethasone dipropionate topical lotion 0.05 % | 1 | |
| betamethasone valerate topical foam 0.12 % betamethasone valerate topical lotion 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % lobetamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % l QL (100 per 23 days) clobetasol topical cream 0.05 % l ST; QL (100 per 23 days) clobetasol topical foam 0.05 % l ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % l ST; QL (120 per 23 days) clobetasol topical ointment 0.05 % l ST; QL (120 per 23 days) clobetasol topical ointment 0.05 % l ST; QL (120 per 23 days) clobetasol topical shampoo 0.05 % l ST; QL (236 per 23 days) clobetasol-emollient topical cream 0.05 % l ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (236 per 23 days) | betamethasone dipropionate topical ointment 0.05 % | 1 | |
| betamethasone valerate topical lotion 0.1 % betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical intment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % 1 QL (120 per 23 days) clobetasol topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical ointment 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical ointment 0.05 % 1 ST; QL (125 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) | betamethasone valerate topical cream 0.1 % | 1 | |
| betamethasone valerate topical ointment 0.1 % betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % 1 QL (100 per 23 days) clobetasol topical cream 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical gel 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 ST; QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) | betamethasone valerate topical foam 0.12 % | 1 | ST |
| betamethasone, augmented topical cream 0.05 % betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical lotion 0.05 % l QL (100 per 23 days) clobetasol scalp solution 0.05 % l QL (120 per 23 days) clobetasol topical cream 0.05 % l ST; QL (100 per 23 days) clobetasol topical gel 0.05 % l QL (120 per 23 days) clobetasol topical lotion 0.05 % l ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % l ST; QL (120 per 23 days) clobetasol topical ointment 0.05 % l ST; QL (120 per 23 days) clobetasol topical shampoo 0.05 % l ST; QL (120 per 23 days) clobetasol topical shampoo 0.05 % l ST; QL (236 per 23 days) clobetasol-emollient topical cream 0.05 % l ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % l ST; QL (120 per 23 days) | betamethasone valerate topical lotion 0.1 % | 1 | |
| betamethasone, augmented topical gel 0.05 % betamethasone, augmented topical lotion 0.05 % lotobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % clobetasol topical foam 0.05 % lotobetasol topical gel 0.05 % lotobetasol topical lotion 0.05 % lotobetasol topical lotion 0.05 % lotobetasol topical ointment 0.05 % lotobetasol topical ointment 0.05 % lotobetasol topical ointment 0.05 % lotobetasol topical shampoo 0.05 % lotobetasol topical shampoo 0.05 % lotobetasol topical spray,non-aerosol 0.05 % lotobetasol topical spray,non-aerosol 0.05 % lotobetasol-emollient topical cream 0.05 % lotobetasol-emollient topical foam 0.05 % | betamethasone valerate topical ointment 0.1 % | 1 | |
| betamethasone, augmented topical lotion 0.05 % betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % 1 QL (100 per 23 days) clobetasol topical cream 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical foam 0.05 % 1 QL (120 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical ointment 0.05 % 1 ST; QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) | betamethasone, augmented topical cream 0.05 % | 1 | |
| betamethasone, augmented topical ointment 0.05 % clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % 1 QL (120 per 23 days) clobetasol topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical gel 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical lotion 0.05 % 1 QL (120 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) | betamethasone, augmented topical gel 0.05 % | 1 | |
| clobetasol scalp solution 0.05 % clobetasol topical cream 0.05 % clobetasol topical foam 0.05 % clobetasol topical foam 0.05 % clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobatasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) | betamethasone, augmented topical lotion 0.05 % | 1 | |
| clobetasol topical cream 0.05 % clobetasol topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) | betamethasone, augmented topical ointment 0.05 % | 1 | |
| clobetasol topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol topical gel 0.05 % 1 QL (120 per 23 days) 1 ST; QL (118 per 23 days) clobetasol topical lotion 0.05 % 1 QL (120 per 23 days) 1 QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) clobatasol-emollient topical foam 0.05 % 1 ST; QL (236 per 23 days) | clobetasol scalp solution 0.05 % | 1 | QL (100 per 23 days) |
| clobetasol topical gel 0.05 % 1 QL (120 per 23 days) clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 QL (120 per 23 days) clobetasol-emollient topical cream 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) 1 ST; QL (236 per 23 days) | clobetasol topical cream 0.05 % | 1 | QL (120 per 23 days) |
| clobetasol topical lotion 0.05 % 1 ST; QL (118 per 23 days) clobetasol topical ointment 0.05 % 1 QL (120 per 23 days) clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clodan topical cream 0.05 % 1 ST; QL (236 per 23 days) | clobetasol topical foam 0.05 % | 1 | ST; QL (100 per 23 days) |
| clobetasol topical ointment 0.05 % clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) desonide topical cream 0.05 % 1 | clobetasol topical gel 0.05 % | 1 | QL (120 per 23 days) |
| clobetasol topical shampoo 0.05 % 1 ST; QL (236 per 23 days) clobetasol topical spray,non-aerosol 0.05 % 1 ST; QL (125 per 23 days) clobetasol-emollient topical cream 0.05 % 1 QL (120 per 23 days) clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) desonide topical cream 0.05 % 1 | clobetasol topical lotion 0.05 % | 1 | ST; QL (118 per 23 days) |
| clobetasol topical spray,non-aerosol 0.05 % clobetasol-emollient topical cream 0.05 % 1 QL (125 per 23 days) Clobetasol-emollient topical foam 0.05 % 1 ST; QL (120 per 23 days) ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) desonide topical cream 0.05 % 1 | clobetasol topical ointment 0.05 % | 1 | QL (120 per 23 days) |
| clobetasol-emollient topical cream 0.05 % clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) desonide topical cream 0.05 % 1 | clobetasol topical shampoo 0.05 % | 1 | ST; QL (236 per 23 days) |
| clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) desonide topical cream 0.05 % | clobetasol topical spray,non-aerosol 0.05 % | 1 | ST; QL (125 per 23 days) |
| clobetasol-emollient topical foam 0.05 % 1 ST; QL (100 per 23 days) clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) desonide topical cream 0.05 % | | 1 | |
| clodan topical shampoo 0.05 % 1 ST; QL (236 per 23 days) desonide topical cream 0.05 % 1 | | 1 | |
| desonide topical cream 0.05 % 1 | | 1 | |
| | | 1 | |
| WODOWWO VOLVOU EU V.VO /V | desonide topical gel 0.05 % | 1 | ST |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|--------------------------|
| desonide topical lotion 0.05 % | 1 | ST |
| desonide topical ointment 0.05 % | 1 | |
| desoximetasone topical cream 0.05 %, 0.25 % | 1 | ST |
| desoximetasone topical gel 0.05 % | 1 | ST |
| desoximetasone topical ointment 0.05 %, 0.25 % | 1 | ST |
| desoximetasone topical spray,non-aerosol 0.25 % | 1 | ST |
| fluocinolone and shower cap scalp oil 0.01 % | 1 | |
| fluocinolone topical cream 0.01 %, 0.025 % | 1 | |
| fluocinolone topical oil 0.01 % | 1 | |
| fluocinolone topical ointment 0.025 % | 1 | |
| fluocinolone topical solution 0.01 % | 1 | |
| fluocinonide topical cream 0.05 % | 1 | QL (120 per 23 days) |
| fluocinonide topical cream 0.1 % | 1 | ST; QL (120 per 23 days) |
| fluocinonide topical gel 0.05 % | 1 | QL (120 per 23 days) |
| fluocinonide topical ointment 0.05 % | 1 | QL (120 per 23 days) |
| fluocinonide topical solution 0.05 % | 1 | QL (120 per 23 days) |
| fluocinonide-e topical cream 0.05 % | 1 | QL (120 per 23 days) |
| fluticasone propionate topical cream 0.05 % | 1 | |
| fluticasone propionate topical lotion 0.05 % | 1 | ST |
| fluticasone propionate topical ointment 0.005 % | 1 | |
| halobetasol propionate topical cream 0.05 % | 1 | |
| halobetasol propionate topical foam 0.05 % | 1 | ST |
| halobetasol propionate topical ointment 0.05 % | 1 | |
| hydrocortisone butyrate topical cream 0.1 % | 1 | QL (120 per 23 days) |
| hydrocortisone butyrate topical lotion 0.1 % | 1 | ST; QL (118 per 23 days) |
| hydrocortisone butyrate topical ointment 0.1 % | 1 | ST; QL (120 per 21 days) |
| hydrocortisone butyrate topical solution 0.1 % | 1 | ST; QL (120 per 23 days) |
| hydrocortisone topical cream 2.5 % | 1 | |
| hydrocortisone topical lotion 2 %, 2.5 % | 1 | |
| hydrocortisone topical ointment 2.5 % | 1 | |
| hydrocortisone topical solution 2.5 % | 1 | |
| hydrocortisone valerate topical cream 0.2 % | 1 | |
| hydrocortisone valerate topical ointment 0.2 % | 1 | |
| mometasone topical cream 0.1 % | 1 | |
| mometasone topical ointment 0.1 % | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|---|
| mometasone topical solution 0.1 % | 1 | |
| prednicarbate topical cream 0.1 % | 1 | |
| prednicarbate topical ointment 0.1 % | 1 | |
| scalacort topical lotion 2 % | 1 | |
| tovet emollient topical foam 0.05 % | 1 | ST; QL (100 per 23 days) |
| triamcinolone acetonide topical aerosol 0.147 mg/gram | 1 | ST; QL (126 per 23 days) |
| triamcinolone acetonide topical cream 0.025 %, 0.1 %, 0.5 % | 1 | |
| triamcinolone acetonide topical lotion 0.025 %, 0.1 % | 1 | |
| triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 % | 1 | |
| triamcinolone acetonide topical ointment 0.05 % | 1 | ST |
| triderm topical cream 0.5 % | 1 | ST |
| TOPICAL ENZYMES | | |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM (collagenase clostridium histolyticum) | 2 | QL (180 per 30 days) |
| TOPICAL SCABICIDES / PEDICULICIDES | | |
| crotan topical lotion 10 % | 1 | |
| malathion topical lotion 0.5 % | 1 | |
| permethrin topical cream 5 % | 1 | |
| pruradik topical lotion 10 % | 1 | |
| spinosad topical suspension 0.9 % | 1 | |
| DIAGNOSTICS & MISCELLANEOUS AGENTS | | |
| ANOREXIANTS | | |
| benzphetamine oral tablet 50 mg | 1 | PA; QL (90 per 30 days) |
| diethylpropion oral tablet 25 mg | 1 | PA; QL (90 per 30 days) |
| diethylpropion oral tablet extended release 75 mg | 1 | PA; QL (30 per 30 days) |
| phendimetrazine tartrate oral capsule, extended release 105 mg | 1 | PA; QL (30 per 30 days) |
| phendimetrazine tartrate oral tablet 35 mg | 1 | PA; QL (180 per 30 days) |
| phentermine oral capsule 15 mg, 30 mg, 37.5 mg | 1 | PA; QL (30 per 30 days) |
| phentermine oral tablet 37.5 mg | 1 | PA; QL (30 per 30 days) |
| phentermine-topiramate oral capsule, er multiphase 24 hr 11.25-69 mg, 15-92 mg, 3.75-23 mg, 7.5-46 mg | 1 | PA; QL (30 per 30 days) |
| WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML (semaglutide) | 2 | PA; QL (8 pens per 365 days; 1 GLP-1 per 21 days) |
| WEGOVY SUBCUTANEOUS PEN INJECTOR 1.7 MG/0.75 ML, 2.4 MG/0.75 ML (semaglutide) | 2 | PA; QL (4 pens per 21 days; 1 GLP-1 per 21 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--|
| ZEPBOUND SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML (tirzepatide) | 2 | PA; QL (4 pens per 21 days; 1 GLP-1 per 21 days) |
| ZEPBOUND SUBCUTANEOUS SOLUTION 10 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML (tirzepatide) | 2 | PA; QL (4 vials per 21 days; 1 GLP-1 per 21 days) |
| IRRIGATING SOLUTIONS | | |
| lactated ringers irrigation solution | 1 | |
| neomycin-polymyxin b gu irrigation solution 40 mg-200,000 unit/ml | 1 | |
| ringer's irrigation solution | 1 | |
| MISCELLANEOUS AGENTS | | |
| acamprosate oral tablet,delayed release (dr/ec) 333 mg | 1 | |
| acetic acid irrigation solution 0.25 % | 1 | |
| anagrelide oral capsule 0.5 mg, 1 mg | 1 | |
| caffeine citrate oral solution 60 mg/3 ml (20 mg/ml) | 1 | |
| CARBAGLU ORAL TABLET, DISPERSIBLE 200 MG (carglumic acid) | 4 | PA; LA |
| carglumic acid oral tablet, dispersible 200 mg | 1 | PA |
| cevimeline oral capsule 30 mg | 1 | |
| CHEMET ORAL CAPSULE 100 MG (succimer) | 2 | PA |
| deferasirox oral granules in packet 180 mg, 360 mg, 90 mg | 1 | PA |
| deferasirox oral tablet 180 mg, 360 mg, 90 mg | 1 | PA |
| deferasirox oral tablet, dispersible 125 mg, 250 mg, 500 mg | 1 | PA |
| deferiprone oral tablet 1,000 mg, 500 mg | 1 | PA |
| disulfiram oral tablet 250 mg, 500 mg | 1 | |
| EMPAVELI SUBCUTANEOUS SOLUTION 1,080 MG/20 ML (pegcetacoplan) | 4 | PA |
| ENJAYMO INTRAVENOUS SOLUTION 50 MG/ML (sutimlimab-jome) | 4 | PA |
| EPYSQLI INTRAVENOUS SOLUTION 300 MG/30 ML (eculi-zumab-aagh) | 4 | PA |
| FABHALTA ORAL CAPSULE 200 MG (iptacopan hcl) | 4 | PA |
| FERRIPROX (2 TIMES A DAY) ORAL TABLET, MODIFIED RELEASE 1,000 MG (deferiprone) | 4 | PA |
| FERRIPROX ORAL SOLUTION 100 MG/ML (deferiprone) | 4 | PA |
| glutamine (sickle cell) oral powder in packet 5 gram | 1 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML (mecasermin) | 4 | PA; LA |
| LAMZEDE INTRAVENOUS RECON SOLN 10 MG (velmanase alfa-tycv) | 4 | PA |
| levocarnitine (with sugar) oral solution 100 mg/ml | 1 | |
| levocarnitine oral solution 100 mg/ml | 1 | |
| levocarnitine oral tablet 330 mg | 1 | |
| midodrine oral tablet 10 mg, 2.5 mg, 5 mg | 1 | |
| nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg | 1 | PA; LA |
| NITYR ORAL TABLET 10 MG, 2 MG, 5 MG (nitisinone) | 4 | PA; LA |
| PHEBURANE ORAL GRANULES 483 MG/GRAM (sodium phenylbutyrate) | 4 | PA |
| PROLASTIN-C INTRAVENOUS SOLUTION 1,000 MG (+/-)/20 ML (alpha-1-proteinase inhibitor) | 4 | PA; LA |
| REVCOVI INTRAMUSCULAR SOLUTION 2.4 MG/1.5 ML (1.6 MG/ML) (elapegademase-lvlr) | 4 | PA; LA |
| REZDIFFRA ORAL TABLET 100 MG, 60 MG, 80 MG (resmetirom) | 4 | PA; QL (30 per 23 days) |
| riluzole oral tablet 50 mg | 1 | PA |
| risedronate oral tablet 30 mg | 1 | QL (30 per 30 days) |
| RYONCIL INTRAVENOUS SUSPENSION 6.68 X 10EXP6 CELL/ML (remestemcel-l-rknd) | 4 | PA |
| sodium chloride 0.9 % injection solution | 1 | |
| sodium chloride 0.9 % intravenous parenteral solution | 1 | |
| sodium chloride 0.9 % intravenous piggyback | 1 | |
| sodium chloride injection syringe 0.9 % | 1 | |
| sodium chloride irrigation solution 0.9 % | 1 | |
| sodium phenylbutyrate oral powder 0.94 gram/gram | 1 | PA |
| sodium phenylbutyrate oral tablet 500 mg | 1 | PA |
| SOLIRIS INTRAVENOUS SOLUTION 300 MG/30 ML (eculizumab) | 4 | PA |
| tiopronin oral tablet 100 mg | 1 | PA |
| tiopronin oral tablet,delayed release (dr/ec) 100 mg, 300 mg | 1 | PA |
| trientine oral capsule 250 mg | 1 | PA |
| venxxiva oral tablet,delayed release (dr/ec) 100 mg, 300 mg | 1 | PA |
| water for irrigation, sterile irrigation solution | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| XENPOZYME INTRAVENOUS RECON SOLN 20 MG, 4 MG (olipudase alfa-rpcp) | 4 | PA |
| XURIDEN ORAL GRANULES IN PACKET 2 GRAM (uridine triacetate) | 4 | PA |
| zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml | 4 | PA |
| SMOKING DETERRENTS | | |
| bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg | \$0 | ACA |
| NICODERM CQ TRANSDERMAL PATCH 24 HOUR 14 MG/24 HR, 21 MG/24 HR, 7 MG/24 HR (nicotine) | \$0 | ACA; OTC |
| NICORETTE BUCCAL GUM 2 MG (nicotine polacrilex) | \$0 | ACA; OTC |
| nicorette buccal gum 4 mg | \$0 | ACA; OTC |
| NICORETTE BUCCAL LOZENGE 2 MG, 4 MG (nicotine polacrilex) | \$0 | ACA; OTC |
| NICORETTE BUCCAL MINI LOZENGE 2 MG, 4 MG (nicotine polacrilex) | \$0 | ACA; OTC |
| nicotine (polacrilex) buccal gum 2 mg, 4 mg | \$0 | ACA; OTC |
| nicotine (polacrilex) buccal lozenge 2 mg, 4 mg | \$0 | ACA; OTC |
| nicotine (polacrilex) buccal mini lozenge 2 mg, 4 mg | \$0 | ACA; OTC |
| nicotine transdermal patch 24 hour 14 mg/24 hr, 21 mg/24 hr, 7 mg/24 hr | \$0 | ACA; OTC |
| nicotine transdermal patch, td daily, sequential 21-14-7 mg/24 hr | \$0 | ACA; OTC |
| NICOTROL NS NASAL SPRAY,NON-AEROSOL 10 MG/ML (nicotine) | \$0 | ACA |
| quit 2 buccal gum 2 mg | \$0 | ACA; OTC |
| quit 2 buccal lozenge 2 mg | \$0 | ACA; OTC |
| quit 4 buccal gum 4 mg | \$0 | ACA; OTC |
| quit 4 buccal lozenge 4 mg | \$0 | ACA; OTC |
| stop smoking aid buccal lozenge 2 mg, 4 mg | \$0 | ACA; OTC |
| varenicline tartrate oral tablet 0.5 mg, 1 mg | \$0 | ACA |
| varenicline tartrate oral tablets,dose pack 0.5 mg (11)- 1 mg (42) | \$0 | ACA |
| EAR, NOSE & THROAT MEDICATIONS | | |
| MISCELLANEOUS AGENTS | | |
| azelastine nasal spray,non-aerosol 137 mcg (0.1 %) | 1 | QL (1 per 30 days) |
| chlorhexidine gluconate mucous membrane mouthwash 0.12 % | 1 | |
| denta 5000 plus dental cream 1.1 % | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| denta 5000 plus sensitive dental paste 1.1-5 % | 1 | |
| dentagel dental gel 1.1 % | 1 | |
| fluoride (sodium) dental cream 1.1 % | 1 | |
| fluoride (sodium) dental gel 1.1 % | 1 | |
| fluoride (sodium) dental paste 1.1 % | 1 | |
| fluoride (sodium) dental solution 0.2 % | 1 | |
| fraiche 5000 dental gel 1.1 % | 1 | |
| ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %), 42 mcg (0.06 %) | 1 | QL (1 per 30 days) |
| kourzeq dental paste 0.1 % | 1 | |
| olopatadine nasal spray,non-aerosol 0.6 % | 1 | QL (1 per 30 days) |
| oralone dental paste 0.1 % | 1 | |
| paroex oral rinse mucous membrane mouthwash 0.12 % | 1 | |
| periogard mucous membrane mouthwash 0.12 % | 1 | |
| pilocarpine hcl oral tablet 5 mg, 7.5 mg | 1 | |
| sf 5000 plus dental cream 1.1 % | 1 | |
| sf dental gel 1.1 % | 1 | |
| sodium fluoride 5000 plus dental cream 1.1 % | 1 | |
| sodium fluoride-pot nitrate dental paste 1.1-5 % | 1 | |
| triamcinolone acetonide dental paste 0.1 % | 1 | |
| MISCELLANEOUS OTIC PREPARATIONS | | |
| acetic acid otic (ear) solution 2 % | 1 | |
| ciprofloxacin hcl otic (ear) dropperette 0.2 % | 1 | |
| flac otic oil otic (ear) drops 0.01 % | 1 | |
| fluocinolone acetonide oil otic (ear) drops 0.01 % | 1 | |
| hydrocortisone-acetic acid otic (ear) drops 1-2 % | 1 | |
| ofloxacin otic (ear) drops 0.3 % | 1 | |
| OTIC STEROID / ANTIBIOTIC | | |
| ciprofloxacin-dexamethasone otic (ear) drops,suspension 0.3-0.1 % | 1 | |
| neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-% | 1 | |
| neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-% | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| ENDOCRINE/DIABETES | | |
| ADRENAL HORMONES | | |
| cortisone oral tablet 25 mg | 1 | |
| deflazacort oral suspension 22.75 mg/ml | 1 | PA |
| deflazacort oral tablet 18 mg, 30 mg, 36 mg, 6 mg | 1 | PA |
| dexabliss oral tablets,dose pack 1.5 mg (39 tabs) | 1 | ST |
| dexamethasone intensol oral drops 1 mg/ml | 1 | |
| dexamethasone oral elixir 0.5 mg/5 ml | 1 | |
| dexamethasone oral solution 0.5 mg/5 ml | 1 | |
| dexamethasone oral tablet 0.5 mg, 0.75 mg, 1.5 mg, 4 mg, 6 mg | 1 | |
| dexamethasone oral tablet 1 mg, 2 mg | 1 | |
| dexamethasone oral tablets,dose pack 1.5 mg (21 tabs), 1.5 mg (35 tabs) | 1 | ST |
| fludrocortisone oral tablet 0.1 mg | 1 | |
| hydrocortisone oral tablet 10 mg, 20 mg, 5 mg | 1 | |
| methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg | 1 | |
| methylprednisolone oral tablets,dose pack 4 mg | 1 | |
| millipred dp oral tablets,dose pack 5 mg (21 tabs), 5 mg (48 tabs) | 1 | |
| millipred oral tablet 5 mg | 1 | |
| prednisolone oral solution 15 mg/5 ml | 1 | |
| prednisolone oral tablet 5 mg | 1 | |
| prednisolone sodium phosphate oral solution 10 mg/5 ml, 15 mg/5 ml (3 mg/ml), 20 mg/5 ml (4 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml) | 1 | |
| prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml) | 1 | |
| prednisolone sodium phosphate oral tablet,disintegrating 10 mg, 15 mg, 30 mg | 1 | |
| prednisone intensol oral concentrate 5 mg/ml | 1 | |
| prednisone oral solution 5 mg/5 ml | 1 | |
| prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg | 1 | |
| prednisone oral tablets,dose pack 10 mg, 5 mg | 1 | |
| ANTITHYROID AGENTS | | |
| methimazole oral tablet 10 mg, 5 mg | 1 | |
| potassium iodide oral solution 1 gram/ml | 1 | |
| propylthiouracil oral tablet 50 mg | 1 | |
| BLOOD GLUCOSE MONITORING DEVICES & SUPPL | LIES | |
| DEXCOM G6 RECEIVER (blood-glucose meter, receiver, continuous) | 2 | PA; QL (1 per 365 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| DEXCOM G6 SENSOR DEVICE (blood-glucose sensor) | 2 | PA; QL (3 per 23 days) |
| DEXCOM G6 TRANSMITTER DEVICE (blood-glucose transmitter) | 2 | PA; QL (1 per 68 days) |
| DEXCOM G7 RECEIVER (blood-glucose meter, receiver, continuous) | 2 | PA; QL (1 per 365 days) |
| DEXCOM G7 SENSOR DEVICE (blood-glucose sensor) | 2 | PA; QL (3 per 23 days) |
| FREESTYLE CONTROL SOLUTION (blood glucose calibration control high and low) | 2 | OTC |
| FREESTYLE FLASH SYSTEM KIT (blood-glucose meter) | 2 | OTC |
| FREESTYLE FREEDOM KIT (blood-glucose meter) | 2 | OTC |
| FREESTYLE FREEDOM LITE KIT (blood-glucose meter) | 2 | OTC |
| FREESTYLE INSULINX (blood-glucose meter) | 2 | OTC |
| FREESTYLE INSULINX STRIP (blood sugar diagnostic) | 2 | OTC |
| FREESTYLE INSULINX TEST STRIPS STRIP (blood sugar diagnostic) | 2 | ОТС |
| FREESTYLE LIBRE 14 DAY READER (flash glucose scanning reader) | 2 | PA |
| FREESTYLE LIBRE 14 DAY SENSOR KIT (flash glucose sensor) | 2 | PA; QL (2 per 21 days) |
| FREESTYLE LIBRE 2 PLUS SENSOR DEVICE (blood-glucose sensor) | 2 | PA; QL (2 per 23 days) |
| FREESTYLE LIBRE 2 READER (flash glucose scanning reader) | 2 | PA; QL (1 per 365 days) |
| FREESTYLE LIBRE 2 SENSOR KIT (flash glucose sensor) | 2 | PA; QL (2 per 21 days) |
| FREESTYLE LIBRE 3 PLUS SENSOR DEVICE (blood-glucose sensor) | 2 | PA; QL (2 per 23 days) |
| FREESTYLE LIBRE 3 READER (blood-glucose meter, receiver, continuous) | 2 | PA; QL (1 per 365 days) |
| FREESTYLE LIBRE 3 SENSOR DEVICE (blood-glucose sensor) | 2 | PA; QL (2 per 21 days) |
| FREESTYLE LITE METER KIT (blood-glucose meter) | 2 | OTC |
| FREESTYLE LITE STRIPS STRIP (blood sugar diagnostic) | 2 | OTC |
| FREESTYLE PRECISION NEO STRIPS STRIP (blood sugar diagnostic) | 2 | ОТС |
| FREESTYLE SIDEKICK II KIT (blood-glucose meter) | 2 | OTC |
| FREESTYLE SYSTEM KIT KIT (blood-glucose meter) | 2 | OTC |
| FREESTYLE TEST STRIP (blood sugar diagnostic) | 2 | OTC |
| MEDISENSE COMBO PACK (blood-glucose calib. control) | 2 | OTC |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| MEDISENSE GLUCOSE KETONE COMBO PACK (blood-glu-cose calib. control) | 2 | OTC |
| ONETOUCH ULTRA CONTROL SOLUTION (blood glucose calibration control solution, normal) | 2 | OTC |
| ONETOUCH ULTRA TEST STRIP (blood sugar diagnostic) | 2 | OTC |
| ONETOUCH ULTRA2 METER (blood-glucose meter) | 2 | OTC |
| ONETOUCH VERIO FLEX METER (blood-glucose meter) | 2 | OTC |
| ONETOUCH VERIO MID CONTROL SOLUTION (blood glucose calibration control solution, normal) | 2 | OTC |
| ONETOUCH VERIO REFLECT METER (blood-glucose meter) | 2 | OTC |
| ONETOUCH VERIO TEST STRIPS STRIP (blood sugar diagnostic) | 2 | OTC |
| PRECISION XTRA KETONE-GLUCOSE KIT (blood ketone and glucose monitor) | 2 | ОТС |
| PRECISION XTRA MONITOR (blood-glucose meter) | 2 | OTC |
| PRECISION XTRA TEST STRIP (blood sugar diagnostic) | 2 | OTC |
| GLUCOSE ELEVATING AGENTS | | |
| BAQSIMI NASAL SPRAY,NON-AEROSOL 3 MG/ACTUATION (glucagon) | 2 | QL (2 per 30 days) |
| diazoxide oral suspension 50 mg/ml | 1 | |
| glucagon emergency kit (human) injection recon soln 1 mg | 1 | QL (2 per 30 days) |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML (glucagon) | 2 | QL (2 per 30 days) |
| GVOKE PFS 2-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML (glucagon) | 2 | QL (2 per 30 days) |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML (glucagon) | 2 | QL (2 per 30 days) |
| INSULIN SYRINGES/MISCELLANEOUS DURABLE MEQU | IEDICAL | |
| AUTOJECT 2 INJECTION DEVICE SUBCUTANEOUS INSU- LIN PEN (insulin admin. supplies) | 2 | ОТС |
| AUTOPEN 1 TO 21 UNITS SUBCUTANEOUS INSULIN PEN (insulin admin. supplies) | 2 | ОТС |
| AUTOSOFT 30 INFUSION SET (infusion set for insulin pump) | 2 | |
| AUTOSOFT 90 INFUSION SET (infusion set for insulin pump) | 2 | |
| AUTOSOFT XC INFUSION SET 32" INFUSION SET (infusion set for insulin pump) | 2 | |
| BD INTEGRA NEEDLE NEEDLE 23 GAUGE X 1" (needles, disposable) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| BD MICROTAINER LANCET 30 GAUGE (lancets) | 2 | OTC |
| BD SPECIALTY USE NEEDLES NEEDLE 30 GAUGE X 1/2" (needles, disposable) | 2 | |
| CEQUR SIMPLICITY DEVICE 2 UNIT (subcutaneous bolus insulin patch pump, 200 unit, disposable) | 2 | |
| ILET INFUSION KIT-INSET 23" COMBO PACK (infusion set for insulin pump/insulin pump cartridge) | 2 | |
| ILET INFUSION-CONTACT DTCH 23" COMBO PACK (infusion set for insulin pump/insulin pump cartridge) | 2 | |
| ILET STARTER KIT-INSET KIT (insulin pump/insulin cartridge/infusion set/syringe/needle) | 2 | |
| LANCETS 33 GAUGE | 2 | OTC |
| LANCING DEVICE | 2 | OTC |
| MEDTRONIC EXT INFUSION SET 23" INFUSION SET (infusion set for insulin pump) | 2 | |
| MINIMED MIO ADVANCE INF SET23" INFUSION SET (infusion set for insulin pump) | 2 | |
| MINIMED QUICK SET 43" INFUSION SET (infusion set for insulin pump) | 2 | |
| MINIMED SILHOUETTE 23" INFUSION SET (infusion set for insulin pump) | 2 | |
| MINIMED SURE T 32" INFUSION SET (infusion set for insulin pump) | 2 | |
| OMNIPOD 5 (G6/LIBRE 2 PLUS) SUBCUTANEOUS CARTRIDGE (insulin pump cartridge, subcut automated dosing, bt, g6/l2) | 2 | QL (15 per 23 days) |
| OMNIPOD 5 G6-G7 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE (insulin pump cartridge, subcut automated dosing, bt, g6/g7) | 2 | QL (15 per 23 days) |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE (insulin pump cartridge,continuous subcut infusion,bluetooth) | 2 | QL (15 per 21 days) |
| T:FLEX SUBCUTANEOUS CARTRIDGE (insulin pump cartridge) | 2 | |
| T:SLIM X2 SUBCUTANEOUS CARTRIDGE (insulin pump cartridge) | 2 | |
| TANDEM MOBI AUTOSOFT 30 KT 23" COMBO PACK (infusion set for insulin pump/insulin pump cartridge) | 2 | |
| TANDEM MOBI AUTOSOFT XC KIT 5" COMBO PACK (infusion set for insulin pump/insulin pump cartridge) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| TANDEM MOBI TRUSTEEL KIT 23" COMBO PACK (infusion set for insulin pump/insulin pump cartridge) | 2 | |
| TRUSTEEL INFUSION SET 32" INFUSION SET (infusion set for insulin pump) | 2 | |
| TWIIST REFILL KT(CSST-NDL-SYR) KIT (insulin pump cartridge/insulin pump syringe/insulin needles) | 2 | |
| TWIIST RFL(INFUS-CSST-NDL-SYR) KIT (insulin pump cartridge/insulin infusion set/syringe/needle) | 2 | |
| TWIIST STARTER KIT KIT (insulin pump/insulin cartridge/infusion set/syringe/needle) | 2 | |
| VARISOFT INFUSION SET 43" INFUSION SET (infusion set for insulin pump) | 2 | |
| V-GO 20 DEVICE (sub-q insulin delivery device, 20 unit, disposable) | 2 | |
| V-GO 30 DEVICE (sub-q insulin delivery device, 30 unit, disposable) | 2 | |
| V-GO 40 DEVICE (sub-q insulin delivery device, 40 unit, disposable) | 2 | |
| INSULIN THERAPY | | |
| HUMALOG JUNIOR KWIKPEN U-100 SUBCUTANEOUS INSULIN PEN, HALF-UNIT 100 UNIT/ML (insulin lispro) | 2 | |
| HUMALOG KWIKPEN INSULIN SUBCUTANEOUS INSU- LIN PEN 100 UNIT/ML, 200 UNIT/ML (3 ML) (insulin lispro) | 2 | |
| HUMALOG MIX 50-50 KWIKPEN SUBCUTANEOUS INSU- LIN PEN 100 UNIT/ML (50-50) (insulin lispro protamine and insulin lispro) | 2 | |
| HUMALOG MIX 75-25 KWIKPEN SUBCUTANEOUS INSU- LIN PEN 100 UNIT/ML (75-25) (insulin lispro protamine and insulin lispro) | 2 | |
| HUMALOG MIX 75-25(U-100)INSULN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (75-25) (insulin lispro protamine and insulin lispro) | 2 | |
| HUMALOG TEMPO PEN(U-100)INSULN SUBCUTANEOUS INSULIN PEN, SENSOR 100 UNIT/ML (insulin lispro) | 2 | |
| HUMALOG U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (insulin lispro) | 2 | |
| HUMULIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) (insulin nph human isophane/insulin regular, human) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| HUMULIN 70/30 U-100 KWIKPEN SUBCUTANEOUS INSU- LIN PEN 100 UNIT/ML (70-30) (insulin nph human isophane/ insulin regular, human) | 2 | |
| HUMULIN N NPH INSULIN KWIKPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) (insulin nph human isophane) | 2 | |
| HUMULIN N NPH U-100 INSULIN SUBCUTANEOUS SUS- PENSION 100 UNIT/ML (insulin nph human isophane) | 2 | |
| HUMULIN R REGULAR U-100 INSULN INJECTION SOLUTION 100 UNIT/ML (insulin regular, human) | 2 | |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML (insulin regular, human) | 2 | |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) (insulin regular, human) | 2 | |
| INSULIN GLARGINE-YFGN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | |
| INSULIN GLARGINE-YFGN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 2 | |
| INSULIN LISPRO PROTAMIN-LISPRO SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (75-25) | 2 | |
| INSULIN LISPRO SUBCUTANEOUS INSULIN PEN 100 UNIT/ML | 2 | |
| INSULIN LISPRO SUBCUTANEOUS INSULIN PEN, HALF-UNIT 100 UNIT/ML | 2 | |
| INSULIN LISPRO SUBCUTANEOUS SOLUTION 100 UNIT/ML | 2 | |
| LYUMJEV KWIKPEN U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (insulin lispro-aabc) | 2 | |
| LYUMJEV KWIKPEN U-200 INSULIN SUBCUTANEOUS INSULIN PEN 200 UNIT/ML (3 ML) (insulin lispro-aabc) | 2 | |
| LYUMJEV TEMPO PEN(U-100)INSULN SUBCUTANEOUS INSULIN PEN, SENSOR 100 UNIT/ML (insulin lispro-aabc) | 2 | |
| LYUMJEV U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML (insulin lispro-aabc) | 2 | |
| SEMGLEE(INSULIN GLARGINE-YFGN) SUBCUTANEOUS SOLUTION 100 UNIT/ML (insulin glargine-yfgn) | 2 | |
| SEMGLEE(INSULIN GLARG-YFGN)PEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) (insulin glargine-yfgn) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSU- LIN PEN 300 UNIT/ML (3 ML) (insulin glargine,human recom- binant analog) | 2 | |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) (insulin glargine,human recombinant analog) | 2 | |
| MISCELLANEOUS HORMONES | | |
| ALDURAZYME INTRAVENOUS SOLUTION 2.9 MG/5 ML (laronidase) | 4 | PA |
| BRINEURA INTRAVENTRICULAR KIT 300 MG/10 ML (150MG/5ML X2) (cerliponase alfa) | 4 | PA |
| cabergoline oral tablet 0.5 mg | 1 | QL (8 per 21 days) |
| calcitonin (salmon) injection solution 200 unit/ml | 1 | |
| calcitonin (salmon) nasal spray,non-aerosol 200 unit/actuation | 1 | |
| CERDELGA ORAL CAPSULE 84 MG (eliglustat tartrate) | 4 | PA; QL (56 per 30 days) |
| CEREZYME INTRAVENOUS RECON SOLN 400 UNIT (imi-glucerase) | 4 | PA |
| cinacalcet oral tablet 30 mg, 60 mg, 90 mg | 1 | PA |
| CRYSVITA SUBCUTANEOUS SOLUTION 10 MG/ML (buro-sumab-twza) | 4 | PA; QL (14 per 21 days) |
| CRYSVITA SUBCUTANEOUS SOLUTION 20 MG/ML (buro-sumab-twza) | 4 | PA; QL (8 per 21 days) |
| CRYSVITA SUBCUTANEOUS SOLUTION 30 MG/ML (buro-sumab-twza) | 4 | PA; QL (12 per 21 days) |
| danazol oral capsule 100 mg, 200 mg, 50 mg | 1 | |
| desmopressin injection solution 4 mcg/ml | 4 | |
| desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml) | 1 | |
| DESMOPRESSIN NASAL SPRAY,NON-AEROSOL 150 MCG/ SPRAY (0.1 ML) | 2 | |
| desmopressin oral tablet 0.1 mg, 0.2 mg | 1 | |
| doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg | 1 | ST |
| ELAPRASE INTRAVENOUS SOLUTION 6 MG/3 ML (idursulfase) | 4 | PA |
| ELFABRIO INTRAVENOUS SOLUTION 2 MG/ML (pegunigal-sidase alfa-iwxj) | 4 | PA |
| FABRAZYME INTRAVENOUS RECON SOLN 35 MG, 5 MG (agalsidase beta) | 4 | PA |
| javygtor oral powder in packet 100 mg, 500 mg | 1 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------------|
| javygtor oral tablet,soluble 100 mg | 1 | PA |
| KANUMA INTRAVENOUS SOLUTION 2 MG/ML (sebelipase alfa) | 4 | PA |
| LUMIZYME INTRAVENOUS RECON SOLN 50 MG (alglucosidase alfa) | 4 | PA |
| MEPSEVII INTRAVENOUS SOLUTION 2 MG/ML (vestronidase alfa-vjbk) | 4 | PA |
| METHITEST ORAL TABLET 10 MG (methyltestosterone) | 2 | |
| methyltestosterone oral capsule 10 mg | 1 | |
| mifepristone oral tablet 300 mg | 1 | PA |
| miglustat oral capsule 100 mg | 1 | PA; LA; QL (90 per 30 days) |
| MYALEPT SUBCUTANEOUS RECON SOLN 5 MG/ML (FINAL CONC.) (metreleptin) | 4 | PA; LA |
| NAGLAZYME INTRAVENOUS SOLUTION 5 MG/5 ML (galsulfase) | 4 | PA; LA |
| ORILISSA ORAL TABLET 150 MG, 200 MG (elagolix sodium) | 2 | PA |
| PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML (pegvaliase-pqpz) | 4 | PA; LA; QL (30 per 30 days) |
| PALYNZIQ SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML (pegvaliase-pqpz) | 4 | PA; LA; QL (8 per 30 days) |
| PALYNZIQ SUBCUTANEOUS SYRINGE 20 MG/ML (pegvaliase-pqpz) | 4 | PA; LA; QL (60 per 30 days) |
| pamidronate intravenous solution 30 mg/10 ml (3 mg/ml), 60 mg/10 ml (6 mg/ml), 90 mg/10 ml (9 mg/ml) | 4 | |
| paricalcitol intravenous solution 2 mcg/ml, 5 mcg/ml | 4 | |
| paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg | 1 | ST |
| sapropterin oral powder in packet 100 mg, 500 mg | 1 | PA |
| sapropterin oral tablet, soluble 100 mg | 1 | PA |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG (pegvisomant) | 4 | PA |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML (asfotase alfa) | 4 | PA; LA |
| testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml | 1 | PA |
| testosterone enanthate intramuscular oil 200 mg/ml | 1 | PA |
| testosterone transdermal gel 50 mg/5 gram (1 %) | 1 | PA; QL (60 per 30 days) |
| testosterone transdermal gel in metered-dose pump 10 mg/0.5 gram /actuation | 1 | PA; QL (120 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|---|
| testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %) | 1 | PA; QL (300 per 30 days) |
| testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %) | 1 | PA; QL (150 per 30 days) |
| testosterone transdermal gel in packet 1 % (25 mg/2.5gram) | 1 | PA; QL (75 per 30 days) |
| testosterone transdermal gel in packet 1 % (50 mg/5 gram) | 1 | PA; QL (300 per 30 days) |
| testosterone transdermal gel in packet 1.62 % (20.25 mg/1.25 gram) | 1 | PA; QL (30 per 30 days) |
| testosterone transdermal gel in packet 1.62 % (40.5 mg/2.5 gram) | 1 | PA; QL (60 per 30 days) |
| testosterone transdermal solution in metered pump w/app 30 mg/actuation (1.5 ml) | 1 | PA; QL (180 per 30 days) |
| tolvaptan (polycys kidney dis) oral tablet 15 mg, 30 mg | 1 | PA; LA; QL (120 per 30 days) |
| tolvaptan (polycys kidney dis) oral tablets, sequential 15 mg (am)/15 mg (pm), 30 mg (am)/15 mg (pm), 45 mg (am)/15 mg (pm), 60 mg (am)/30 mg (pm), 90 mg (am)/30 mg (pm) | 1 | PA; LA |
| tolvaptan oral tablet 15 mg | 1 | PA; LA; QL (30 per 30 days) |
| tolvaptan oral tablet 30 mg | 1 | PA; LA; QL (60 per 30 days) |
| VIMIZIM INTRAVENOUS SOLUTION 5 MG/5 ML (1 MG/ML) (elosulfase alfa) | 4 | PA |
| zoledronic acid intravenous recon soln 4 mg | 4 | |
| zoledronic acid intravenous solution 4 mg/5 ml | 4 | |
| zoledronic acid-mannitol-water intravenous piggyback 4 mg/100 ml | 4 | |
| NON-INSULIN HYPOGLYCEMIC AGENTS | | |
| acarbose oral tablet 100 mg, 25 mg, 50 mg | 1 | |
| BYDUREON BCISE SUBCUTANEOUS AUTO-INJECTOR 2 MG/0.85 ML (exenatide microspheres) | 2 | PA; QL (4 pens per 21 days; 1 GLP-1 per 21 days) |
| exenatide subcutaneous pen injector 10 mcg/dose(250 mcg/ml) 2.4 ml, 5 mcg/dose (250 mcg/ml) 1.2 ml | 1 | PA; QL (1 pen per 23 days; 1 GLP-1 per 21 days) |
| FARXIGA ORAL TABLET 10 MG, 5 MG (dapagliflozin propanediol) | 2 | ST; QL (30 per 30 days) |
| glimepiride oral tablet 1 mg, 2 mg, 4 mg | 1 | |
| glipizide oral tablet 10 mg, 5 mg | 1 | |
| glipizide oral tablet extended release 24hr 10 mg, 2.5 mg, 5 mg | 1 | |
| glipizide-metformin oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg | 1 | |
| glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg | 1 | |
| glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|---|
| glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg | 1 | |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG (empagliflozin/linagliptin) | 2 | ST; QL (30 per 30 days) |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG (sita-gliptin phosphate/metformin hcl) | 2 | ST; QL (60 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG (sitagliptin phosphate/metformin hcl) | 2 | ST; QL (30 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG, 50-500 MG (sitagliptin phosphate/metformin hcl) | 2 | ST; QL (60 per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG (sitagliptin phosphate) | 2 | ST; QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG (empagliflozin) | 2 | ST; QL (30 per 30 days) |
| liraglutide subcutaneous pen injector 0.6 mg/0.1 ml (18 mg/3 ml) | 1 | PA; QL (2 pens per 23 days; 1 GLP-1 per 21 days) |
| metformin oral solution 500 mg/5 ml | 1 | ST |
| metformin oral tablet 1,000 mg, 500 mg | 1 | |
| metformin oral tablet 750 mg | 1 | ST |
| metformin oral tablet 850 mg | 1 | ACA |
| metformin oral tablet extended release 24 hr 500 mg | 1 | QL (120 per 30 days) |
| metformin oral tablet extended release 24 hr 750 mg | 1 | QL (60 per 30 days) |
| metformin oral tablet extended release 24hr 1,000 mg | 1 | ST; QL (60 per 30 days) |
| metformin oral tablet extended release 24hr 500 mg | 1 | ST; QL (30 per 30 days) |
| metformin oral tablet,er gast.retention 24 hr 1,000 mg | 1 | ST; QL (60 per 30 days) |
| metformin oral tablet,er gast.retention 24 hr 500 mg | 1 | ST; QL (120 per 30 days) |
| miglitol oral tablet 100 mg, 25 mg, 50 mg | 1 | |
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML (tirzepatide) | 2 | PA; QL (4 pens per 21 days; 1 GLP-1 per 21 days) |
| nateglinide oral tablet 120 mg, 60 mg | 1 | |
| NESINA ORAL TABLET 12.5 MG, 25 MG (alogliptin benzoate) | 3 | ST; QL (30 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) (semaglutide) | 2 | PA; QL (1 pen per 21 days; 1 GLP-1 per 21 days) |
| pioglitazone oral tablet 15 mg, 30 mg, 45 mg | 1 | QL (30 per 30 days) |
| pioglitazone-glimepiride oral tablet 30-2 mg, 30-4 mg | 1 | QL (30 per 30 days) |
| pioglitazone-metformin oral tablet 15-500 mg, 15-850 mg | 1 | QL (90 per 30 days) |
| repaglinide oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|---|
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG (semaglutide) | 2 | PA; QL (30 tabs per 23 days; 1 GLP-1 per 21 days) |
| saxagliptin oral tablet 2.5 mg, 5 mg | 1 | ST; QL (30 per 30 days) |
| saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg | 1 | ST; QL (60 per 30 days) |
| saxagliptin-metformin oral tablet, er multiphase 24 hr 5-1,000 mg, 5-500 mg | 1 | ST; QL (30 per 30 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG (empagliflozin/metformin hcl) | 2 | ST; QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG (empagliflozin/metformin hcl) | 2 | ST; QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG (empagliflozin/metformin hcl) | 2 | ST; QL (60 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 12.5-2.5-1,000 MG, 25-5-1,000 MG, 5-2.5-1,000 MG (empagliflozin/linagliptin/metformin hcl) | 2 | ST |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML (dulaglutide) | 2 | PA; QL (4 pens per 21 days; 1 GLP-1 per 21 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG (dapagliflozin propanediol/metformin hcl) | 2 | ST; QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG (dapagliflozin propanediol/metformin hcl) | 2 | ST; QL (60 per 30 days) |
| THYROID HORMONES | | |
| adthyza oral tablet 120 mg, 15 mg, 30 mg, 60 mg, 90 mg | 1 | |
| ARMOUR THYROID ORAL TABLET 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG (thyroid,pork) | 2 | |
| euthyrox oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg | 1 | |
| levo-t oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg | 1 | |
| levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg | 1 | |
| levoxyl oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg | 1 | |
| liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg | 1 | |
| niva thyroid oral tablet 120 mg, 15 mg, 30 mg, 60 mg, 90 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| np thyroid oral tablet 120 mg, 15 mg, 30 mg, 60 mg, 90 mg | 1 | |
| renthyroid oral tablet 120 mg, 15 mg, 30 mg, 60 mg, 90 mg | 1 | |
| thyroid (pork) oral tablet 120 mg, 15 mg, 30 mg, 60 mg, 90 mg | 1 | |
| unithroid oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg | 1 | |
| GASTROENTEROLOGY | | |
| ANTIDIARRHEALS & ANTISPASMODICS | | |
| anaspaz oral tablet, disintegrating 0.125 mg | 1 | |
| belladonna alkaloids-opium rectal suppository 16.2-30 mg, 16.2-60 mg | 1 | |
| chlordiazepoxide-clidinium oral capsule 5-2.5 mg | 1 | |
| dicyclomine oral capsule 10 mg | 1 | |
| dicyclomine oral solution 10 mg/5 ml | 1 | |
| dicyclomine oral tablet 20 mg | 1 | |
| diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml | 1 | |
| diphenoxylate-atropine oral tablet 2.5-0.025 mg | 1 | |
| ed-spaz oral tablet,disintegrating 0.125 mg | 1 | |
| glycopyrrolate oral solution 1 mg/5 ml (0.2 mg/ml) | 1 | |
| glycopyrrolate oral tablet 1 mg, 1.5 mg, 2 mg | 1 | |
| hyoscyamine sulfate oral drops 0.125 mg/ml | 1 | |
| hyoscyamine sulfate oral elixir 0.125 mg/5 ml | 1 | |
| hyoscyamine sulfate oral tablet 0.125 mg | 1 | |
| hyoscyamine sulfate oral tablet extended release 12 hr 0.375 mg | 1 | |
| hyoscyamine sulfate oral tablet, disintegrating 0.125 mg | 1 | |
| hyoscyamine sulfate sublingual tablet 0.125 mg | 1 | |
| hyosyne oral drops 0.125 mg/ml | 1 | |
| hyosyne oral elixir 0.125 mg/5 ml | 1 | |
| opium tincture oral tincture 10 mg/ml (morphine) | 1 | |
| oscimin oral tablet 0.125 mg | 1 | |
| oscimin sl sublingual tablet 0.125 mg | 1 | |
| phenobarb-hyoscy-atropine-scop oral elixir 16.2-0.1037 -0.0194 mg/5 ml | 1 | |
| phenobarb-hyoscy-atropine-scop oral tablet 16.2-0.1037 -0.0194 mg | 1 | |
| phenohytro oral elixir 16.2-0.1037 -0.0194 mg/5 ml | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|---|
| phenohytro oral tablet 16.2-0.1037 -0.0194 mg | 1 | |
| symax fastabs oral tablet, disintegrating 0.125 mg | 1 | |
| symax-sl sublingual tablet 0.125 mg | 1 | |
| symax-sr oral tablet extended release 12 hr 0.375 mg | 1 | |
| MISCELLANEOUS GASTROINTESTINAL AGENTS | | |
| alosetron oral tablet 0.5 mg, 1 mg | 1 | |
| alvimopan oral capsule 12 mg | 1 | |
| anucort-hc rectal suppository 25 mg | 1 | |
| aprepitant oral capsule 125 mg, 40 mg | 1 | QL (1 per 30 days) |
| aprepitant oral capsule 80 mg | 1 | QL (2 per 30 days) |
| aprepitant oral capsule,dose pack 125 mg (1)- 80 mg (2) | 1 | QL (3 per 30 days) |
| balsalazide oral capsule 750 mg | 1 | |
| betaine oral powder 1 gram/scoop | 1 | PA |
| bisacodyl oral tablet,delayed release (dr/ec) 5 mg | \$0 | ACA; OTC |
| budesonide oral capsule,delayed,extend.release 3 mg | 1 | |
| budesonide oral tablet,delayed and ext.release 9 mg | 1 | |
| budesonide rectal foam 2 mg/actuation | 1 | |
| CHENODAL ORAL TABLET 250 MG (chenodiol) | 4 | PA; LA |
| CHOLBAM ORAL CAPSULE 250 MG (cholic acid) | 4 | PA |
| CHOLBAM ORAL CAPSULE 50 MG (cholic acid) | 4 | PA; QL (120 per 30 days) |
| citrate of magnesia oral solution | \$0 | ACA; OTC |
| citroma oral solution | \$0 | ACA; OTC |
| clearlax oral powder 17 gram/dose | \$0 | ACA; OTC |
| compro rectal suppository 25 mg | 1 | |
| constulose oral solution 10 gram/15 ml | 1 | |
| cromolyn oral concentrate 100 mg/5 ml | 1 | |
| CTEXLI ORAL TABLET 250 MG (chenodiol) | 4 | PA |
| doxylamine-pyridoxine (vit b6) oral tablet,delayed release (dr/ec) 10-10 mg | 1 | QL (720 per 365 days; 120 per dispense) |
| dronabinol oral capsule 10 mg, 2.5 mg, 5 mg | 1 | PA |
| dulcolax (magnesium hydroxide) oral suspension 400 mg/5 ml | \$0 | ACA; OTC |
| ENTYVIO INTRAVENOUS RECON SOLN 300 MG (vedoli-zumab) | 4 | PA |
| enulose oral solution 10 gram/15 ml | 1 | |
| gavilax oral powder 17 gram/dose | \$0 | ACA; OTC |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| gavilyte-c oral recon soln 240-22.72-6.72 -5.84 gram | \$0 | ACA |
| gavilyte-g oral recon soln 236-22.74-6.74 -5.86 gram | \$0 | ACA |
| gavilyte-n oral recon soln 420 gram | \$0 | ACA |
| generlac oral solution 10 gram/15 ml | 1 | |
| gentle laxative (bisacodyl) oral tablet, delayed release (dr/ec) 5 mg | \$0 | ACA; OTC |
| gentle laxative (mag hydrox) oral suspension 400 mg/5 ml | \$0 | ACA; OTC |
| gentlelax oral powder 17 gram/dose | \$0 | ACA; OTC |
| granisetron hcl oral tablet 1 mg | 1 | QL (6 per 30 days) |
| hemmorex-hc rectal suppository 25 mg, 30 mg | 1 | |
| hydrocortisone acetate rectal suppository 25 mg, 30 mg | 1 | |
| hydrocortisone rectal enema 100 mg/60 ml | 1 | |
| hydrocortisone topical cream with perineal applicator 1 %, 2.5 % | 1 | |
| hydrocortisone-pramoxine rectal cream 1-1 % | 1 | |
| hydrocortisone-pramoxine rectal cream 2.5-1 %, 2.5-1 % (4g) | 1 | ST |
| INFLECTRA INTRAVENOUS RECON SOLN 100 MG (inflix-imab-dyyb) | 4 | PA |
| IQIRVO ORAL TABLET 80 MG (elafibranor) | 4 | PA |
| lactulose oral packet 10 gram, 20 gram | 1 | |
| lactulose oral solution 10 gram/15 ml | 1 | |
| laxative (bisacodyl) oral tablet,delayed release (dr/ec) 5 mg | \$0 | ACA; OTC |
| laxative peg 3350 oral powder 17 gram/dose | \$0 | ACA; OTC |
| lidocaine hcl-hydrocortison ac rectal cream 3-0.5 % | 1 | |
| lidocaine hcl-hydrocortison ac rectal kit 2 %-2 % (7 gram) | 1 | |
| lidocaine hcl-hydrocortison ac rectal kit 3-0.5 %, 3-2.5 % (7 gram) | 1 | |
| lidocaine-hydrocortisone-aloe rectal gel 2.8-0.55 % | 1 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG (linaclotide) | 2 | QL (30 per 30 days) |
| lubiprostone oral capsule 24 mcg, 8 mcg | 1 | QL (60 per 30 days) |
| magnesium citrate oral solution | \$0 | ACA; OTC |
| meclizine oral tablet 50 mg | 1 | |
| mesalamine oral capsule (with del rel tablets) 400 mg | 1 | |
| mesalamine oral capsule, extended release 500 mg | 1 | |
| mesalamine oral capsule, extended release 24hr 0.375 gram | 1 | |
| mesalamine oral tablet,delayed release (dr/ec) 1.2 gram, 800 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------------|
| mesalamine rectal enema 4 gram/60 ml | 1 | |
| mesalamine rectal suppository 1,000 mg | 1 | |
| mesalamine with cleansing wipe rectal enema kit 4 gram/60 ml | 1 | |
| metoclopramide hcl oral solution 5 mg/5 ml | 1 | |
| metoclopramide hcl oral tablet 10 mg, 5 mg | 1 | |
| milk of magnesia concentrated oral suspension 2,400 mg/10 ml | \$0 | ACA; OTC |
| milk of magnesia oral suspension 400 mg/5 ml | \$0 | ACA; OTC |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG (naloxegol oxalate) | 2 | QL (30 per 30 days) |
| natura-lax oral powder 17 gram/dose | \$0 | ACA; OTC |
| nitroglycerin rectal ointment 0.4 % (w/w) | 1 | |
| OCALIVA ORAL TABLET 10 MG, 5 MG (obeticholic acid) | 4 | PA; LA; QL (30 per 30 days) |
| OMVOH INTRAVENOUS SOLUTION 300 MG/15 ML (20 MG/ML) (mirikizumab-mrkz) | 4 | PA |
| OMVOH PEN SUBCUTANEOUS PEN INJECTOR 100 MG/ML (mirikizumab-mrkz) | 4 | PA; QL (2 per 21 days) |
| OMVOH PEN SUBCUTANEOUS PEN INJECTOR 300MG/3ML(100MG /ML-200 MG/2ML) (mirikizumab-mrkz) | 4 | PA; QL (3 per 21 days) |
| OMVOH SUBCUTANEOUS SYRINGE 100 MG/ML (miriki-zumab-mrkz) | 4 | PA; QL (2 per 21 days) |
| OMVOH SUBCUTANEOUS SYRINGE 300MG/3ML(100MG / ML-200 MG/2ML) (mirikizumab-mrkz) | 4 | PA; QL (3 per 21 days) |
| ondansetron hcl oral solution 4 mg/5 ml | 1 | QL (100 per 30 days) |
| ondansetron hcl oral tablet 4 mg, 8 mg | 1 | QL (9 per 30 days) |
| ondansetron oral tablet, disintegrating 4 mg, 8 mg | 1 | QL (9 per 30 days) |
| onelax magnesium citrate oral solution | \$0 | ACA; OTC |
| oral saline laxative oral liquid 7.2-2.7 gram/15 ml | \$0 | ACA; OTC |
| PANCREAZE ORAL CAPSULE, DELAYED RELEASE (DR/EC) 10,500-35,500-61,500 UNIT, 16,800-56,800-98,400 UNIT, 2,600-8,800-15,200 UNIT, 21,000-54,700-83,900 UNIT, 37,000-97,300-149,900 UNIT, 4,200-14,200-24,600 UNIT (lipase/prote-ase/amylase) | 2 | |
| peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram | \$0 | ACA |
| peg3350-sod sul-nacl-kcl-asb-c oral powder in packet 100-7.5-2.691 gram | \$0 | ACA |
| peg-electrolyte soln oral recon soln 420 gram | \$0 | ACA |
| PENTASA ORAL CAPSULE, EXTENDED RELEASE 250 MG (mesalamine) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| phosphate laxative oral liquid 7.2-2.7 gram/15 ml | \$0 | ACA; OTC |
| polyethylene glycol 3350 oral powder 17 gram/dose | \$0 | ACA; OTC |
| powderlax oral powder 17 gram/dose | \$0 | ACA; OTC |
| prochlorperazine maleate oral tablet 10 mg, 5 mg | 1 | |
| prochlorperazine rectal suppository 25 mg | 1 | |
| procto-med hc topical cream with perineal applicator 2.5 % | 1 | |
| proctosol hc topical cream with perineal applicator 2.5 % | 1 | |
| proctozone-hc topical cream with perineal applicator 2.5 % | 1 | |
| prucalopride oral tablet 1 mg, 2 mg | 1 | QL (30 per 30 days) |
| purelax oral powder 17 gram/dose | \$0 | ACA; OTC |
| RECTIV RECTAL OINTMENT 0.4 % (W/W) (nitroglycerin) | 2 | |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML (methylnaltrexone bromide) | 2 | ST |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML (methylnaltrexone bromide) | 2 | ST |
| scopolamine base transdermal patch 3 day 1 mg over 3 days | 1 | |
| SKYRIZI INTRAVENOUS SOLUTION 60 MG/ML (risankizum-ab-rzaa) | 2 | PA |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) (risankizumab-rzaa) | 2 | PA; QL (1 per 56 days) |
| smoothlax oral powder 17 gram/dose | \$0 | ACA; OTC |
| sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram | \$0 | ACA |
| SUCRAID ORAL SOLUTION 8,500 UNIT/ML (sacrosidase) | 4 | PA |
| sulfasalazine oral tablet 500 mg | 1 | |
| sulfasalazine oral tablet,delayed release (dr/ec) 500 mg | 1 | |
| SUTAB ORAL TABLET 1.479-0.188- 0.225 GRAM (sodium sulfate/potassium chloride/magnesium sulfate) | \$0 | ACA |
| trimethobenzamide oral capsule 300 mg | 1 | |
| TRULANCE ORAL TABLET 3 MG (plecanatide) | 2 | |
| ursodiol oral capsule 200 mg, 300 mg, 400 mg | 1 | |
| ursodiol oral tablet 250 mg, 500 mg | 1 | |
| VARUBI ORAL TABLET 90 MG (rolapitant hcl) | 2 | QL (2 per 30 days) |
| VELSIPITY ORAL TABLET 2 MG (etrasimod arginine) | 4 | PA; QL (30 per 23 days) |
| VIBERZI ORAL TABLET 100 MG, 75 MG (eluxadoline) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| VIOKACE ORAL TABLET 10,440-39,150- 39,150 UNIT, 20,880-78,300-78,300 UNIT (<i>lipase/protease/amylase</i>) | 2 | |
| women's gentle laxative(bisac) oral tablet,delayed release (dr/ec) 5 mg | \$0 | ACA; OTC |
| ZENPEP ORAL CAPSULE, DELAYED RELEASE (DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000-84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT (lipase/protease/amylase) | 2 | |
| ZYMFENTRA SUBCUTANEOUS PEN INJECTOR KIT 120 MG/ML (infliximab-dyyb) | 4 | PA; QL (2 per 21 days) |
| ZYMFENTRA SUBCUTANEOUS SYRINGE KIT 120 MG/ML (infliximab-dyyb) | 4 | PA; QL (2 per 21 days) |
| ULCER THERAPY | | |
| amoxicil-clarithromy-lansopraz oral combo pack 500-500-30 mg | 1 | QL (112 per 30 days) |
| bismuth subcit k-metronidz-tcn oral capsule 140-125-125 mg | 1 | |
| cimetidine hcl oral solution 300 mg/5 ml | 1 | |
| cimetidine oral tablet 300 mg, 400 mg, 800 mg | 1 | |
| esomeprazole magnesium oral capsule,delayed release(dr/ec) 40 mg | 1 | |
| esomeprazole magnesium oral granules dr for susp in packet 10 mg, 2.5 mg, 20 mg, 5 mg | 1 | ST; QL (30 per 30 days) |
| esomeprazole magnesium oral granules dr for susp in packet 40 mg | 1 | ST |
| famotidine oral suspension for reconstitution 40 mg/5 ml (8 mg/ml) | 1 | |
| famotidine oral tablet 40 mg | 1 | |
| lansoprazole oral capsule,delayed release(dr/ec) 30 mg | 1 | |
| lansoprazole oral tablet,disintegrat, delay rel 15 mg | 1 | ST; QL (30 per 30 days) |
| lansoprazole oral tablet,disintegrat, delay rel 30 mg | 1 | ST |
| misoprostol oral tablet 100 mcg, 200 mcg | 1 | ACA |
| nizatidine oral capsule 150 mg, 300 mg | 1 | |
| omeprazole oral capsule,delayed release(dr/ec) 10 mg, 20 mg | 1 | QL (30 per 30 days) |
| omeprazole oral capsule,delayed release(dr/ec) 40 mg | 1 | |
| omeprazole-sodium bicarbonate oral capsule 40-1.1 mg-gram | 1 | ST |
| omeprazole-sodium bicarbonate oral packet 20-1,680 mg | 1 | ST; QL (30 per 30 days) |
| omeprazole-sodium bicarbonate oral packet 40-1,680 mg | 1 | ST |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|----------------------------|
| pantoprazole oral granules dr for susp in packet 40 mg | 1 | ST |
| pantoprazole oral tablet,delayed release (dr/ec) 20 mg | 1 | QL (30 per 30 days) |
| pantoprazole oral tablet,delayed release (dr/ec) 40 mg | 1 | |
| rabeprazole oral tablet,delayed release (dr/ec) 20 mg | 1 | |
| sucralfate oral suspension 100 mg/ml | 1 | |
| sucralfate oral tablet 1 gram | 1 | |
| VOQUEZNA DUAL PAK ORAL COMBO PACK 20 MG (28)-500 MG (84) (vonoprazan fumarate/amoxicillin trihydrate) | 2 | |
| VOQUEZNA TRIPLE PAK ORAL COMBO PACK 20-500-500 MG (vonoprazan fumarate/amoxicillin trihydrate/clarithromycin) | 2 | |
| IMMUNOLOGY, VACCINES & BIOTECHNOLO | OGY | |
| BIOTECHNOLOGY DRUGS | | |
| FULPHILA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML (peg-filgrastim-jmdb) | 4 | PA; QL (2 per 23 days) |
| ILARIS (PF) SUBCUTANEOUS SOLUTION 150 MG/ML (canakinumab/pf) | 4 | PA; LA; QL (2 per 21 days) |
| LEUKINE INJECTION RECON SOLN 250 MCG (sargramos-tim) | 4 | PA |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML (filgrastim-aafi) | 4 | PA |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML (<i>filgrastim-aafi</i>) | 4 | PA |
| plerixafor subcutaneous solution 24 mg/1.2 ml (20 mg/ml) | 4 | |
| PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML (epoetin alfa) | 4 | PA |
| PROLEUKIN INTRAVENOUS RECON SOLN 22 MILLION UNIT (aldesleukin) | 4 | PA |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML (epoetin alfa-epbx) | 4 | PA |
| ZIEXTENZO SUBCUTANEOUS SYRINGE 6 MG/0.6 ML (pegfilgrastim-bmez) | 4 | PA; QL (2 per 23 days) |
| ZYNTEGLO INTRAVENOUS SUSPENSION 2 X TO 20 X 10EXP6 CELL/ML (betibeglogene autotemcel) | 4 | PA |
| GROWTH HORMONES | | |
| EGRIFTA SV SUBCUTANEOUS RECON SOLN 2 MG (tesamorelin acetate) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| OMNITROPE SUBCUTANEOUS CARTRIDGE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) (somatropin) | 4 | PA |
| OMNITROPE SUBCUTANEOUS RECON SOLN 5.8 MG (so-matropin) | 4 | PA |
| INTERFERONS | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML (interferon gamma-lb,recomb.) | 4 | PA |
| ALFERON N INJECTION SOLUTION 5 MILLION UNIT/ML (interferon alfa-n3) | 4 | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML (peginterferon alfa-2a) | 4 | QL (4 per 21 days) |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML (peginterferon alfa-2a) | 4 | QL (2 per 21 days) |
| VACCINES & MISCELLANEOUS IMMUNOLOGICAL | S | |
| ABRYSVO (PF) INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML (respiratory syncytial virus vaccine, pref a and b/pf) | \$0 | ACA |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML (haemophilus b conjugate vaccine(tetanus toxoid conjugate)/pf) | \$0 | ACA |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML (diphtheria,per tussis(acellular),tetanus vaccine/pf) | \$0 | ACA |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML (diphtheria, pertuss is (acellular), tetanus vaccine/pf) | \$0 | ACA |
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RE- CONSTITUTION 120 MCG/0.5 ML (respiratory syncytial virus vacc. antigen/as0le adjuvant/pf) | \$0 | ACA |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG (bcg vaccine, live/pf) | 4 | |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML (meningococcal group b vaccine, 4-component) | \$0 | ACA |
| BIOTHRAX INTRAMUSCULAR SUSPENSION 0.5 ML/DOSE (anthrax vaccine adsorbed) | \$0 | ACA |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML (diphtheria,pertussis(acellular),tetanus vaccine) | \$0 | ACA |
| CAPVAXIVE INTRAMUSCULAR SYRINGE 0.5 ML (pneumococcal 21-valent conjugate vaccine (diphtheria crm)/pf) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| COMIRNATY 2024-25 (12Y UP)(PF) INTRAMUSCULAR SYRINGE 30 MCG/0.3 ML (covid vaccine 2024-2025 (12 yrs up) (pfizer)/pf) | \$0 | ACA |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG-LF/0.5ML (diphtheria, pertussis (acell), tetanus pediatric vaccine/pf) | \$0 | ACA |
| DENGVAXIA (PF) SUBCUTANEOUS SUSPENSION FOR RE- CONSTITUTION 10EXP4.5-6 CCID50/0.5 ML (dengue tetrava- lent vaccine, live, vero cell/pf) | \$0 | ACA |
| DYSPORT INTRAMUSCULAR RECON SOLN 300 UNIT, 500 UNIT (abobotulinumtoxina) | 4 | PA |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML (hepatitis b virus vaccine recombinant/pf) | \$0 | ACA |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML (hepatitis b virus vaccine recombinant/pf) | \$0 | ACA |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML (hepatitis b virus vaccine recombinant/pf) | \$0 | ACA |
| GAMASTAN INTRAMUSCULAR SOLUTION 15-18 % RANGE (immune globulin,gamma(igg)/glycine) | 4 | |
| GAMMAGARD LIQUID INJECTION SOLUTION 10 % (immune globulin,gamm(igg)/glycine/iga greater than 50 mcg/ml) | 4 | PA |
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RE- CON SOLN 10 GRAM, 5 GRAM (immune globulin,gamm(igg)/ glycine/glucose/iga 0 to 50 mcg/ml) | 4 | PA |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) (immune globulin,gamma(igg)/glycine/iga average 46 mcg/ml) | 4 | PA |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML (human papillomavirus vaccine, 9-valent/pf) | \$0 | ACA |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML (human papillomavirus vaccine, 9-valent/pf) | \$0 | ACA |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML (hepatitis a virus vaccine/pf) | \$0 | ACA |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML (hepatitis b vaccine recombinant/vaccine adjuvant cpg 1018/pf) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML (haemophilus b conjugate vaccine(tetanus toxoid conjugate)/pf) | \$0 | ACA |
| HYPERHEP B INTRAMUSCULAR SOLUTION 220 UNIT/ML, 220 UNIT/ML (5 ML) (hepatitis b immune globulin) | 4 | |
| HYPERHEP B NEONATAL INTRAMUSCULAR SYRINGE 110 UNIT/0.5 ML (hepatitis b immune globulin) | 4 | |
| HYPERRAB (PF) INTRAMUSCULAR SOLUTION 300 UNIT/ ML (rabies immune globulin/pf) | 4 | |
| IMOGAM RABIES-HT (PF) INTRAMUSCULAR SOLUTION 150 UNIT/ML (rabies immune globulin/pf) | 4 | |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT (rabies vaccine, human diploid cell/pf) | \$0 | ACA |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25-58-10 LF-MCG-LF/0.5ML (diphtheria, pertussis (acell), tetanus pediatric vaccine/pf) | \$0 | ACA |
| IPOL INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML (poliomyelitis vaccine, killed) | \$0 | ACA |
| IXCHIQ (PF) INTRAMUSCULAR RECON SOLN 1,000 TCID50/0.5 ML (chikungunya vaccine, live/preservative free) | \$0 | ACA |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML (japanese encephalitis vaccine/pf) | \$0 | ACA |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 (smallpox and mpox vaccine, live, non-replicating/pf) | \$0 | ACA |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML (diphtheria, pertussis(acell),tetanus,polio vaccine/pf) | \$0 | ACA |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML (meningococcal vaccine a,c,y and w-135,conj tetanus toxoid/pf) | \$0 | ACA |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML (meningococcal vaccine a,c,y,w-135,diphtheria toxoid conj/pf) | \$0 | ACA |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR SO- LUTION 10-5 MCG/0.5 ML (meningococcal vaccine a,c,y,w- 135,diphtheria toxoid conj/pf) | \$0 | ACA |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML (measles, mumps, and rubella vaccine live/pf) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| MODERNA COVID 24-25(6M-11Y)PF INTRAMUSCULAR SY-RINGE 25 MCG/0.25 ML (covid vaccine 2024-2025 (6 months-11 years)(moderna)/pf) | \$0 | ACA |
| MRESVIA (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML (respiratory syncytial virus vaccine, pref protein, mrna/pf) | \$0 | ACA |
| MYOBLOC INTRAMUSCULAR SOLUTION 10,000 UNIT/2 ML, 2,500 UNIT/0.5 ML, 5,000 UNIT/ML (rimabotulinumtoxinb) | 4 | PA |
| NOVAVAX COVID 2024-25(PF)(EUA) INTRAMUSCULAR SYRINGE 5 MCG/0.5 ML (covid vaccine 2024-2025 (12 yrs up)/adjuvant-matrix/pf) | \$0 | ACA |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML (hep b virus,rcmb/dipth,pertus(acell),tet,polio vaccine/pf) | \$0 | ACA |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML (haemophilus b conjugate vaccine (meningococcal prot.conj)/pf) | \$0 | ACA |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML (meningococ a,c,y,w-135,tt comp/n. mening b,fhbp rec comp/pf) | \$0 | ACA |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF-20MCG-5LF-62 DU/0.5 ML (diphtheria,pertussis(acell),tetanus,polio/haemophilus b/pf) | \$0 | ACA |
| PFIZER COVID 2024-25(5Y-11Y)PF INTRAMUSCULAR SUS-PENSION 10 MCG/0.3 ML (covid vacc 2024-2025 (5-11 years) (pfizer)/pf) | \$0 | ACA |
| PFIZER COVID 2024-25(6MO-4Y)PF INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 3 MCG/0.3 ML (covid vacc 2024-2025 (6 months-4 years old) (pfizer)/pf) | \$0 | ACA |
| PNEUMOVAX-23 INJECTION SYRINGE 25 MCG/0.5 ML (pneumococcal 23-valent polysaccharide vaccine) | \$0 | ACA |
| PREVNAR 20 (PF) INTRAMUSCULAR SYRINGE 0.5 ML (pneumococcal 20-valent conjugate vaccine (diphtheria crm)/pf) | \$0 | ACA |
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2- 3.3CCID50/0.5ML (measles, mumps, and rubella vaccine live/pf) | \$0 | ACA |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RE- CONSTITUTION 10EXP3-4.3-3- 3.99 TCID50/0.5 (measles, mumps, rubella, and varicella vaccine live/pf) | \$0 | ACA |
| QUADRACEL (PF) INTRAMUSCULAR SUSPEN- SION 15 LF-48 MCG- 5 LF UNIT/0.5ML (diphtheria, pertussis(acell),tetanus,polio vaccine/pf) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| QUADRACEL (PF) INTRAMUSCULAR SY- RINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML (diphtheria, pertussis(acell),tetanus,polio vaccine/pf) | \$0 | ACA |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT (rabies vaccine, purified chicken embryo cell (pcec)/pf) | \$0 | ACA |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML (hepatitis b virus vaccine recombinant/pf) | \$0 | ACA |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML (hepatitis b virus vaccine recombinant/pf) | \$0 | ACA |
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML (rotavirus vaccine, live oral attenuated,89-12 strain, glp(8)) | \$0 | ACA |
| ROTATEQ VACCINE ORAL SOLUTION 2 ML (rotavirus vaccine, live oral pentavalent) | \$0 | ACA |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RE- CONSTITUTION 50 MCG/0.5 ML (varicella-zoster virus glyco- protein e,rec/as01b adjuvant/pf) | \$0 | ACA |
| SPIKEVAX 2024-2025(12Y UP)(PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML (covid vaccine 2024-2025 (12 yrs up) (moderna)/pf) | \$0 | ACA |
| STAMARIL (PF) SUBCUTANEOUS SUSPENSION FOR RE- CONSTITUTION 1,000 UNIT/0.5 ML (<i>yellow fever vaccine live/</i> <i>pf</i>) | \$0 | ACA |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT-2 LF UNIT/0.5ML (tetanus and diphtheria toxoids, adsorbed, adult/pf) | \$0 | ACA |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML (tetanus and diphtheria toxoids, adsorbed, adult/pf) | \$0 | ACA |
| TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION 50 MG (bcg live) | 4 | |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML, 2.4 MCG/0.5 ML (tick-borne encephalitis vaccine) | \$0 | ACA |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML (neisseria meningitidis group b, lipidated fhbp recombinant) | \$0 | ACA |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML (hepatitis a virus and hepatitis b virus vaccine/pf) | \$0 | ACA |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML (typhoid vaccine vi capsular polysaccharide) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML (typhoid vaccine vi capsular polysaccharide) | \$0 | ACA |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML, 50 UNIT/ML (hepatitis a virus vaccine/pf) | \$0 | ACA |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML, 50 UNIT/ML (hepatitis a virus vaccine/pf) | \$0 | ACA |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RE- CONSTITUTION 1,350 UNIT/0.5 ML (varicella virus vaccine live/pf) | \$0 | ACA |
| VAXCHORA VACCINE ORAL SUSPENSION FOR RECONSTITUTION 4X10EXP8 TO 2X 10EXP9 CF UNIT (cholera vaccine, live) | \$0 | ACA |
| VAXELIS (PF) INTRAMUSCULAR SUSPENSION 15 UNIT-5 UNIT- 10 MCG/0.5 ML (diphtheria, pertus (acell), tetanus/hepb/polio/hib conj-meng/pf) | \$0 | ACA |
| VAXELIS (PF) INTRAMUSCULAR SYRINGE 15 UNIT-5 UNIT- 10 MCG/0.5 ML (diphtheria, pertus (acell), tetanus/hepb/polio/hib conj-meng/pf) | \$0 | ACA |
| VAXNEUVANCE (PF) INTRAMUSCULAR SYRINGE 0.5 ML (pneumococcal 15-valent conjugate vaccine (diphtheria crm)/pf) | \$0 | ACA |
| VIMKUNYA INTRAMUSCULAR SYRINGE 40 MCG/0.8 ML (chikungunya vaccine, recombinant/pf) | \$0 | ACA |
| VIVOTIF ORAL CAPSULE, DELAYED RELEASE (DR/EC) 2 BILLION UNIT (typhoid vacc, live, attenuated) | \$0 | ACA |
| XEMBIFY SUBCUTANEOUS SOLUTION 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) (immune globulin,gamma (igg)-klhw human) | 4 | PA |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML (yellow fever vaccine live/pf) | \$0 | ACA |
| MUSCULOSKELETAL & RHEUMATOLOGY | | |
| GOUT THERAPY | | |
| allopurinol oral tablet 100 mg, 300 mg | 1 | |
| allopurinol oral tablet 200 mg | 1 | |
| colchicine oral capsule 0.6 mg | 1 | ST |
| colchicine oral tablet 0.6 mg | 1 | |
| febuxostat oral tablet 40 mg, 80 mg | 1 | ST |
| KRYSTEXXA INTRAVENOUS SOLUTION 8 MG/ML (pegloticase) | 4 | PA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| MITIGARE ORAL CAPSULE 0.6 MG (colchicine) | 2 | ST |
| probenecid oral tablet 500 mg | 1 | |
| probenecid-colchicine oral tablet 500-0.5 mg | 1 | |
| OSTEOPOROSIS THERAPY | | |
| alendronate oral solution 70 mg/75 ml | 1 | QL (4 per 21 days) |
| alendronate oral tablet 10 mg, 5 mg | 1 | QL (30 per 30 days) |
| alendronate oral tablet 35 mg, 70 mg | 1 | QL (4 per 21 days) |
| ibandronate intravenous solution 3 mg/3 ml | 4 | PA |
| ibandronate intravenous syringe 3 mg/3 ml | 4 | PA |
| ibandronate oral tablet 150 mg | 1 | QL (1 per 23 days) |
| raloxifene oral tablet 60 mg | 1 | ACA |
| risedronate oral tablet 150 mg | 1 | QL (1 per 23 days) |
| risedronate oral tablet 35 mg | 1 | QL (4 per 21 days) |
| risedronate oral tablet 5 mg | 1 | QL (30 per 30 days) |
| risedronate oral tablet,delayed release (dr/ec) 35 mg | 1 | QL (4 per 21 days) |
| teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml) | 1 | PA; QL (1 per 21 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) (abaloparatide) | 4 | PA; QL (1 per 30 days) |
| OTHER RHEUMATOLOGICALS | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML (tocilizumab) | 2 | PA; QL (4 per 21 days) |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) (tocilizumab) | 4 | PA |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML (tocilizumab) | 2 | PA; QL (4 per 21 days) |
| ADALIMUMAB-ADAZ SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML | 2 | PA; QL (2 per 21 days) |
| ADALIMUMAB-ADAZ SUBCUTANEOUS SYRINGE 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 2 | PA; QL (2 per 21 days) |
| ADALIMUMAB-ADBM SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML | 2 | PA; QL (2 per 21 days) |
| ADALIMUMAB-ADBM SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML | 2 | PA; QL (2 per 21 days) |
| ADALIMUMAB-ADBM(CF) PEN CROHNS SUBCUTANE- OUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 2 | PA; QL (6 per 365 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| ADALIMUMAB-ADBM(CF) PEN PS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimum-ab-adbm) | 2 | PA; QL (4 per 365 days) |
| ADALIMUMAB-RYVK SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML | 2 | PA; QL (2 per 21 days) |
| ADALIMUMAB-RYVK SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML | 2 | PA; QL (2 per 21 days) |
| AURANOFIN ORAL CAPSULE 3 MG | 2 | |
| BENLYSTA INTRAVENOUS RECON SOLN 120 MG, 400 MG (belimumab) | 4 | PA |
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML (belimumab) | 4 | PA; QL (4 per 21 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML (belimumab) | 4 | PA; QL (4 per 21 days) |
| CYLTEZO(CF) PEN CROHN'S-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumabadbm) | 2 | PA; QL (6 per 365 days) |
| CYLTEZO(CF) PEN PSORIASIS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumabadbm) | 2 | PA; QL (4 per 365 days) |
| CYLTEZO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 2 | PA; QL (2 per 21 days) |
| CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML (adalimum-ab-adbm) | 2 | PA; QL (2 per 21 days) |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) (etanercept) | 2 | PA; QL (4 per 21 days) |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML (etan-ercept) | 2 | PA; QL (8 per 21 days) |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5) (etanercept) | 2 | PA; QL (8 per 21 days) |
| ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML) (etanercept) | 2 | PA; QL (4 per 21 days) |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) (etanercept) | 2 | PA; QL (4 per 21 days) |
| KEVZARA SUBCUTANEOUS PEN INJECTOR 150 MG/1.14 ML, 200 MG/1.14 ML (sarilumab) | 4 | PA; QL (2 per 21 days) |
| KEVZARA SUBCUTANEOUS SYRINGE 150 MG/1.14 ML, 200 MG/1.14 ML (sarilumab) | 4 | PA; QL (2 per 21 days) |
| leflunomide oral tablet 10 mg, 20 mg | 1 | QL (30 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--------------------------|
| OTEZLA ORAL TABLET 20 MG, 30 MG (apremilast) | 2 | PA; QL (60 per 23 days) |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47) (apremilast) | 2 | PA; QL (55 per 365 days) |
| penicillamine oral capsule 250 mg | 1 | PA |
| penicillamine oral tablet 250 mg | 1 | PA |
| RIDAURA ORAL CAPSULE 3 MG (auranofin) | 2 | |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML (upadacitinib) | 4 | PA; QL (360 per 23 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG (<i>upadacitinib</i>) | 2 | PA; QL (30 per 23 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG (<i>upadacitinib</i>) | 2 | PA; QL (56 per 365 days) |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG (milnacipran hcl) | 2 | ST; QL (60 per 30 days) |
| SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) (milnacipran hcl) | 2 | ST; QL (55 per 30 days) |
| SIMLANDI(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML (adalimumab-ryvk) | 2 | PA; QL (2 per 21 days) |
| SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML, 80 MG/0.8 ML (adalimumab-ryvk) | 2 | PA; QL (2 per 21 days) |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML (golimumab) | 2 | PA; QL (1 per 23 days) |
| SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML (golim-umab) | 2 | PA; QL (1 per 23 days) |
| TYENNE AUTOINJECTOR SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML (tocilizumab-aazg) | 4 | PA; QL (4 per 21 days) |
| TYENNE INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) (tocilizumab-aazg) | 4 | PA |
| TYENNE SUBCUTANEOUS SYRINGE 162 MG/0.9 ML (tocilizumab-aazg) | 4 | PA; QL (4 per 21 days) |
| XELJANZ ORAL SOLUTION 1 MG/ML (tofacitinib citrate) | 2 | PA; QL (480 per 30 days) |
| XELJANZ ORAL TABLET 10 MG, 5 MG (tofacitinib citrate) | 2 | PA; QL (60 per 30 days) |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG (tofacitinib citrate) | 2 | PA; QL (30 per 30 days) |
| OBSTETRICS & GYNECOLOGY | | |
| DIAPHRAGMS AND OTHER NON-ORAL CONTRACEPTI | VES | |
| CAYA CONTOURED VAGINAL DIAPHRAGM 65-80 MM (diaphragms, contoured) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| FC2 FEMALE CONDOM (condoms, female) | \$0 | ACA; OTC |
| FEMCAP VAGINAL DEVICE 22 MM (cervical cap) | \$0 | ACA |
| KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 17.5 MCG/24 HR (5 YRS) 19.5 MG (levonorgestrel) | \$0 | ACA |
| LILETTA INTRAUTERINE INTRAUTERINE DEVICE 20.4 MCG/24 HR (8 YRS) 52 MG (levonorgestrel) | \$0 | ACA |
| MIRENA INTRAUTERINE INTRAUTERINE DEVICE 21 MCG/24HR (UP TO 8 YRS) 52 MG (levonorgestrel) | \$0 | ACA |
| MIUDELLA INTRAUTERINE INTRAUTERINE DEVICE 175 SQUARE MM (copper) | \$0 | ACA |
| PARAGARD T 380A INTRAUTERINE INTRAUTERINE DE- VICE 380 SQUARE MM (copper) | \$0 | ACA |
| SKYLA INTRAUTERINE INTRAUTERINE DEVICE 14 MCG/24 HR (3 YRS) 13.5 MG (levonorgestrel) | \$0 | ACA |
| TRUSTEX-RIA NON-LUB CONDOMS DEVICE (condoms, latex, non-lubricated) | \$0 | ACA; OTC |
| WIDE-SEAL DIAPHRAGM 60 VAGINAL DIAPHRAGM 60 MM (diaphragms, wide seal) | \$0 | ACA |
| ESTROGENS & PROGESTINS | | |
| camila oral tablet 0.35 mg | \$0 | ACA |
| covaryx h.s. oral tablet 0.625-1.25 mg | 1 | |
| covaryx oral tablet 1.25-2.5 mg | 1 | |
| deblitane oral tablet 0.35 mg | \$0 | ACA |
| DEPO-PROVERA INTRAMUSCULAR SUSPENSION 150 MG/ ML (medroxyprogesterone acetate) | \$0 | ACA |
| DEPO-PROVERA INTRAMUSCULAR SYRINGE 150 MG/ML (medroxyprogesterone acetate) | \$0 | ACA |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML (medroxyprogesterone acetate) | \$0 | ACA |
| dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr | 1 | QL (8 per 21 days) |
| eemt hs oral tablet 0.625-1.25 mg | 1 | |
| eemt oral tablet 1.25-2.5 mg | 1 | |
| emzahh oral tablet 0.35 mg | \$0 | ACA |
| errin oral tablet 0.35 mg | \$0 | ACA |
| estradiol oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |
| estradiol transdermal gel in metered-dose pump 1.25 gram/actua- tion | 1 | QL (1 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| estradiol transdermal gel in packet 0.25 mg/0.25 gram (0.1 %), 0.5 mg/0.5 gram (0.1 %), 0.75 mg/0.75 gram (0.1%), 1 mg/gram (0.1%), 1.25 mg/1.25 gram (0.1 %) | 1 | QL (30 per 30 days) |
| estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr | 1 | QL (8 per 21 days) |
| estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr | 1 | QL (4 per 21 days) |
| estradiol vaginal cream 0.01 % (0.1 mg/gram) | 1 | |
| estradiol vaginal tablet 10 mcg | 1 | |
| estradiol valerate intramuscular oil 10 mg/ml, 20 mg/ml, 40 mg/ml | 1 | |
| estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg | 1 | |
| estrogens-methyltestosterone oral tablet 0.625-1.25 mg, 1.25-2.5 mg | 1 | |
| fyavolv oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg | 1 | |
| gallifrey oral tablet 5 mg | 1 | |
| heather oral tablet 0.35 mg | \$0 | ACA |
| incassia oral tablet 0.35 mg | \$0 | ACA |
| jencycla oral tablet 0.35 mg | \$0 | ACA |
| jinteli oral tablet 1-5 mg-mcg | 1 | |
| lyleq oral tablet 0.35 mg | \$0 | ACA |
| lyllana transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr | 1 | QL (8 per 21 days) |
| lyza oral tablet 0.35 mg | \$0 | ACA |
| medroxyprogesterone intramuscular suspension 150 mg/ml | \$0 | ACA |
| medroxyprogesterone intramuscular syringe 150 mg/ml | \$0 | ACA |
| medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg | 1 | |
| meleya oral tablet 0.35 mg | \$0 | ACA |
| mimvey oral tablet 1-0.5 mg | 1 | |
| nora-be oral tablet 0.35 mg | \$0 | ACA |
| norethindrone (contraceptive) oral tablet 0.35 mg | \$0 | ACA |
| norethindrone acetate oral tablet 5 mg | 1 | |
| norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg | 1 | |
| OPILL ORAL TABLET 0.075 MG (norgestrel) | \$0 | ACA; OTC |
| progesterone intramuscular oil 50 mg/ml | 4 | |
| progesterone micronized oral capsule 100 mg, 200 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| sharobel oral tablet 0.35 mg | \$0 | ACA |
| tulana oral tablet 0.35 mg | \$0 | ACA |
| yuvafem vaginal tablet 10 mcg | 1 | |
| MISCELLANEOUS OB/GYN | | |
| ANNOVERA VAGINAL RING 0.15-0.013 MG/24 HOUR (segesterone acetate/ethinyl estradiol) | \$0 | ACA |
| clindamycin phosphate vaginal cream 2 % | 1 | |
| eluryng vaginal ring 0.12-0.015 mg/24 hr | \$0 | ACA |
| enilloring vaginal ring 0.12-0.015 mg/24 hr | \$0 | ACA |
| etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr | \$0 | ACA |
| fem ph vaginal gel 0.9-0.025 % | 1 | |
| haloette vaginal ring 0.12-0.015 mg/24 hr | \$0 | ACA |
| metronidazole vaginal gel 0.75 % (37.5mg/5 gram) | 1 | |
| miconazole-3 vaginal suppository 200 mg | 1 | |
| mifepristone oral tablet 200 mg | \$0 | ACA |
| MYFEMBREE ORAL TABLET 40-1-0.5 MG (relugolix/estra-diol/norethindrone acetate) | 2 | PA |
| NEXPLANON SUBDERMAL IMPLANT 68 MG (etonogestrel) | \$0 | ACA |
| norelgestromin-ethin.estradiol transdermal patch weekly 150-35 mcg/24 hr | \$0 | ACA |
| NUVARING VAGINAL RING 0.12-0.015 MG/24 HR (etonogestrel/ethinyl estradiol) | \$0 | ACA |
| ORIAHNN ORAL CAPSULE, SEQUENTIAL 300-1-0.5MG(AM) /300 MG(PM) (elagolix sodium/estradiol/nor-ethindrone acetate) | 2 | PA |
| PHEXXI VAGINAL GEL 1.8-1-0.4 % (lactic acid/citric acid/potassium bitartrate) | \$0 | ACA |
| terconazole vaginal cream 0.4 %, 0.8 % | 1 | |
| terconazole vaginal suppository 80 mg | 1 | |
| tranexamic acid oral tablet 650 mg | 1 | |
| TRIMO-SAN JELLY VAGINAL GEL 0.025-0.01 % (oxyquino-line sulfate/sodium lauryl sulfate) | 2 | |
| TWIRLA TRANSDERMAL PATCH WEEKLY 120-30 MCG/24 HR (levonorgestrel/ethinyl estradiol) | \$0 | ACA |
| vandazole vaginal gel 0.75 % (37.5mg/5 gram) | 1 | |
| VCF CONTRACEPTIVE FILM VAGINAL FILM 28 % (non-oxynol 9) | \$0 | ACA; OTC |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| VCF CONTRACEPTIVE GEL VAGINAL GEL 4 % (nonoxynol 9) | \$0 | ACA; OTC |
| xulane transdermal patch weekly 150-35 mcg/24 hr | \$0 | ACA |
| zafemy transdermal patch weekly 150-35 mcg/24 hr | \$0 | ACA |
| ORAL CONTRACEPTIVES & RELATED AGENTS | | |
| afirmelle oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| after pill oral tablet 1.5 mg | \$0 | ACA; OTC |
| AFTERA ORAL TABLET 1.5 MG (levonorgestrel) | \$0 | ACA; OTC |
| altavera (28) oral tablet 0.15-0.03 mg | \$0 | ACA |
| alyacen 1/35 (28) oral tablet 1-35 mg-mcg | \$0 | ACA |
| alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg | \$0 | ACA |
| amethia oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7) | \$0 | ACA |
| amethyst (28) oral tablet 90-20 mcg (28) | \$0 | ACA |
| apri oral tablet 0.15-0.03 mg | \$0 | ACA |
| aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg | \$0 | ACA |
| ashlyna oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7) | \$0 | ACA |
| aubra eq oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| aubra oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| aurovela 1.5/30 (21) oral tablet 1.5-30 mg-mcg | \$0 | ACA |
| aurovela 1/20 (21) oral tablet 1-20 mg-mcg | \$0 | ACA |
| aurovela 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | \$0 | ACA |
| aviane oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| ayuna oral tablet 0.15-0.03 mg | \$0 | ACA |
| azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5 | \$0 | ACA |
| BALCOLTRA ORAL TABLET 0.1 MG-0.02 MG (21)/IRON (7) (levonorgestrel/ethinyl estradiol/iron) | \$0 | ACA |
| balziva (28) oral tablet 0.4-35 mg-mcg | \$0 | ACA |
| BEYAZ ORAL TABLET 3-0.02-0.451 MG (24) (4) (drospirenone/ethinyl estradiol/levomefolate calcium) | \$0 | ACA |
| blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| briellyn oral tablet 0.4-35 mg-mcg | \$0 | ACA |
| camrese lo oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7) | \$0 | ACA |
| camrese oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7) | \$0 | ACA |
| caziant (28) oral tablet 0.1/.125/.15-25 mg-mcg | \$0 | ACA |
| charlotte 24 fe oral tablet,chewable 1 mg-20 mcg(24) /75 mg (4) | \$0 | ACA |
| chateal eq (28) oral tablet 0.15-0.03 mg | \$0 | ACA |
| cryselle (28) oral tablet 0.3-30 mg-mcg | \$0 | ACA |
| cyred eq oral tablet 0.15-0.03 mg | \$0 | ACA |
| cyred oral tablet 0.15-0.03 mg | \$0 | ACA |
| dasetta 1/35 (28) oral tablet 1-35 mg-mcg | \$0 | ACA |
| dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg | \$0 | ACA |
| daysee oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7) | \$0 | ACA |
| desog-e.estradiol/e.estradiol oral tablet 0.15-0.02 mgx21 /0.01 mg \pm 5 | \$0 | ACA |
| dolishale oral tablet 90-20 mcg (28) | \$0 | ACA |
| drospirenone-e.estradiol-lm.fa oral tablet 3-0.02-0.451 mg (24) (4), 3-0.03-0.451 mg (21) (7) | \$0 | ACA |
| drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg | \$0 | ACA |
| econtra ez oral tablet 1.5 mg | \$0 | ACA; OTC |
| econtra one-step oral tablet 1.5 mg | \$0 | ACA; OTC |
| elinest oral tablet 0.3-30 mg-mcg | \$0 | ACA |
| ELLA ORAL TABLET 30 MG (ulipristal acetate) | \$0 | ACA |
| enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10) | \$0 | ACA |
| enskyce oral tablet 0.15-0.03 mg | \$0 | ACA |
| estarylla oral tablet 0.25-0.035 mg | \$0 | ACA |
| ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg- mcg | \$0 | ACA |
| falmina (28) oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| feirza oral tablet 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| FEMLYV ORAL TABLET, DISINTEGRATING 1 MG- 20 MCG (norethindrone acetate/ethinyl estradiol) | \$0 | ACA |
| finzala oral tablet,chewable 1 mg-20 mcg(24) /75 mg (4) | \$0 | ACA |
| galbriela oral tablet,chewable 0.8mg-25mcg(24) and 75 mg (4) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| gemmily oral capsule 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| hailey fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | \$0 | ACA |
| hailey oral tablet 1.5-30 mg-mcg | \$0 | ACA |
| iclevia oral tablets,dose pack,3 month 0.15 mg-30 mcg (91) | \$0 | ACA |
| isibloom oral tablet 0.15-0.03 mg | \$0 | ACA |
| jaimiess oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7) | \$0 | ACA |
| jasmiel (28) oral tablet 3-0.02 mg | \$0 | ACA |
| jolessa oral tablets,dose pack,3 month 0.15 mg-30 mcg (91) | \$0 | ACA |
| joyeaux oral tablet 0.1 mg-0.02 mg (21)/iron (7) | \$0 | ACA |
| juleber oral tablet 0.15-0.03 mg | \$0 | ACA |
| junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg | \$0 | ACA |
| junel 1/20 (21) oral tablet 1-20 mg-mcg | \$0 | ACA |
| junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | \$0 | ACA |
| junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| kaitlib fe oral tablet,chewable 0.8mg-25mcg(24) and 75 mg (4) | \$0 | ACA |
| kalliga oral tablet 0.15-0.03 mg | \$0 | ACA |
| kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5 | \$0 | ACA |
| kelnor 1/35 (28) oral tablet 1-35 mg-mcg | \$0 | ACA |
| kelnor 1/50 (28) oral tablet 1-50 mg-mcg | \$0 | ACA |
| kurvelo (28) oral tablet 0.15-0.03 mg | \$0 | ACA |
| l norgest/e.estradiol-e.estrad oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7) | \$0 | ACA |
| larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg | \$0 | ACA |
| larin 1/20 (21) oral tablet 1-20 mg-mcg | \$0 | ACA |
| larin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | \$0 | ACA |
| leena 28 oral tablet 0.5/1/0.5-35 mg-mcg | \$0 | ACA |
| lessina oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10) | \$0 | ACA |
| levonorgest-eth.estradiol-iron oral tablet 0.1 mg-0.02 mg (21)/iron (7) | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| levonorgestrel oral tablet 1.5 mg | \$0 | ACA; OTC |
| levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-0.03 mg, 90-20 mcg (28) | \$0 | ACA |
| levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91) | \$0 | ACA |
| levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10) | \$0 | ACA |
| levora-28 oral tablet 0.15-0.03 mg | \$0 | ACA |
| LO LOESTRIN FE ORAL TABLET 1 MG-10 MCG (24)/10 MCG (2) (norethindrone acetate-ethinyl estradiol/ferrous fumarate) | \$0 | ACA |
| LOESTRIN 1.5/30 (21) ORAL TABLET 1.5-30 MG-MCG (nor-ethindrone acetate/ethinyl estradiol) | \$0 | ACA |
| LOESTRIN 1/20 (21) ORAL TABLET 1-20 MG-MCG (norethindrone acetate/ethinyl estradiol) | \$0 | ACA |
| LOESTRIN FE 1.5/30 (28-DAY) ORAL TABLET 1.5 MG-30 MCG (21)/75 MG (7) (norethindrone acetate-ethinyl estradiol/ferrous fumarate) | \$0 | ACA |
| LOESTRIN FE 1/20 (28-DAY) ORAL TABLET 1 MG-20 MCG (21)/75 MG (7) (norethindrone acetate-ethinyl estradiol/ferrous fumarate) | \$0 | ACA |
| lojaimiess oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7) | \$0 | ACA |
| loryna (28) oral tablet 3-0.02 mg | \$0 | ACA |
| low-ogestrel (28) oral tablet 0.3-30 mg-mcg | \$0 | ACA |
| lo-zumandimine (28) oral tablet 3-0.02 mg | \$0 | ACA |
| lutera (28) oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| marlissa (28) oral tablet 0.15-0.03 mg | \$0 | ACA |
| merzee oral capsule 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| mibelas 24 fe oral tablet,chewable 1 mg-20 mcg(24) /75 mg (4) | \$0 | ACA |
| microgestin 1.5/30 (21) oral tablet 1.5-30 mg-mcg | \$0 | ACA |
| microgestin 1/20 (21) oral tablet 1-20 mg-mcg | \$0 | ACA |
| microgestin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | \$0 | ACA |
| mili oral tablet 0.25-0.035 mg | \$0 | ACA |
| minzoya oral tablet 0.1 mg-0.02 mg (21)/iron (7) | \$0 | ACA |
| mono-linyah oral tablet 0.25-0.035 mg | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| my choice oral tablet 1.5 mg | \$0 | ACA; OTC |
| my way oral tablet 1.5 mg | \$0 | ACA; OTC |
| NATAZIA ORAL TABLET 3 MG/2 MG-2 MG/2 MG-3 MG/1 MG (estradiol valerate/dienogest) | \$0 | ACA |
| necon 0.5/35 (28) oral tablet 0.5-35 mg-mcg | \$0 | ACA |
| new day oral tablet 1.5 mg | \$0 | ACA; OTC |
| NEXTSTELLIS ORAL TABLET 3 MG- 14.2 MG (28) (drospire-none/estetrol) | \$0 | ACA |
| nikki (28) oral tablet 3-0.02 mg | \$0 | ACA |
| noreth-ethinyl estradiol-iron oral tablet,chewable 0.8mg-25mcg(24) and 75 mg (4) | \$0 | ACA |
| norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg | \$0 | ACA |
| norethindrone-e.estradiol-iron oral capsule 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| norethindrone-e.estradiol-iron oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | \$0 | ACA |
| norethindrone-e.estradiol-iron oral tablet,chewable 1 mg-20 mcg(24) /75 mg (4) | \$0 | ACA |
| norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.025 mg, 0.18/0.215/0.25 mg-0.035mg (28), 0.25-0.035 mg | \$0 | ACA |
| nortrel 0.5/35 (28) oral tablet 0.5-35 mg-mcg | \$0 | ACA |
| nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21) | \$0 | ACA |
| nortrel 1/35 (28) oral tablet 1-35 mg-mcg | \$0 | ACA |
| nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg | \$0 | ACA |
| nylia 1/35 (28) oral tablet 1-35 mg-mcg | \$0 | ACA |
| nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg | \$0 | ACA |
| ocella oral tablet 3-0.03 mg | \$0 | ACA |
| opcicon one-step oral tablet 1.5 mg | \$0 | ACA; OTC |
| option-2 oral tablet 1.5 mg | \$0 | ACA; OTC |
| philith oral tablet 0.4-35 mg-mcg | \$0 | ACA |
| pimtrea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5 | \$0 | ACA |
| PLAN B ONE-STEP ORAL TABLET 1.5 MG (levonorgestrel) | \$0 | ACA; OTC |
| portia 28 oral tablet 0.15-0.03 mg | \$0 | ACA |
| reclipsen (28) oral tablet 0.15-0.03 mg | \$0 | ACA |
| rivelsa oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| rosyrah oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg | \$0 | ACA |
| SAFYRAL ORAL TABLET 3-0.03-0.451 MG (21) (7) (drospire-none/ethinyl estradiol/levomefolate calcium) | \$0 | ACA |
| setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91) | \$0 | ACA |
| simliya (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5 | \$0 | ACA |
| simpesse oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7) | \$0 | ACA |
| SLYND ORAL TABLET 4 MG (28) (drospirenone) | \$0 | ACA |
| sprintec (28) oral tablet 0.25-0.035 mg | \$0 | ACA |
| sronyx oral tablet 0.1-20 mg-mcg | \$0 | ACA |
| syeda oral tablet 3-0.03 mg | \$0 | ACA |
| TAKE ACTION ORAL TABLET 1.5 MG (levonorgestrel) | \$0 | ACA; OTC |
| tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4) | \$0 | ACA |
| tarina fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | \$0 | ACA |
| TAYTULLA ORAL CAPSULE 1 MG-20 MCG (24)/75 MG (4) (norethindrone acetate-ethinyl estradiol/ferrous fumarate) | \$0 | ACA |
| tilia fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9) | \$0 | ACA |
| tri-estarylla oral tablet 0.18/0.215/0.25 mg-0.035mg (28) | \$0 | ACA |
| tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9) | \$0 | ACA |
| tri-linyah oral tablet 0.18/0.215/0.25 mg-0.035mg (28) | \$0 | ACA |
| tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-0.025 mg | \$0 | ACA |
| tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-0.025 mg | \$0 | ACA |
| tri-lo-mili oral tablet 0.18/0.215/0.25 mg-0.025 mg | \$0 | ACA |
| tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-0.025 mg | \$0 | ACA |
| tri-mili oral tablet 0.18/0.215/0.25 mg-0.035mg (28) | \$0 | ACA |
| tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-0.035mg (28) | \$0 | ACA |
| tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-0.025 mg | \$0 | ACA |
| tri-vylibra oral tablet 0.18/0.215/0.25 mg-0.035mg (28) | \$0 | ACA |
| turqoz (28) oral tablet 0.3-30 mg-mcg | \$0 | ACA |
| TYBLUME ORAL TABLET, CHEWABLE 0.1 MG- 20 MCG (levonorgestrel/ethinyl estradiol) | \$0 | ACA |
| valtya oral tablet 1-50 mg-mcg | \$0 | ACA |
| velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg | \$0 | ACA |
| vestura (28) oral tablet 3-0.02 mg | \$0 | ACA |
| vienva oral tablet 0.1-20 mg-mcg | \$0 | ACA |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5 | \$0 | ACA |
| volnea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5 | \$0 | ACA |
| vyfemla (28) oral tablet 0.4-35 mg-mcg | \$0 | ACA |
| vylibra oral tablet 0.25-0.035 mg | \$0 | ACA |
| wera (28) oral tablet 0.5-35 mg-mcg | \$0 | ACA |
| wymzya fe oral tablet,chewable 0.4mg-35mcg(21) and 75 mg (7) | \$0 | ACA |
| xarah fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9) | \$0 | ACA |
| xelria fe oral tablet,chewable 0.4mg-35mcg(21) and 75 mg (7) | \$0 | ACA |
| YASMIN (28) ORAL TABLET 3-0.03 MG (ethinyl estradiol/drospirenone) | \$0 | ACA |
| YAZ (28) ORAL TABLET 3-0.02 MG (ethinyl estradiol/drospirenone) | \$0 | ACA |
| zarah oral tablet 3-0.03 mg | \$0 | ACA |
| zovia 1-35 (28) oral tablet 1-35 mg-mcg | \$0 | ACA |
| zumandimine (28) oral tablet 3-0.03 mg | \$0 | ACA |
| OXYTOCICS | | |
| methylergonovine oral tablet 0.2 mg | 1 | QL (240 per 30 days) |
| OPHTHALMOLOGY | | |
| ANTIBIOTICS | | |
| bacitracin ophthalmic (eye) ointment 500 unit/gram | 1 | |
| bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram | 1 | |
| ciprofloxacin hcl ophthalmic (eye) drops 0.3 % | 1 | |
| erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %) | 1 | |
| gatifloxacin ophthalmic (eye) drops 0.5 % | 1 | |
| gentamicin ophthalmic (eye) drops 0.3 % | 1 | |
| levofloxacin ophthalmic (eye) drops 0.5 %, 1.5 % | 1 | |
| moxifloxacin ophthalmic (eye) drops 0.5 % | 1 | |
| moxifloxacin ophthalmic (eye) drops, viscous 0.5 % | 1 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % (natamycin) | 2 | |
| neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g | 1 | |
| neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g | 1 | |
| ofloxacin ophthalmic (eye) drops 0.3 % | 1 | |
| polycin ophthalmic (eye) ointment 500-10,000 unit/gram | 1 | |
| polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit-1 mg/ml | 1 | |
| povidone-iodine ophthalmic (eye) solution 5 % | 1 | |
| tobramycin ophthalmic (eye) drops 0.3 % | 1 | |
| ANTIVIRALS | | T. |
| trifluridine ophthalmic (eye) drops 1 % | 1 | |
| BETA-BLOCKERS | | |
| betaxolol ophthalmic (eye) drops 0.5 % | 1 | |
| carteolol ophthalmic (eye) drops 1 % | 1 | |
| levobunolol ophthalmic (eye) drops 0.5 % | 1 | |
| timolol maleate (pf) ophthalmic (eye) dropperette 0.25 %, 0.5 % | 1 | ST |
| timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 % | 1 | |
| timolol maleate ophthalmic (eye) drops, once daily 0.5 % | 1 | ST |
| timolol maleate ophthalmic (eye) gel forming solution 0.25 %, 0.5 % | 1 | ST |
| timolol ophthalmic (eye) drops 0.5 % | 1 | ST |
| CHOLINESTERASE INHIBITOR MIOTICS | | |
| PHOSPHOLINE IODIDE OPHTHALMIC (EYE) DROPS 0.125 % (echothiophate iodide) | 4 | |
| CYCLOPLEGIC MYDRIATICS | | |
| atropine ophthalmic (eye) drops 0.01 % | 1 | |
| atropine ophthalmic (eye) drops 1 % | 1 | |
| cyclopentolate ophthalmic (eye) drops 1 % | 1 | |
| cyclopen-tropic-phenyleph-watr ophthalmic (eye) drops 1-1-2.5 % | 1 | |
| homatropaire ophthalmic (eye) drops 5 % | 1 | |
| phenyleph-tropicamide in water ophthalmic (eye) drops 2.5-1 % | 1 | |
| tropicamide ophthalmic (eye) drops 0.5 %, 1 % | 1 | |
| DIRECT ACTING MIOTICS | | |
| pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 % | 1 | |
| MISCELLANEOUS OPHTHALMOLOGICS | | 1. |
| altacaine ophthalmic (eye) drops 0.5 % | 1 | |
| azelastine ophthalmic (eye) drops 0.05 % | 1 | |
| I (V / I | | L |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-------------------------|
| bepotastine besilate ophthalmic (eye) drops 1.5 % | 1 | ST |
| BYOOVIZ INTRAVITREAL SOLUTION 0.5 MG/0.05 ML (ranibizumab-nuna) | 4 | PA |
| CIMERLI INTRAVITREAL SOLUTION 0.3 MG/0.05 ML, 0.5 MG/0.05 ML (ranibizumab-eqrn) | 4 | PA |
| cromolyn ophthalmic (eye) drops 4 % | 1 | |
| cyclosporine ophthalmic (eye) dropperette 0.05 % | 1 | PA; QL (60 per 30 days) |
| CYSTARAN OPHTHALMIC (EYE) DROPS 0.44 % (cysteamine hcl) | 4 | PA |
| epinastine ophthalmic (eye) drops 0.05 % | 1 | |
| fluorescein-proparacaine ophthalmic (eye) drops 0.25-0.5 % | 1 | |
| LUXTURNA SUBRETINAL SUSPENSION 1.5 X 10EXP11 VG/0.3 ML (FNL) (voretigene neparvovec-rzyl) | 4 | PA |
| MIEBO (PF) OPHTHALMIC (EYE) DROPS 100 % (perfluoro-hexyloctane/pf) | 2 | PA; QL (3 per 30 days) |
| OXERVATE OPHTHALMIC (EYE) DROPS 0.002 % (cenegermin-bkbj) | 4 | PA |
| PAVBLU INTRAVITREAL SOLUTION 2 MG/0.05 ML (afliber-cept-ayyh) | 4 | PA |
| PAVBLU INTRAVITREAL SYRINGE 2 MG/0.05 ML (afliber-cept-ayyh) | 4 | PA |
| prednisoln sp-moxiflox-bromfen ophthalmic (eye) drops 1-0.5-0.075 % | 1 | |
| prednisolone sod ph-bromfenac ophthalmic (eye) drops 1-0.075 % | 1 | |
| proparacaine ophthalmic (eye) drops 0.5 % | 1 | |
| RESTASIS MULTIDOSE OPHTHALMIC (EYE) DROPS 0.05 % (cyclosporine) | 2 | PA; QL (6 per 30 days) |
| tetracaine hcl ophthalmic (eye) drops 0.5 % | 1 | |
| XDEMVY OPHTHALMIC (EYE) DROPS 0.25 % (lotilaner) | 4 | QL (10 per 30 days) |
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % (lifite-grast) | 2 | PA; QL (60 per 30 days) |
| NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | | |
| bromfenac ophthalmic (eye) drops 0.07 %, 0.075 %, 0.09 % | 1 | |
| diclofenac sodium ophthalmic (eye) drops 0.1 % | 1 | |
| flurbiprofen sodium ophthalmic (eye) drops 0.03 % | 1 | |
| ketorolac ophthalmic (eye) drops 0.4 %, 0.5 % | 1 | |
| ORAL DRUGS FOR GLAUCOMA | | |
| acetazolamide oral capsule, extended release 500 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits | |
|--|-----------|-----------------------|--|
| acetazolamide oral tablet 125 mg, 250 mg | 1 | | |
| methazolamide oral tablet 25 mg, 50 mg | 1 | | |
| OTHER GLAUCOMA DRUGS | | | |
| bimatoprost ophthalmic (eye) drops 0.03 % | 1 | PA | |
| brimonidine-timolol ophthalmic (eye) drops 0.2-0.5 % | 1 | | |
| brinzolamide ophthalmic (eye) drops, suspension 1 % | 1 | | |
| dorzolamide ophthalmic (eye) drops 2 % | 1 | | |
| dorzolamide-timolol (pf) ophthalmic (eye) dropperette 2-0.5 % | 1 | | |
| dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml | 1 | | |
| latanoprost ophthalmic (eye) drops 0.005 % | 1 | PA | |
| miostat intraocular solution 0.01 % | 1 | | |
| tafluprost (pf) ophthalmic (eye) dropperette 0.0015 % | 1 | PA | |
| travoprost ophthalmic (eye) drops 0.004 % | 1 | PA | |
| STEROID-ANTIBIOTIC COMBINATIONS | | | |
| neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1% | 1 | | |
| neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 % | 1 | | |
| neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 % | 1 | | |
| neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml | 1 | | |
| neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1% | 1 | | |
| tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 % | 1 | | |
| STEROIDS | | | |
| dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 % | 1 | | |
| difluprednate ophthalmic (eye) drops 0.05 % | 1 | | |
| fluorometholone ophthalmic (eye) drops,suspension 0.1 % | 1 | | |
| loteprednol etabonate ophthalmic (eye) drops,gel 0.5 % | 1 | ST | |
| loteprednol etabonate ophthalmic (eye) drops, suspension 0.2 %, 0.5 % | 1 | ST | |
| OZURDEX INTRAVITREAL IMPLANT 0.7 MG (dexamethasone) | 4 | | |
| prednisolone acetate ophthalmic (eye) drops, suspension 1 % | 1 | | |
| prednisolone sodium phosphate ophthalmic (eye) drops 1 % | 1 | | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|--|
| STEROID-SULFONAMIDE COMBINATIONS | | <u>, </u> |
| sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %) | 1 | |
| SULFONAMIDES | | |
| sulfacetamide sodium ophthalmic (eye) drops 10 % | 1 | |
| sulfacetamide sodium ophthalmic (eye) ointment 10 % | 1 | |
| SYMPATHOMIMETICS | | |
| apraclonidine ophthalmic (eye) drops 0.5 % | 1 | |
| brimonidine ophthalmic (eye) drops 0.1 %, 0.15 %, 0.2 % | 1 | |
| VASOCONSTRICTOR DECONGESTANTS | | |
| ohenylephrine hcl ophthalmic (eye) drops 10 %, 2.5 % | 1 | |
| RESPIRATORY, ALLERGY, COUGH & COLD | | |
| ANTIHISTAMINE & ANTIALLERGENIC AGENTS | | |
| carbinoxamine maleate oral liquid 4 mg/5 ml | 1 | |
| carbinoxamine maleate oral tablet 4 mg | 1 | |
| carbinoxamine maleate oral tablet 6 mg | 1 | ST |
| cyproheptadine oral syrup 2 mg/5 ml | 1 | |
| cyproheptadine oral tablet 4 mg | 1 | |
| desloratadine oral tablet 5 mg | 1 | QL (30 per 30 days) |
| desloratadine oral tablet, disintegrating 2.5 mg, 5 mg | 1 | QL (30 per 30 days) |
| dexchlorpheniramine maleate oral solution 2 mg/5 ml | 1 | |
| epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml | 1 | QL (4 per 30 days) |
| EPIPEN INJECTION AUTO-INJECTOR 0.3 MG/0.3 ML (epinephrine) | 2 | ST; QL (4 per 30 days) |
| EPIPEN JR INJECTION AUTO-INJECTOR 0.15 MG/0.3 ML (epinephrine) | 2 | ST; QL (4 per 30 days) |
| hydroxyzine hcl oral solution 10 mg/5 ml | 1 | |
| hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg | 1 | |
| hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg | 1 | |
| NEFFY NASAL SPRAY,NON-AEROSOL 1 MG/SPRAY (0.1 ML) (epinephrine) | 2 | |
| NEFFY NASAL SPRAY,NON-AEROSOL 2 MG/SPRAY (0.1 ML) (epinephrine) | 2 | QL (4 per 30 days) |
| promethazine oral syrup 6.25 mg/5 ml | 1 | |
| promethazine oral tablet 12.5 mg, 25 mg, 50 mg | 1 | |
| promethazine rectal suppository 12.5 mg, 25 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------------|
| promethegan rectal suppository 12.5 mg, 25 mg, 50 mg | 1 | |
| COUGH & COLD THERAPY | | |
| benzonatate oral capsule 100 mg, 150 mg, 200 mg | 1 | |
| brompheniramine-pseudoeph-dm oral syrup 2-30-10 mg/5 ml | 1 | |
| codeine-guaifenesin oral liquid 10-100 mg/5 ml | 1 | |
| g tussin ac oral liquid 10-100 mg/5 ml | 1 | |
| hydrocodone-chlorpheniramine oral suspension,extended rel 12 hr 10-8 mg/5 ml | 1 | |
| hydrocodone-homatropine oral solution 5-1.5 mg/5 ml | 1 | |
| hydrocodone-homatropine oral tablet 5-1.5 mg | 1 | |
| hydromet oral solution 5-1.5 mg/5 ml | 1 | |
| maxi-tuss ac oral liquid 10-100 mg/5 ml | 1 | |
| promethazine-codeine oral syrup 6.25-10 mg/5 ml | 1 | |
| promethazine-dm oral syrup 6.25-15 mg/5 ml | 1 | |
| promethazine-phenylephrine oral syrup 6.25-5 mg/5 ml | 1 | |
| PULMONARY AGENTS | | |
| acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %) | 1 | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG (<i>riociguat</i>) | 4 | PA; LA; QL (90 per 30 days) |
| albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation | 1 | QL (1 per 30 days) |
| albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 5 mg/ml | 1 | |
| albuterol sulfate inhalation solution for nebulization 2.5 mg/0.5 ml | 1 | |
| albuterol sulfate oral syrup 2 mg/5 ml | 1 | |
| albuterol sulfate oral tablet 2 mg, 4 mg | 1 | |
| albuterol sulfate oral tablet extended release 12 hr 4 mg, 8 mg | 1 | |
| ALYFTREK ORAL TABLET 10-50-125 MG (vanzacaftor calcium/tezacaftor/deutivacaftor) | 4 | PA; QL (56 per 30 days) |
| ALYFTREK ORAL TABLET 4-20-50 MG (vanzacaftor calcium/tezacaftor/deutivacaftor) | 4 | PA; QL (84 per 30 days) |
| alyq oral tablet 20 mg | 1 | PA; QL (60 per 30 days) |
| ambrisentan oral tablet 10 mg, 5 mg | 1 | PA; LA; QL (30 per 30 days) |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION (umeclidinium bromide/vilanterol trifenatate) | 2 | QL (1 per 30 days) |
| arformoterol inhalation solution for nebulization 15 mcg/2 ml | 1 | QL (120 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-------------------------|
| azelastine-fluticasone nasal spray,non-aerosol 137-50 mcg/spray | 1 | ST; QL (1 per 30 days) |
| bosentan oral tablet 125 mg, 62.5 mg | 1 | PA; QL (60 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE, 50-25 MCG/DOSE (fluticasone furoate/vilanterol trifenatate) | 2 | PA; QL (1 per 30 days) |
| breyna inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation | 1 | PA; QL (1 per 30 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION (budesonide/glycopyrrolate/formoterol fumarate) | 2 | QL (1 per 30 days) |
| budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml | 1 | QL (120 per 30 days) |
| budesonide inhalation suspension for nebulization 1 mg/2 ml | 1 | QL (60 per 30 days) |
| budesonide-formoterol inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation | 1 | PA; QL (1 per 30 days) |
| CINRYZE INTRAVENOUS RECON SOLN 500 UNIT (5 ML) (c1 esterase inhibitor) | 4 | PA; QL (32 per 21 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ ACTUATION (ipratropium bromide/albuterol sulfate) | 2 | QL (8 per 30 days) |
| cromolyn inhalation solution for nebulization 20 mg/2 ml | 1 | |
| DULERA INHALATION HFA AEROSOL INHALER 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION (mometasone furoate/formoterol fumarate) | 2 | PA; QL (1 per 30 days) |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML (benralizumab) | 4 | PA; QL (1 per 56 days) |
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML (benralizumab) | 4 | PA; QL (1 per 42 days) |
| FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML (benralizumab) | 4 | PA; QL (1 per 56 days) |
| flunisolide nasal spray,non-aerosol 25 mcg (0.025 %) | 1 | ST; QL (1 per 30 days) |
| fluticasone propionate nasal spray,suspension 50 mcg/actuation | 1 | QL (1 per 30 days) |
| FLUTICASONE PROPION-SALMETEROL INHALATION AEROSOL POWDR BREATH ACTIVATED 113-14 MCG/ ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUA- TION | 2 | PA; QL (1 per 30 days) |
| fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose | 1 | PA; QL (1 per 30 days) |
| formoterol fumarate inhalation solution for nebulization 20 mcg/2 ml | 1 | QL (120 per 30 days) |
| icatibant subcutaneous syringe 30 mg/3 ml | 1 | PA; QL (12 per 21 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------------|
| INCRUSE ELLIPTA INHALATION BLISTER WITH DEVICE 62.5 MCG/ACTUATION (umeclidinium bromide) | 2 | QL (1 per 30 days) |
| ipratropium bromide inhalation solution 0.02 % | 1 | |
| ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml | 1 | QL (540 per 30 days) |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG (ivacaftor) | 4 | PA; QL (56 per 30 days) |
| KALYDECO ORAL TABLET 150 MG (ivacaftor) | 4 | PA; QL (56 per 30 days) |
| levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml | 1 | |
| mometasone nasal spray,non-aerosol 50 mcg/actuation | 1 | ST; QL (1 per 30 days) |
| montelukast oral granules in packet 4 mg | 1 | |
| montelukast oral tablet 10 mg | 1 | |
| montelukast oral tablet,chewable 4 mg, 5 mg | 1 | |
| nebusal inhalation solution for nebulization 3 % | 1 | |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML (mepolizumab) | 4 | PA; LA; QL (1 per 21 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG (mepoli-zumab) | 4 | PA; LA; QL (1 per 21 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML (mepolizumab) | 4 | PA; LA; QL (1 per 21 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG (nintedanib esylate) | 4 | PA; QL (60 per 30 days) |
| OPSUMIT ORAL TABLET 10 MG (macitentan) | 4 | PA; LA; QL (30 per 30 days) |
| OPSYNVI ORAL TABLET 10-20 MG, 10-40 MG (macitentan/tadalafil) | 4 | PA; QL (30 per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG, 75-94 MG (lumacaftor/ivacaftor) | 4 | PA; QL (56 per 30 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG (luma-caftor/ivacaftor) | 4 | PA; QL (112 per 30 days) |
| pirfenidone oral capsule 267 mg | 1 | PA; QL (270 per 30 days) |
| pirfenidone oral tablet 267 mg | 1 | PA; QL (270 per 30 days) |
| pirfenidone oral tablet 801 mg | 1 | PA; QL (90 per 30 days) |
| pulmosal inhalation solution for nebulization 7 % | 1 | |
| PULMOZYME INHALATION SOLUTION 1 MG/ML (dornase alfa) | 4 | PA |
| QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION, 80 MCG/ACTUATION (beclomethasone dipropionate) | 2 | QL (1 per 30 days) |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|----------------------------|
| roflumilast oral tablet 250 mcg | 1 | ST; QL (30 per 30 days) |
| roflumilast oral tablet 500 mcg | 1 | ST |
| RUCONEST INTRAVENOUS RECON SOLN 2,100 UNIT (cl esterase inhibitor, recombinant) | 4 | PA; QL (16 per 21 days) |
| sajazir subcutaneous syringe 30 mg/3 ml | 1 | PA; QL (12 per 21 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE (salmeterol xinafoate) | 3 | QL (60 per 30 days) |
| sildenafil (pulm.hypertension) intravenous solution 10 mg/12.5 ml | 4 | |
| sildenafil (pulm.hypertension) oral suspension for reconstitution 10 mg/ml | 1 | PA; QL (112 per 30 days) |
| sildenafil (pulm.hypertension) oral tablet 20 mg | 1 | PA; QL (90 per 30 days) |
| sodium chloride inhalation solution for nebulization 0.9 %, 10 %, 3 %, 7 % | 1 | |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION (tiotropium bromide) | 2 | QL (1 per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION (tiotropium bromide/olodaterol hcl) | 2 | QL (1 per 30 days) |
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/AC-TUATION (olodaterol hcl) | 2 | QL (1 per 30 days) |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) (tezacaftor/ivacaftor) | 4 | PA; QL (56 per 30 days) |
| tadalafil (pulm. hypertension) oral tablet 20 mg | 1 | PA; QL (60 per 30 days) |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2 ML (150 MG/ML) (lanadelumab-flyo) | 4 | PA; LA; QL (2 per 21 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML (150 MG/ML) (lanadelumab-flyo) | 4 | PA; LA; QL (2 per 21 days) |
| terbutaline oral tablet 2.5 mg, 5 mg | 1 | |
| TEZSPIRE SUBCUTANEOUS PEN INJECTOR 210 MG/1.91 ML (110 MG/ML) (tezepelumab-ekko) | 4 | PA; QL (1 per 21 days) |
| TEZSPIRE SUBCUTANEOUS SYRINGE 210 MG/1.91 ML (110 MG/ML) (tezepelumab-ekko) | 4 | PA; QL (1 per 21 days) |
| theophylline oral elixir 80 mg/15 ml | 1 | |
| theophylline oral solution 80 mg/15 ml | 1 | |
| theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg | 1 | |
| theophylline oral tablet extended release 24 hr 400 mg, 600 mg | 1 | |
| tiotropium bromide inhalation capsule, w/inhalation device 18 mcg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|------------------------------|
| TRACLEER ORAL TABLET FOR SUSPENSION 32 MG (bosentan) | 4 | PA; LA; QL (120 per 30 days) |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG (fluticasone furoate/ume-clidinium bromide/vilanterol trifenat) | 2 | QL (1 per 30 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) (elexacaftor/tezacaftor/ivacaftor) | 4 | PA; QL (56 per 30 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) (elexacaftor/tezacaftor/ivacaftor) | 4 | PA; QL (84 per 30 days) |
| TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16(112)-32(112) -48(28) MCG, 32 MCG, 48 MCG, 64 MCG (treprostinil) | 4 | PA |
| TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) (treprostinil) | 4 | PA |
| TYVASO REFILL KIT INHALATION SOLUTION FOR NEB- ULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) (treprostinil/nebu- lizer accessories) | 4 | PA |
| TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (treprostinil/nebulizer and accessories) | 4 | PA |
| wixela inhub inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose | 1 | PA; QL (1 per 30 days) |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML (omalizumab) | 4 | PA; LA; QL (2 per 28 days) |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG (omalizumab) | 4 | PA; LA; QL (6 per 28 days) |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML (omalizumab) | 4 | PA; LA; QL (2 per 28 days) |
| zafirlukast oral tablet 10 mg, 20 mg | 1 | |
| PULMONARY DEVICES | | |
| ACE AEROSOL CLOUD ENHANCER SPACER (inhaler, assist devices) | 2 | |
| AEROCHAMBER MECHANICAL VENT SPACER (inhaler, assist devices) | 2 | |
| AEROCHAMBER MINI SPACER (inhaler, assist devices) | 2 | |
| AEROCHAMBER PLUS FLOW-VU SPACER (inhaler, assist devices) | 2 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| AEROCHAMBER PLUS Z STAT SPACER (inhaler, assist devices) | 2 | |
| AEROTRACH PLUS SPACER (inhaler, assist devices) | 2 | |
| AEROVENT PLUS SPACER (inhaler, assist devices) | 2 | |
| BREATHERITE MDI SPACER SPACER (inhaler, assist devices) | 2 | |
| COMPACT SPACE CHAMBER SPACER (inhaler, assist devices) | 2 | |
| EASIVENT HOLDING CHAMBER SPACER (inhaler, assist devices) | 2 | |
| FLEXICHAMBER SPACER (inhaler, assist devices) | 2 | |
| LITEAIRE MDI CHAMBER SPACER (inhaler, assist devices) | 2 | |
| MICROCHAMBER SPACER (inhaler, assist devices) | 2 | |
| MICROSPACER SPACER (inhaler, assist devices) | 2 | |
| OPTICHAMBER DIAMOND VHC SPACER (inhaler, assist devices) | 2 | |
| POCKET CHAMBER SPACER (inhaler, assist devices) | 2 | |
| PRIMEAIRE SPACER (inhaler, assist devices) | 2 | |
| PROCHAMBER SPACER (inhaler, assist devices) | 2 | |
| RITEFLO AEROCHAMBER SPACER (inhaler, assist devices) | 2 | |
| SPACE CHAMBER SPACER (inhaler, assist devices) | 2 | |
| VORTEX HOLDING CHAMBER SPACER (inhaler, assist devices) | 2 | |
| UROLOGICALS | | |
| ANTICHOLINERGICS & ANTISPASMODICS | | |
| darifenacin oral tablet extended release 24 hr 15 mg, 7.5 mg | 1 | |
| fesoterodine oral tablet extended release 24 hr 4 mg, 8 mg | 1 | |
| flavoxate oral tablet 100 mg | 1 | |
| mirabegron oral tablet extended release 24 hr 25 mg, 50 mg | 1 | |
| oxybutynin chloride oral syrup 5 mg/5 ml | 1 | |
| oxybutynin chloride oral tablet 5 mg | 1 | |
| oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg, 5 mg | 1 | |
| solifenacin oral tablet 10 mg, 5 mg | 1 | |
| tolterodine oral capsule, extended release 24hr 2 mg, 4 mg | 1 | |
| tolterodine oral tablet 1 mg, 2 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| trospium oral capsule,extended release 24hr 60 mg | 1 | |
| trospium oral tablet 20 mg | 1 | |
| BENIGN PROSTATIC HYPERPLASIA (BPH) THERAP | PΥ | |
| alfuzosin oral tablet extended release 24 hr 10 mg | 1 | |
| dutasteride oral capsule 0.5 mg | 1 | ST |
| dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg | 1 | ST |
| finasteride oral tablet 5 mg | 1 | |
| silodosin oral capsule 4 mg, 8 mg | 1 | |
| tamsulosin oral capsule 0.4 mg | 1 | |
| CHOLINERGIC STIMULANTS | | |
| bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg | 1 | |
| MISCELLANEOUS UROLOGICALS | | |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG (cysteamine bitartrate) | 4 | LA |
| ELMIRON ORAL CAPSULE 100 MG (pentosan polysulfate sodium) | 2 | |
| K-PHOS ORIGINAL ORAL TABLET, SOLUBLE 500 MG (potassium phosphate, monobasic) | 2 | |
| mb caps oral capsule 120-10.8-40.8 mg | 1 | |
| methen-sod phos-meth blue-hyos oral tablet 81.6-40.8-0.12 mg | 1 | |
| potassium citrate oral tablet extended release 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) | 1 | |
| RENACIDIN IRRIGATION SOLUTION 1980.6 MG-59.4 MG-980.4MG/30ML (citric acid/gluconolactone/magnesium carbonate) | 2 | |
| sodium citrate-citric acid oral solution 490-640 mg/5 ml | 1 | |
| uretron d-s oral tablet 81.6-10.8-40.8 mg | 1 | |
| urimar-t oral tablet 120-10.8-0.12 mg | 1 | |
| urogesic-blue oral tablet 81.6-40.8-0.12 mg | 1 | |
| uro-mp oral capsule 118-10-40.8-36 mg | 1 | |
| uro-sp oral capsule 118-10-40.8-36 mg | 1 | |
| uryl oral tablet 81.6-40.8-0.12 mg | 1 | |
| URINARY ANESTHETICS | | |
| phenazopyridine oral tablet 100 mg, 200 mg | 1 | |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| VITAMINS, HEMATINICS & ELECTROLYTES | | |
| ELECTROLYTES | | |
| calcium acetate(phosphat bind) oral capsule 667 mg | 1 | QL (360 per 30 days) |
| calcium acetate(phosphat bind) oral tablet 667 mg | 1 | QL (360 per 30 days) |
| effer-k oral tablet, effervescent 25 meq | 1 | |
| klor-con 10 oral tablet extended release 10 meq | 1 | |
| klor-con 8 oral tablet extended release 8 meq | 1 | |
| klor-con m10 oral tablet,er particles/crystals 10 meq | 1 | |
| klor-con m15 oral tablet,er particles/crystals 15 meq | 1 | |
| klor-con m20 oral tablet,er particles/crystals 20 meq | 1 | |
| klor-con oral packet 20 meq | 1 | |
| klor-con/ef oral tablet, effervescent 25 meq | 1 | |
| lanthanum oral tablet,chewable 1,000 mg, 500 mg, 750 mg | 1 | QL (90 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM (sodium zirconium cyclosilicate) | 2 | QL (30 per 30 days) |
| lugols oral solution 5 % | 1 | |
| potassium chloride oral capsule, extended release 10 meq, 8 meq | 1 | |
| potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml | 1 | |
| potassium chloride oral packet 20 meq | 1 | |
| potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq | 1 | |
| potassium chloride oral tablet,er particles/crystals 10 meq, 15 meq, 20 meq | 1 | |
| sevelamer carbonate oral powder in packet 0.8 gram | 1 | QL (180 per 30 days) |
| sevelamer carbonate oral powder in packet 2.4 gram | 1 | QL (90 per 30 days) |
| sevelamer carbonate oral tablet 800 mg | 1 | QL (270 per 30 days) |
| sevelamer hcl oral tablet 400 mg | 1 | QL (450 per 30 days) |
| sevelamer hcl oral tablet 800 mg | 1 | QL (270 per 30 days) |
| sodium polystyrene sulfonate oral powder | 1 | |
| sps (with sorbitol) oral suspension 15-20 gram/60 ml | 1 | |
| sps (with sorbitol) rectal enema 30-40 gram/120 ml | 1 | |
| strong iodine oral solution 5 % | 1 | |
| VITAMINS & HEMATINICS | | |
| b complex 1 (with folic acid) oral tablet 0.4 mg | \$0 | ACA; OTC |
| b complex-vitamin c-folic acid oral tablet 400 mcg | \$0 | ACA; OTC |
| balanced b-100 oral tablet 0.4 mg | \$0 | ACA; OTC |
| b-complex with vitamin c oral tablet 400-500 mcg-mg | \$0 | ACA; OTC |

| Drug Name | Drug Tier | Requirements / Limits |
|--|-----------|-----------------------|
| classic prenatal oral tablet 28 mg iron- 800 mcg | \$0 | ACA; OTC |
| dialyvite 800 oral tablet 0.8 mg | \$0 | ACA; OTC |
| flotrex oral tablet,chewable 0.25 mg, 0.5 mg | \$0 | ACA; OTC |
| fluoride (sodium) oral drops 0.5 mg (1.1 mg sod.fluorid)/ml | \$0 | ACA; OTC |
| fluoride (sodium) oral tablet,chewable 0.25 mg(0.55 mg sod. fluoride), 0.5 mg (1.1 mg sodium fluorid), 1 mg (2.2 mg sod. fluoride) | \$0 | ACA; OTC |
| folic acid oral tablet 1 mg | 1 | |
| folic acid oral tablet 400 mcg, 800 mcg | \$0 | ACA; OTC |
| folitab oral tablet extended release 105 mg iron- 500 mg-800 mcg | \$0 | ACA; OTC |
| foltabs 800 oral tablet 0.8-10-115 mg-mg-mcg | \$0 | ACA; OTC |
| full spectrum b-vitamin c oral tablet 0.8 mg | \$0 | ACA; OTC |
| kobee oral tablet 0.4 mg | \$0 | ACA; OTC |
| ludent fluoride oral tablet, chewable 0.25 mg(0.55 mg sod. fluoride), 0.5 mg (1.1 mg sodium fluorid), 1 mg (2.2 mg sod. fluoride) | \$0 | ACA; OTC |
| multi-vitamin with fluoride oral drops 0.25 mg/ml, 0.5 mg/ml | \$0 | ACA; OTC |
| multi-vitamin with fluoride oral tablet,chewable 0.25 mg, 0.5 mg, 1 mg | \$0 | ACA; OTC |
| mvc-fluoride oral tablet,chewable 0.25 mg, 0.5 mg, 1 mg | \$0 | ACA; OTC |
| one daily prenatal oral combo pack 28-800-440 mg-mcg-mg | \$0 | ACA; OTC |
| prenatal complete oral tablet 14 mg iron- 400 mcg | \$0 | ACA; OTC |
| prenatal multi-dha (algal oil) oral capsule 27mg iron- 800 mcg- 250 mg | \$0 | ACA; OTC |
| prenatal multivitamins oral tablet 28 mg iron- 800 mcg | \$0 | ACA; OTC |
| prenatal one daily oral tablet 27 mg iron- 800 mcg | \$0 | ACA; OTC |
| prenatal oral tablet 28 mg iron- 800 mcg | \$0 | ACA; OTC |
| prenatal vit no.179-iron-folic oral tablet 28 mg iron- 800 mcg | \$0 | ACA; OTC |
| prenatal vitamin oral tablet 27 mg iron- 0.8 mg | \$0 | ACA; OTC |
| prenatal vitamin with minerals oral tablet 28 mg iron-800 mcg | \$0 | ACA; OTC |
| rena-vite oral tablet 0.8 mg | \$0 | ACA; OTC |
| soluvita a,c,d with fluoride oral drops 0.25 mg fluor. (0.55 mg)/ml | \$0 | ACA; OTC |
| soluvita oral drops 0.5 mg (1.1 mg sod.fluorid)/ml | \$0 | ACA; OTC |
| stress formula with iron oral tablet 500 mg-400 mcg- 18 mg iron | \$0 | ACA; OTC |
| stress formula with iron(sulf) oral tablet 500 mg-400 mcg- 27 mg iron | \$0 | ACA; OTC |
| super b-50 complex oral capsule 400 mcg-20 mg- 50 mg | \$0 | ACA; OTC |

| Drug Name | Drug Tier | Requirements / Limits |
|---|-----------|-----------------------|
| super quints oral tablet 0.4 mg | \$0 | ACA; OTC |
| tricon oral capsule 110-0.5 mg | \$0 | ACA; OTC |
| tri-vitamin with fluoride oral drops 0.25 mg fluor. (0.55 mg)/ml, 0.5 mg fluoride (1.1 mg)/ml | \$0 | ACA; OTC |
| vitamin b complex-folic acid oral tablet 0.4 mg | \$0 | ACA; OTC |
| vitamins a,c,d and fluoride oral drops 0.25 mg fluor. (0.55 mg)/ml, 0.5 mg fluoride (1.1 mg)/ml | \$0 | ACA; OTC |

| Index | AEROTRACH PLUS | | amoxicil-clarithromy- | |
|---------------------------------|-----------------------------|-------|-----------------------------|-----|
| | AEROVENT PLUS | | lansopraz | 98 |
| A | afirmelle | | amoxicillin | 22 |
| <i>abacavir</i> 14 | | | amoxicillin-pot clavulanate | 22 |
| abacavir-lamivudine14 | v 1 | | amphetamine sulfate | 49 |
| <i>ABILIFY MAINTENA</i> 48, 49 | | | ampicillin | 22 |
| abiraterone24 | | 41 | AMTAGVI | 24 |
| abirtega24 | | 41 | anagrelide | 78 |
| <i>ABRYSVO (PF)</i> 100 | albendazole | 20 | anaspaz | 93 |
| acamprosate78 | albuterol sulfate | 123 | anastrozole | |
| acarbose90 | alclometasone | 75 | ANNOVERA | 111 |
| accutane71 | ALDURAZYME | 88 | ANORO ELLIPTA | 123 |
| ACE AEROSOL CLOUD | ALECENSA | 24 | anucort-hc | 94 |
| ENHANCER127 | alendronate | 106 | apomorphine | 40 |
| acebutolol57 | ALFERON N | 100 | apraclonidine | |
| acetaminophen-caff-dihydrocod44 | alfuzosin | 129 | aprepitant | |
| acetaminophen-codeine44 | ALINIA | 20 | APRETUDE | |
| acetazolamide 120, 121 | | 24 | apri | |
| acetic acid78, 81 | ~ | | APTIVUS | |
| acetylcysteine123 | | | aranelle (28) | |
| acitretin68 | _ | | AREXVY (PF) | |
| ACTEMRA106 | T | | arformoterol | |
| ACTEMRA ACTPEN106 | | | argatroban in 0.9 % s | 123 |
| <i>ACTHIB (PF)</i> 100 | | | od chlor | 62 |
| ACTIMMUNE | * | | ARIKAYCE | |
| acyclovir | 1 | | aripiprazole | |
| ADACEL(TDAP | altavera (28) | | | |
| ADOLESN/ADULT)(PF)100 | · · · | | armodafinilARMOUR THYROID | |
| ADAKVEO24 | | | arsenic trioxide | |
| ADALIMUMAB-ADAZ106 | | | | |
| ADALIMUMAB-ADBM106 | 1 | | ascomp with codeine | |
| ADALIMUMAB-ADBM(CF) | alyacen 7/7/7 (28) | | asenapine maleate | |
| PEN CROHNS106 | | | ashlyna | |
| ADALIMUMAB-ADBM(CF) | alyq | | aspirin | |
| PEN PS-UV107 | <i>v</i> 1 | | aspirin childrens | |
| ADALIMUMAB-RYVK 107 | | | aspirin-dipyridamole | |
| | | | atazanavir | |
| adapalene71 | | | atenolol | |
| adapalene-benzoyl peroxide71 | | | atenolol-chlorthalidone | |
| ADBRY70 | 2 () | | atomoxetine | |
| ADCETRIS24 | | | atorvastatin | |
| adefovir | | | atovaquone | |
| ADEMPAS123 | 1 | | atovaquone-proguanil | |
| adrucil24 | | | atropine | |
| adthyza92 | | | ATTRUBY | |
| <i>ADVATE</i> 62 | 1 7 | | aubra | 112 |
| <i>ADYNOVATE</i> 62 | 1 | | aubra eq | |
| AEROCHAMBER MECHANICAL | amlodipine-atorvastatin | | AUGMENTIN | |
| VENT127 | 1 1 | | AURANOFIN | 107 |
| AEROCHAMBER MINI127 | T | | aurovela 1.5/30 (21) | 112 |
| AEROCHAMBER PLUS | amlodipine-valsartan | | aurovela 1/20 (21) | 112 |
| FLOW-VU127 | amlodipine-valsartan-hcthia | zid57 | aurovela 24 fe | 112 |
| AEROCHAMBER PLUS | amnesteem | 71 | aurovela fe 1.5/30 (28) | 112 |
| Z STAT128 | amoxapine | 49 | aurovela fe 1-20 (28) | |

| AUSTEDO | | LYSTA | | brinzolamide | 121 |
|------------------------------------|-----------|---------------------------------|-----|-------------------------------|--------|
| AUSTEDO XR | 42 benze | pro | 71 | BRIXADI | 44 |
| AUSTEDO XR TITRATION KT | BENZ | ZNIDAZOLE | 20 | bromfenac | 120 |
| (WK1-4) | 42 benzo | natate | 123 | bromocriptine | 40 |
| AUTOJECT 2 INJECTION | benzo | yl peroxide | 71 | brompheniramine- | |
| DEVICE | 84 benzp | hetamine | 77 | pseudoeph-dm | 123 |
| AUTOPEN 1 TO 21 UNITS | _ | ropine | | BRUKINSA | |
| AUTOSOFT 30 | | astine besilate | | budesonide94 | 4, 124 |
| AUTOSOFT 90 | | | | budesonide-formoterol | 124 |
| AUTOSOFT XC INFUSION | | ONSA | | bumetanide | |
| SET 32 | 84 betaii | ne | 94 | buprenorphine | 44 |
| AUVELITY | 49 betan | nethasone dipropionate | 75 | buprenorphine hcl | |
| avar | | nethasone valerate | | buprenorphine-naloxone | |
| aviane1 | | nethasone, augmented | | bupropion hcl | |
| avidoxy2 | | SERON | | bupropion hcl (smoking deter) | |
| AVONEX | | olol | | buspirone | |
| <i>ayuna</i> 1 | | nechol chloride | | busulfan | |
| azacitidine2 | | eizumab | | butalbital-acetaminop-caf-cod | |
| azathioprine2 | | otene | | butalbital-acetaminophen | |
| azelaic acid | | SERO | | butalbital-acetaminophen-caff | |
| azelastine | | Z | | butalbital-aspirin-caffeine | |
| azelastine-fluticasone | | ORTUS | | butorphanol | |
| azithromycin | | ıtamide | | BYDUREON BCISE | |
| azurette (28) | | ARVY | | BYOOVIZ | |
| D | | toprost | | C | 120 |
| b complex I (with folio gold) | | HRAX | | CABENUVA | 15 |
| b complex 1 (with folic acid) | | | | | |
| b complex-vitamin c-folic | | odyl ıth subcit k-metronidz- | 94 | cabergoline | |
| acid | | | 00 | CABOMETYN | |
| bacitracin | | 1.1.6 | | CABOMETYX | |
| bacitracin-polymyxin b1 | _ | rolol fumarate | 38 | caffeine citrate | |
| baclofen | _ | rolol- | 70 | calcipotriene | |
| balanced b-100 | - | drochlorothiazide | | calcipotriene-betamethasone | |
| BALCOLTRA1 | | NGRI | | calcitonin (salmon) | |
| balsalazide | | ıycin | | calcitriol | 68 |
| BALVERSA2 | | CYTO | | calcium acetate | |
| balziva (28) 13 | | ri 24 fe | | (phosphat bind) | 130 |
| BAQSIMI | | ri fe 1.5/30 (28) | | CALQUENCE | |
| BARACLUDE | | ri fe 1/20 (28) | | (ACALABRUTINIB MAL) | |
| BAVENCIO | | STRIX TDAP | | camila | |
| bayer low dose aspirin | | zomib | | camrese | 113 |
| BCG VACCINE, LIVE (PF)10 | BORT | TEZOMIB | 25 | camrese lo | 113 |
| <i>b-complex with vitamin c</i> 13 | 30 bosen | ntan | 124 | CAMZYOS | 68 |
| BD INTEGRA NEEDLE | 84 BOSU | <i>JLIF</i> | 25 | candesartan | 58 |
| BD MICROTAINER LANCET | 85 bp 10 | -1 | 71 | candesartan- | |
| BD SPECIALTY USE | BREA | ATHERITE MDI | | hydrochlorothiazid | 58 |
| NEEDLES | 85 SP | ACER | 128 | capecitabine | 25 |
| belladonna alkaloids-opium | 93 BREC | O ELLIPTA | 124 | <i>CAPLYTA</i> | 49 |
| benazepril | 57 breyn | a | 124 | CAPRELSA | 26 |
| benazepril- | | ZTRI AEROSPHERE | 124 | captopril | 58 |
| hydrochlorothiazide | 57 briell | yn | 113 | captopril- | |
| bendamustine2 | - | onidine | | hydrochlorothiazide | 58 |
| BENDEKA | | onidine-timolol | - | CAPVAXIVE | |
| | | EUR A | | CARBAGLU | |

| carbamazepine | 37 | <i>CIMDUO</i> | 15 | COMPACT SPACE | |
|-----------------------------|-----|---------------------------|-------------|-------------------------|--------------|
| carbidopa | 40 | CIMERLI | 120 | CHAMBER | 128 |
| carbidopa-levodopa | 40 | cimetidine | 98 | compro | 94 |
| carbidopa-levodopa- | | cimetidine hcl | 98 | constulose | 94 |
| entacapone | 40 | cinacalcet | 88 | CORIFACT | 63 |
| carbinoxamine maleate | 122 | <i>CINRYZE</i> | 124 | cortisone | 82 |
| carboplatin | 26 | ciprofloxacin | 22 | COTELLIC | 26 |
| carglumic acid | 78 | ciprofloxacin hcl | 22, 81, 118 | covaryx | 109 |
| carmustine | | ciprofloxacin-dexamethas | | covaryx h.s | 109 |
| carteolol | 119 | cisplatin | 26 | CRESEMBA | 14 |
| cartia xt | 58 | citalopram | 49 | cromolyn | 94, 120, 124 |
| carvedilol | 58 | citrate of magnesia | 94 | crotan | |
| carvedilol phosphate | 58 | citroma | | cryselle (28) | 113 |
| CARVYKTI | | cladribine | 26 | CRYSVITA | |
| CAYA CONTOURED | 108 | claravis | 71 | CTEXLI | 94 |
| CAYSTON | 20 | clarithromycin | 20 | cyclobenzaprine | 43, 44 |
| caziant (28) | | classic prenatal | | cyclopentolate | |
| cefaclor | | clearlax | | cyclopen-tropic-phenyle | |
| cefadroxil | | clindacin | | watr | - |
| cefdinir | | clindacin etz | | cyclophosphamide | |
| cefixime | | clindacin p | | cycloserine | |
| cefpodoxime | | clindamycin hcl | | cyclosporine | |
| cefprozil | | clindamycin pediatric | | cyclosporine modified | |
| cefuroxime axetil | | clindamycin phosphate | | CYLTEZO(CF) | |
| celecoxib | | clindamycin-benzoyl | /2, 111 | CYLTEZO(CF) PEN | |
| cephalexin | | peroxide | 72 | CYLTEZO(CF) PEN | |
| CEPROTIN (BLUE BAR) | | clindamycin-tretinoin | | CROHN'S-UC-HS | 107 |
| CEPROTIN (GREEN BAR) | | clobazam | | CYLTEZO(CF) PEN | 107 |
| CEQUR SIMPLICITY | | clobetasol | | PSORIASIS-UV | 107 |
| CERDELGA | | clobetasol-emollient | | cyproheptadine | |
| CEREZYME | | clodan | | CYRAMZA | |
| cevimeline | | clofarabine | | cyred | |
| charlotte 24 fe | | clomipramine | | cyred eq | |
| | | • | | CYSTAGON | |
| chateal eq (28) CHEMET | | clonazepamclonidine | | CYSTARAN | |
| | | | | | |
| CHENODAL | | clonidine hcl | | cytarabine | |
| chlordiazepoxide hcl | | clopidogrel | | cytarabine (pf) | ∠0 |
| chlordiazepoxide-clidinium | | clorazepate dipotassium | | 2 | 62 |
| chlorhexidine gluconate | | clotrimazole | | dabigatran etexilate | |
| chloroquine phosphate | | clotrimazole-betamethaso | | dacarbazine | |
| chlorpromazine | | clozapine | | dactinomycin | |
| chlorthalidone | | COAGADEX | | dalfampridine | |
| chlorzoxazone | | COARTEM | | danazol | |
| CHOLBAM | | codeine sulfate | | dantrolene | |
| cholestyramine (with sugar) | | codeine-butalbital-asa-ca | - | DANZITEN | |
| cholestyramine light | | codeine-guaifenesin | | dapsone | 20, 72 |
| CIBINQO | | colchicine | | DAPTACEL | (DE) |
| ciclodan | | colesevelam | | (DTAP PEDIATRIC) | |
| ciclopirox | 74 | colestipol | | darifenacin | |
| ciclopirox-ure-camph- | | COMBIVENT RESPIMAT | | darunavir | |
| menth-euc | | COMETRIQ | 26 | DARZALEX | |
| cidofovir | | COMIRNATY 2024-25 | | dasatinib | • |
| cilostazol | 62 | (12Y UP)(PF) | 101 | dasetta 1/35 (28) | 113 |

| dasetta 7/7/7 (28) | 113 | dicyclomine | 93 | econazole nitrate | 74 |
|--|-----|--------------------------------|-----|--|-----|
| daunorubicin | 27 | diethylpropion | 77 | econtra ez | 113 |
| daysee | 113 | diflunisal | 47 | econtra one-step | 113 |
| deblitane | 109 | difluprednate | 121 | ecotrin low strength | 47 |
| decitabine | 27 | digoxin | 62 | edaravone | 42 |
| deferasirox | 78 | dihydroergotamine | 41 | ed-spaz | 93 |
| deferiprone | 78 | DILANTIN | 38 | EDURANT | 15 |
| deflazacort | | diltiazem | 58 | eemt | 109 |
| DELSTRIGO | | dilt-xr | 58 | eemt hs | 109 |
| demeclocycline | 23 | dimethyl fumarate | 55 | efavirenz | 15 |
| DENGVAXIA (PF) | | diphenoxylate-atropine | | efavirenz-emtricitabin- | |
| denta 5000 plus | | dipyridamole | | tenofov | 15 |
| denta 5000 plus sensitive | 81 | diskets | 45 | efavirenz-lamivu-tenofov | |
| dentagel | | disulfiram | 78 | disop | 15 |
| DEPO-PROVERA | | divalproex | | effer-k | |
| DEPO-SUBQ PROVERA | | docetaxel | | EGRIFTA SV | |
| 104 | 109 | dofetilide | 57 | ELAPRASE | |
| dermacinrx lidocan | | dolishale | | eletriptan | |
| DESCOVY | | donepezil | | ELFABRIO | |
| desipramine | | DOPTELET (15 TAB PACK) | | ELIGARD | |
| desloratadine | | dorzolamide | | ELIGARD (3 MONTH) | |
| desmopressin | | dorzolamide-timolol | | ELIGARD (4 MONTH) | |
| DESMOPRESSIN | | dorzolamide-timolol (pf) | | ELIGARD (6 MONTH) | |
| desog-e.estradiol/e.estradiol | | dotti | | elinest | |
| desonide | | DOVATO | | ELIQUIS | |
| desoximetasone | - | doxazosin | | ELIQUIS DVT-PE TREAT | |
| desvenlafaxine succinate | | doxepin | | 30D START | 63 |
| dexabliss | | doxercalciferol | | ELITEK | |
| dexamethasone | | doxorubicin | | ELLA | |
| dexamethasone intensol | | doxorubicin, peg-liposomal | | ELMIRON | |
| dexamethasone sodium | 02 | doxycycline hyclate | | ELOCTATE | |
| phosphate | 121 | doxycycline monohydrate | | eltrombopag olamine | |
| dexchlorpheniramine maleate | | doxylamine-pyridoxine (vit b6) | | eluryng | |
| DEXCOM G6 RECEIVER | | dronabinol | | ELZONRIS | |
| DEXCOM G6 SENSOR | | drospirenone-e.estradiol-lm.fa | | EMGALITY PEN | |
| DEXCOM G6 TRANSMITTER. | | drospirenone-ethinyl estradiol | | EMGALITY SYRINGE | |
| DEXCOM GO TRANSMITTER. DEXCOM GO TRANSMITTER. | | DROXIA | | EMPAVELI | |
| DEXCOM G7 RECEIVER | | dulcolax (magnesium | 21 | EMSAM | |
| dexmethylphenidate | | hydroxide) | 0.4 | emtricitabine | |
| dexrazoxane hcl | | DULERA | | emtricitabine-tenofovir (tdf) | |
| dextroamphetamine sulfate | | duloxetine | | | |
| _ | | DUOPA | | emtricita-rilpivirine-tenof df EMTRIVA | |
| dextroamphetamine- | 50 | DUPIXENT PEN | | EMVERM | |
| amphetamine | | DUPIXENT SYRINGE | | emzahh | |
| DIACOMIT | | dutasteride | | | |
| dialyvite 800 | | dutasteride-tamsulosin | | enalapril maleate | |
| diazepam | | | | enalapril-hydrochlorothiazide | |
| diazepam intensol | | DYSPORT | 101 | ENBREL MINI | |
| diazoxide | | E | 20 | ENBREL MINI | |
| dichlorphenamide | | e.e.s. 400 | 20 | ENBREL SURECLICK | |
| diclofenac potassium | | EASIVENT HOLDING | 100 | endocet | |
| diclofenac sodium 47, | | CHAMBER | _ | ENGERIX-B (PF) | 101 |
| diclofenac-misoprostol | | EBGLYSS PEN | | ENGERIX-B PEDIATRIC | 101 |
| dicloxacillin | 22 | EBGLYSS SYRINGE | 70 | (PF) | 101 |

| enilloring | 111 | eszopiclone | 51 | fingolimod | 55 |
|------------------------------|---------|--------------------------------|------|--------------------------------|-----|
| ENJAYMO | | ethacrynic acid | 59 | FINTEPLA | 38 |
| enoxaparin | | ethambutol | 21 | finzala | 113 |
| enpresse | | ethosuximide | 38 | FIRDAPSE | 42 |
| enskyce | | ethynodiol diac-eth estradiol | 113 | flac otic oil | 81 |
| ENSPRYNG | | etodolac | | flavoxate | 128 |
| | | etonogestrel-ethinyl estradiol | | flecainide | |
| entacapone | | ETOPOPHOS | | FLEXICHAMBER | |
| entecavir ENTRESTO | | etoposide | | flotrex | |
| ENTRESTO SPRINKLE | | etravirine | 16 | floxuridine | |
| | | EUCRISA | 71 | fluconazole | |
| ENTYVIO | | euthyrox | | flucytosine | |
| enulose | | everolimus (antineoplastic) | | fludarabine | |
| ENVARSUS XR | | everolimus | | fludrocortisone | |
| EPCLUSA | | (immunosuppressive) | 28 | flunisolide | |
| EPIDIOLEX | | EVOTAZ | | fluocinolone | |
| epinastine | | exemestane | | fluocinolone acetonide oil | |
| epinephrine | | exenatide | | fluocinolone and shower cap | |
| EPIPEN | 122 | ezetimibe | | | |
| EPIPEN JR | 122 | | | fluocinonide | |
| epirubicin | 27 | ezetimibe-simvastatin | 00 | fluocinonide-e | |
| epitol | 38 | F | | fluorescein-proparacaine | |
| eplerenone | 59 | FABHALTA | | fluoride (sodium)8 | |
| epoprostenol | | FABRAZYME | | fluorometholone | |
| eprosartan | | falmina (28) | 113 | fluorouracil | |
| EPYSQLI | | famciclovir | 16 | fluoxetine | |
| ERBITUX | | famotidine | 98 | fluphenazine decanoate | 51 |
| ergoloid | | <i>FANAPT</i> | 51 | fluphenazine hcl | 51 |
| ergotamine-caffeine | | FANAPT TITRATION PACK A. | 51 | flurazepam | 51 |
| eribulin | | FARXIGA | 90 | flurbiprofen | 47 |
| ERIVEDGE | | FASENRA | 124 | flurbiprofen sodium | |
| ERLEADA | | FASENRA PEN | 124 | fluticasone propionate70 | |
| | | FC2 FEMALE CONDOM | | fluticasone propion-salmeterol | |
| erlotinib | | febuxostat | | FLUTICASONE PROPION- | |
| errin | | FEIBA NF | | SALMETEROL | 124 |
| ery pads | | feirza | | fluvastatin | |
| erygel | | felbamate | | fluvoxamine | |
| ery-tab | | felodipine | | folic acid | |
| erythrocin (as stearate) | | fem ph | | folitab | |
| erythromycin | 20, 118 | FEMCAP | | FOLOTYN | |
| erythromycin ethylsuccinate. | 20 | | | | |
| erythromycin with ethanol | 72 | FEMLYV | | foltabs 800 | |
| erythromycin-benzoyl | | fenofibrate | | fondaparinux | |
| peroxide | 72 | fenofibrate micronized | | formoterol fumarate | |
| escitalopram oxalate | 50 | fenofibrate nanocrystallized | | fosamprenavir | |
| eslicarbazepine | 38 | fenofibric acid | | fosfomycin tromethamine | |
| esomeprazole magnesium | | fenofibric acid (choline) | | fosinopril | |
| ESPEROCT | | fenoprofen | | fosinopril-hydrochlorothiazide | |
| estarylla | | FENSOLVI | 28 | fraiche 5000 | |
| estazolam | | fentanyl | 45 | FREESTYLE CONTROL | 83 |
| estradiol | | FERRIPROX | 78 | FREESTYLE FLASH SYSTEM | 83 |
| estradiol valerate | - | FERRIPROX (2 TIMES A DAY) |) 78 | FREESTYLE FREEDOM | 83 |
| estradiol-norethindrone | 110 | fesoterodine | | FREESTYLE FREEDOM LITE | |
| | 110 | FETZIMA | | FREESTYLE INSULINX | |
| acet | | finasteride | | FREESTYLE INSULINX | |
| estrogens-methyltestosterone | 110 | | - | | |

| <i>TEST STRIPS</i> 83 | gemfibrozil67 | HEMOFIL M SUPER HIGH64 |
|--|--------------------------------|------------------------------------|
| FREESTYLE LIBRE 14 DAY | gemmily114 | hep flush-10 (pf)64 |
| <i>READER</i> 83 | generlac95 | heparin (porcine)64 |
| FREESTYLE LIBRE 14 DAY | gengraf28 | heparin (porcine) in 0.9% nacl64 |
| SENSOR83 | gentamicin73, 118 | heparin (porcine) in 5 % dex64 |
| FREESTYLE LIBRE 2 PLUS | gentle laxative (bisacodyl)95 | heparin (porcine) in nacl (pf)64 |
| <i>SENSOR</i> 83 | gentle laxative (mag hydrox)95 | heparin lock flush (porcine)64 |
| FREESTYLE LIBRE 2 | gentlelax95 | heparin lockflush(porcine)(pf)64 |
| <i>READER</i> 83 | <i>GENVOYA</i> 16 | heparin(porcine) in 0.45% nacl64 |
| FREESTYLE LIBRE 2 SENSOR83 | <i>GILOTRIF</i> 28 | heparin, porcine (pf)64 |
| FREESTYLE LIBRE 3 | glatiramer55 | HEPLISAV-B (PF) 101 |
| <i>PLUS SENSOR</i> 83 | glatopa55 | HIBERIX (PF)102 |
| FREESTYLE LIBRE 3 | <i>GLEOSTINE</i> 29 | homatropaire 119 |
| <i>READER</i> 83 | glimepiride90 | HUMALOG JUNIOR |
| FREESTYLE LIBRE 3 SENSOR83 | glipizide90 | KWIKPEN U-10086 |
| FREESTYLE LITE METER83 | glipizide-metformin90 | HUMALOG KWIKPEN |
| FREESTYLE LITE STRIPS83 | glucagon emergency kit | INSULIN86 |
| FREESTYLE PRECISION | (human)84 | HUMALOG MIX 50-50 |
| <i>NEO STRIPS</i> 83 | glutamine (sickle cell)78 | KWIKPEN86 |
| FREESTYLE SIDEKICK II83 | glyburide90 | HUMALOG MIX 75-25 |
| FREESTYLE SYSTEM KIT83 | glyburide micronized90 | KWIKPEN86 |
| FREESTYLE TEST83 | glyburide-metformin91 | HUMALOG MIX 75-25(U-100) |
| frovatriptan41 | glycopyrrolate93 | INSULN86 |
| full spectrum b-vitamin c131 | GLYXAMBI91 | HUMALOG TEMPO PEN(U-100) |
| FULPHILA99 | GOMEKLI29 | INSULN86 |
| fulvestrant28 | granisetron hcl95 | HUMALOG U-100 INSULIN86 |
| furosemide59 | griseofulvin microsize14 | HUMATE-P64 |
| <i>FUZEON</i> 16 | griseofulvin ultramicrosize14 | HUMULIN 70/30 U-100 |
| fyavolv10 | guanfacine51, 59 | INSULIN86 |
| <i>FYCOMPA</i> 38 | <i>GVOKE</i> 84 | HUMULIN 70/30 U-100 |
| G | GVOKE HYPOPEN 2-PACK84 | KWIKPEN87 |
| g tussin ac123 | GVOKE PFS 2-PACK | HUMULIN N NPH INSULIN |
| gabapentin38 | <i>SYRINGE</i> 84 | KWIKPEN87 |
| galantamine42, 43 | H | HUMULIN N NPH U-100 |
| galbriela | hailev114 | |
| O . | √ | HUMULIN R REGULAR U-100 |
| gallifrey 110 GAMASTAN 101 | hailey 24 fe | |
| <i>GAMIFANT</i> 28 | hailey fe 1.5/30 (28) | INSULN87 HUMULIN R U-500 (CONC) |
| GAMMAGARD LIQUID101 | hailey fe 1/20 (28) | INSULIN87 |
| GAMMAGARD S-D | halobetasol propionate76 | HUMULIN R U-500 (CONC) |
| | haloette11 | KWIKPEN87 |
| (IGA < 1 MCG/ML) 101 GAMUNEX-C 101 | | HYCAMTIN29 |
| | haloperidol51 | |
| ganciclovir sodium | haloperidol decanoate51 | hydralazine59 |
| GARDASIL 9 (PF) | haloperidol lactate51 | hydrochlorothiazide59 |
| gatifloxacin | HARVONI | hydrocodone bitartrate |
| gavilax94 | HAVRIX (PF) | hydrocodone-acetaminophen45 |
| gavilyte-c95 | heather | hydrocodone- |
| gavilyte-g95 | HEMGENIX63 | chlorpheniramine123 |
| gavilyte-n95 | HEMLIBRA63 | hydrocodone-homatropine123 |
| GAVRETO28 | hemmorex-hc95 | hydrocodone-ibuprofen45 |
| <i>GAZYVA</i> | HEMOFIL M HIGH63 | hydrocortisone |
| gefitinib28 | HEMOFIL M LOW63 | hydrocortisone acetate95 |
| gemcitabine 28 | HEMOFIL M MID64 | |

| hydrocortisone butyrate | 76 | INLYTA | 29 | junel fe 24 | 114 |
|----------------------------|--------|----------------------------|---------|------------------------------|--------|
| hydrocortisone valerate | 76 | INSULIN GLARGINE- | | JUXTAPID | 67 |
| hydrocortisone-acetic acid | 81 | YFGN | 87 | JYNNEOS (PF) | 102 |
| hydrocortisone-pramoxine | 68, 95 | INSULIN LISPRO | 87 | K | |
| hydromet | 123 | INSULIN LISPRO PROTAI | MIN- | KADCYLA | 30 |
| hydromorphone | 45 | LISPRO | 87 | kaitlib fe | 114 |
| hydroxychloroquine | 21 | INTELENCE | 16 | kalliga | |
| hydroxyurea | | <i>IPOL</i> | 102 | KALYDECO | |
| hydroxyzine hcl | | ipratropium bromide | 81, 125 | KANJINTI | 30 |
| hydroxyzine pamoate | | ipratropium-albuterol | | <i>KANUMA</i> | 89 |
| hyoscyamine sulfate | | IQIRVO | | kariva (28) | 114 |
| hyosyne | | irbesartan | | kelnor 1/35 (28) | |
| HYPERHEP B | | irbesartan-hydrochlorothia | zide59 | kelnor 1/50 (28) | |
| HYPERHEP B NEONATAL | 102 | irinotecan | | kemoplat | |
| HYPERRAB (PF) | 102 | ISENTRESS | | KEPIVANCE | |
| I | | ISENTRESS HD | 16 | KERENDIA | 59 |
| ibandronate | 106 | isibloom | | KESIMPTA PEN | |
| ibu | | isoniazid | | ketoconazole | |
| ibuprofen | | isosorbide dinitrate | | ketodan | - |
| icatibant | | isosorbide mononitrate | | ketodan kit | |
| iclevia | | isosorbide-hydralazine | | ketoprofen | |
| ICLUSIG | | isotretinoin | | ketorolac | |
| icosapent ethyl | | isradipine | | KEVZARA | |
| idarubicinidarubicin | | ISTODAX | | KEYTRUDA | |
| IDELVION | | itraconazole | | KIMMTRAK | |
| IDHIFA | | ivabradine | | KINRIX (PF) | |
| ifosfamide | | ivermectin | | kiprofen | |
| ILARIS (PF) | | IWILFIN | * | KISQALI | |
| ILET INFUSION KIT- | | <i>IXCHIQ (PF)</i> | | KITABIS PAK | |
| INSET 23 | 05 | IXEMPRA | | klayesta | |
| ILET INFUSION-CONTACT | 03 | | | klor-con | |
| DTCH 23 | 0.5 | IXIARO (PF) | 102 | klor-con 10 | |
| | | • | 114 | | |
| ILET STARTER KIT-INSET | | jaimiess | | klor-con 8 | |
| imatinib | | JAKAFI | | klor-con m10 | |
| IMBRUVICA | | jantoven | | klor-con m15 | |
| IMFINZI | | JANUMET | | klor-con m20 | |
| imipenem-cilastatin | | JANUMET XR | | klor-con/ef | |
| imipramine hcl | | JANUVIA | | kobee | |
| imipramine pamoate | | JARDIANCE | | KOGENATE FS | |
| imiquimod | | jasmiel (28) | | kourzeq | |
| IMKELDI | | javygtor | | KOVALTRY | |
| IMOGAM RABIES-HT (PF) | 102 | jencycla | | K-PHOS ORIGINAL | |
| IMOVAX RABIES | | jinteli | | KRYSTEXXA | |
| <i>VACCINE (PF)</i> | 102 | JIVI | | kurvelo (28) | |
| IMPAVIDO | | jolessa | 114 | KYLEENA | 109 |
| INBRIJA | 41 | joyeaux | 114 | KYMRIAH | 30 |
| incassia | | juleber | | KYPROLIS | 30 |
| INCRELEX | 79 | JULUCA | | L | |
| INCRUSE ELLIPTA | 125 | junel 1.5/30 (21) | 114 | l norgest/e.estradiol-e.estr | ad 114 |
| indapamide | 59 | junel 1/20 (21) | 114 | labetalol | 59 |
| indomethacin | 47 | junel fe 1.5/30 (28) | 114 | lacosamide | 38 |
| INFANRIX (DTAP) (PF) | 102 | junel fe 1/20 (28) | 114 | lactated ringers | 78 |
| INFLECTRA | | | | _ | |

| lactulose | | lidocan iv | 73 | LUXTURNA | 120 |
|-------------------------------|--------|---|-----|--------------------------|-----|
| LAGEVRIO (EUA) | 16 | lidocan v | 73 | LYBALVI | 52 |
| lamivudine | 16, 17 | lidocort | 73 | lyleq | 110 |
| lamivudine-zidovudine | 17 | LILETTA | 109 | lyllana | 110 |
| lamotrigine | 38, 39 | linezolid | 21 | LYNPARZA | 31 |
| <i>LAMZEDE</i> | 79 | LINZESS | 95 | LYSODREN | 31 |
| LANCETS | 85 | liothyronine | 92 | <i>LYTGOBI</i> | 31 |
| LANCING DEVICE | 85 | liraglutide | 91 | LYUMJEV KWIKPEN U-100 | |
| lanreotide | 30 | lisdexamfetamine | 52 | INSULIN | 87 |
| lansoprazole | 98 | lisinopril | 59 | LYUMJEV KWIKPEN U-200 | |
| lanthanum | | lisinopril-hydrochlorothiazide | 59 | INSULIN | 87 |
| lapatinib | 30 | LITEAIRE MDI CHAMBER | 128 | LYUMJEV TEMPO PEN(U-100) |) |
| larin 1.5/30 (21) | | lithium carbonate | 52 | INSULN | 87 |
| larin 1/20 (21) | | lithium citrate | 52 | LYUMJEV U-100 INSULIN | |
| larin 24 fe | | LO LOESTRIN FE | 115 | lyza | 110 |
| larin fe 1.5/30 (28) | | LOESTRIN 1.5/30 (21) | 115 | M | |
| larin fe 1/20 (28) | | LOESTRIN 1/20 (21) | | mafenide acetate | 73 |
| latanoprost | | LOESTRIN FE 1.5/30 | | magnesium citrate | |
| laxative (bisacodyl) | | (28-DAY) | 115 | malathion | |
| laxative peg 3350 | | LOESTRIN FE 1/20 | 110 | maraviroc | |
| leena 28 | | (28-DAY) | 115 | marlissa (28) | |
| leflunomide | | lofena | | MARPLAN | |
| lenalidomide | | lofexidine | | MATULANE | |
| LENVIMA | | lojaimiess | | matzim la | |
| lessina | | LOKELMA | | MAVENCLAD | |
| letrozole | | LONSURF | | (10 TABLET PACK) | 55 |
| leucovorin calcium | | lopinavir-ritonavir | | MAVENCLAD | |
| LEUKERAN | | LOQTORZI | | (4 TABLET PACK) | 55 |
| LEUKINE | | lorazepam | | MAVENCLAD | |
| leuprolide | | lorazepam intensol | | (5 TABLET PACK) | 55 |
| levalbuterol hcl | | LORBRENA | | MAVENCLAD | 33 |
| levetiracetam | | loryna (28) | | (6 TABLET PACK) | 56 |
| levobunolol | | losartan | | MAVENCLAD | 50 |
| levocarnitine | | | | (7 TABLET PACK) | 56 |
| levocarnitine (with sugar) | | losartan-hydrochlorothiazide loteprednol etabonate | | MAVENCLAD | 50 |
| (0 / | | 1 | | | 5.0 |
| levofloxacin | | lovastatin | | (8 TABLET PACK) | 30 |
| levonest (28) | | low-ogestrel (28) | | MAVENCLAD | 5.0 |
| levonorgest-eth.estradiol-ire | | loxapine succinate | | (9 TABLET PACK) | |
| levonorgestrel | | lo-zumandimine (28) | | maxi-tuss ac | |
| levonorgestrel-ethinyl estrac | | lubiprostone | | MAYZENT STADTED | 36 |
| levonorg-eth estrad triphasi | | ludent fluoride | | MAYZENT STARTER | 5.0 |
| levora-28 | | lugols7 | | (FOR 1MG MAINT) | 56 |
| levo-t | | LUMIZYME | | MAYZENT STARTER | 5.0 |
| levothyroxine | | LUMRYZ | | (FOR 2MG MAINT) | |
| levoxyl | | LUMRYZ STARTER PACK | | mb caps | |
| LIBTAYO | | LUNSUMIO | | meclizine | |
| lidocaine | | LUPKYNIS | | meclofenamate | |
| lidocaine hcl | | LUPRON DEPOT | | MEDISENSE | 83 |
| lidocaine hcl-hydrocortison | | LUPRON DEPOT (3 MONTH) | | MEDISENSE GLUCOSE | _ |
| lidocaine viscous | | LUPRON DEPOT (4 MONTH) | | <i>KETONE</i> | |
| lidocaine-hydrocortisone-al | | LUPRON DEPOT (6 MONTH) | | medroxyprogesterone | 110 |
| lidocaine-prilocaine | | lurasidone | | MEDTRONIC EXT | |
| lidocan iii | 73 | lutera (28) | 115 | INFUSION SET 23 | 85 |

| mefenamic acid47 | metronidazole21, 72, 111 | morphine concentrate45 |
|----------------------------------|---|---|
| mefloquine21 | metyrosine60 | <i>MOUNJARO</i> 91 |
| <i>megestrol.</i> 31 | mexiletine57 | <i>MOVANTIK</i> 96 |
| <i>MEKINIST</i> 31 | <i>mibelas 24 fe</i> 115 | moxifloxacin22, 118 |
| meleya110 | miconazole-3111 | MRESVIA (PF)103 |
| meloxicam47 | <i>MICROCHAMBER</i> 128 | multi-vitamin with fluoride131 |
| meloxicam submicronized47 | microgestin 1.5/30 (21)115 | mupirocin74 |
| melphalan hcl31 | microgestin 1/20 (21)115 | mupirocin calcium74 |
| memantine43 | microgestin fe 1.5/30 (28) 115 | <i>mvc-fluoride</i> 131 |
| memantine-donepezil43 | microgestin fe 1/20 (28) 115 | <i>my choice</i> |
| <i>MENQUADFI (PF)</i> 102 | <i>MICROSPACER</i> 128 | <i>my way</i> |
| MENVEO A-C-Y-W-135- | midazolam53 | <i>MYALEPT</i> 89 |
| <i>DIP (PF)</i> 102 | midodrine79 | mycophenolate mofetil32 |
| <i>meperidine</i> 45 | MIEBO (PF)120 | mycophenolate mofetil (hcl)32 |
| <i>MEPSEVII</i> 89 | mifepristone89, 111 | mycophenolate sodium32 |
| mercaptopurine31 | migergot42 | MYFEMBREE111 |
| <i>merzee</i> | miglitol91 | <i>MYHIBBIN</i> 32 |
| mesalamine95, 96 | miglustat89 | <i>MYLERAN</i> |
| mesalamine with cleansing | mili | MYLOTARG32 |
| wipe96 | milk of magnesia96 | MYOBLOC |
| mesna24 | milk of magnesia concentrated96 | N |
| MESNEX24 | millipred82 | nabumetone48 |
| metaxalone44 | millipred dp82 | nadolol60 |
| metformin91 | minipred up | natifine74 |
| methadone45 | MINIMED MIO ADVANCE | <i>NAGLAZYME</i> 89 |
| methadose45 | INF SET2385 | |
| | | naloxone 48 naltrexone 48 |
| methamphetamine | MINIMED QUICK SET 4385 | |
| methazolamide | MINIMED SILHOUETTE 2385 MINIMED SURE T 3285 | naproxen |
| methenamine hippurate23 | | naproxen sodium48 |
| methenamine mandelate23 | minocycline23 | naratriptan42 |
| methen-sod phos-meth | minoxidil60 | <i>NATACYN</i> |
| blue-hyos129 | <i>minzoya</i> | <i>NATAZIA</i> |
| methimazole | miostat121 | nateglinide91 |
| <i>METHITEST</i> 89 | mirabegron128 | natura-lax96 |
| methocarbamol44 | MIRENA109 | NAYZILAM39 |
| methotrexate sodium31 | mirtazapine53 | nebivolol60 |
| methotrexate sodium (pf)31 | misoprostol98 | nebusal125 |
| methoxsalen71 | <i>MITIGARE</i> 106 | necon 0.5/35 (28) |
| methsuximide39 | mitomycin31 | nefazodone53 |
| methyl salicylate71 | mitoxantrone31 | <i>NEFFY</i> |
| methyldopa59 | MIUDELLA109 | nelarabine32 |
| methyldopa- | <i>M-M-R II (PF)</i> 102 | NEMLUVIO32 |
| hydrochlorothiazide59 | modafinil53 | neomycin21 |
| methylergonovine118 | MODERNA COVID 24-25 | neomycin-bacitracin-poly-hc 121 |
| methylphenidate53 | (6M-11Y)PF103 | neomycin-bacitracin- |
| methylphenidate hcl52 | moexipril60 | polymyxin118 |
| methylprednisolone82 | molindone53 | neomycin-polymyxin b gu78 |
| methyltestosterone89 | <i>mometasone</i> 76, 77, 125 | neomycin-polymyxin |
| metoclopramide hcl96 | <i>mondoxyne nl</i> 23 | <i>b-dexameth</i> 121 |
| <i>metolazone</i> 59 | <i>mono-linyah</i> 115 | neomycin-polymyxin- |
| metoprolol succinate60 | <i>montelukast</i> 125 | gramicidin118 |
| metoprolol ta-hydrochlorothiaz60 | <i>morphine</i> 45, 46 | neomycin-polymyxin-hc81, 121 |
| metoprolol tartrate60 | | |

| neo-polycin | 119 | nortrel 7/7/7 (28) | 116 | OMVOH PEN | 96 |
|-------------------------------|-----------|---------------------------|-----|---------------------------|-----|
| neo-polycin hc | 121 | nortriptyline | 53 | ONCASPAR | 33 |
| neostigmine methylsulfate | 44 | NORVIR | 17 | ondansetron | 96 |
| NERLYNX | 32 | NOURIANZ | 41 | ondansetron hcl | 96 |
| NESINA | 91 | NOVAVAX COVID 2024-2 | 25 | one daily prenatal | 131 |
| neuac | 72 | (PF)(EUA) | 103 | onelax magnesium citrate | 96 |
| <i>NEUPRO</i> | 41 | NOVOEIGHT | 65 | ONETOUCH ULTRA | |
| nevirapine | 17 | <i>NOXAFIL</i> | 14 | CONTROL | 84 |
| new day | 116 | np thyroid | 93 | ONETOUCH | |
| NEXPLANON | 111 | NPLATE | 65 | ULTRA TEST | 84 |
| NEXTSTELLIS | 116 | NUBEQA | 32 | ONETOUCH | |
| niacin | 67 | NUCALA | 125 | ULTRA2 METER | 84 |
| nicardipine | 60 | NUEDEXTA | 43 | ONETOUCH VERIO FLEX | |
| NICODERM CQ | | <i>NULOJIX</i> | 32 | <i>METER</i> | 84 |
| nicorette | | NURTEC ODT | 42 | ONETOUCH VERIO MID | |
| NICORETTE | | NUVARING | 111 | CONTROL | 84 |
| nicotine | | nyamyc | | ONETOUCH VERIO REFLECT | |
| nicotine (polacrilex) | | nylia 1/35 (28) | | <i>METER</i> | |
| NICOTROL NS | | nylia 7/7/7 (28) | | ONETOUCH VERIO | |
| nifedipine | | nystatin | | TEST STRIPS | 84 |
| nikki (28) | | nystatin-triamcinolone | | ONIVYDE | |
| nilotinib hcl | | nystop | | opcicon one-step | |
| nilutamide | | 0 | | OPDIVO | |
| nimodipine | | OBIZUR | 65 | OPDIVO QVANTIG | |
| NINLARO | | OCALIVA | | OPDUALAG | |
| nisoldipine | | ocella | | <i>OPILL</i> | |
| nitazoxanide | | OCREVUS | | opium tincture | |
| nitisinone | | OCREVUS ZUNOVO | | OPSUMIT | |
| nitro-bid | | octreotide acetate | | <i>OPSYNVI</i> | |
| nitrofurantoin | | octreotide, microspheres. | | OPTICHAMBER DIAMOND | 123 |
| nitrofurantoin macrocrystal | | ODEFSEY | | VHC | 128 |
| - | 23 | ODEFSET ODOMZO | | option-2 | |
| nitrofurantoin | 22 | OFEV | | _ | |
| monohyd/m-cryst | | | | oral saline laxative | |
| nitroglycerin | | ofloxacin OJEMDA | | oralone | |
| nitro-time | | | | ORIAHNN | |
| NITYR | | olanzapine | | ORILISSA | |
| niva thyroid | | olanzapine-fluoxetine | | ORKAMBI | |
| NIVESTYM | | olmesartan | | ormalvi | |
| nizatidine | | olmesartan-amlodipin-hc | | orphenadrine citrate | |
| nora-be | | olmesartan-hydrochloroti | | orphenadrine-asa-caffeine | |
| norelgestromin-ethin.estradio | | olopatadine | | orphengesic forte | |
| noreth-ethinyl estradiol-iron | | omega-3 acid ethyl esters | | ORSERDU | |
| norethindrone (contraceptive) | | omeprazole | 98 | oscimin | |
| norethindrone acetate | 110 | omeprazole-sodium | | oscimin sl | |
| norethindrone ac-eth | | bicarbonate | 98 | oseltamivir | |
| estradiol | .110, 116 | OMNIPOD 5 | | OTEZLA | |
| norethindrone- | | (G6/LIBRE 2 PLUS) | | OTEZLA STARTER | |
| e.estradiol-iron | 116 | OMNIPOD 5 G6-G7 POI | | oxaliplatin | 33 |
| norgestimate- | | (GEN 5) | | oxaprozin | 48 |
| ethinyl estradiol | 116 | OMNIPOD DASH PODS | | oxcarbazepine | 39 |
| nortrel 0.5/35 (28) | 116 | (GEN 4) | 85 | OXERVATE | 120 |
| nortrel 1/35 (21) | 116 | <i>OMNITROPE</i> | 100 | oxiconazole | 74 |
| nortrel 1/35 (28) | 116 | OMVOH | 96 | oxybutynin chloride | 128 |

| oxycodone | 46 | phenazopyridine | 129 | prasugrel hcl | 65 |
|-------------------------------|-----|-------------------------------|--------|--------------------------------|---------|
| oxycodone-acetaminophen | 46 | phendimetrazine tartrate | 77 | pravastatin | 67 |
| oxymorphone | 46 | phenelzine | 53 | praziquantel | 21 |
| <i>OZEMPIC</i> | 91 | phenobarb-hyoscy-atropine- | | prazosin | 60 |
| <i>OZURDEX</i> | 121 | scop | 93 | PRECISION XTRA KETONE- | |
| P | | phenobarbital | 39 | GLUCOSE | 84 |
| pacerone | 57 | phenohytro | 93, 94 | PRECISION XTRA | |
| paclitaxel | 33 | phenoxybenzamine | | <i>MONITOR</i> | 84 |
| paclitaxel protein-bound | 33 | phentermine | | PRECISION XTRA TEST | 84 |
| paliperidone | | phentermine-topiramate | 77 | prednicarbate | 77 |
| PALYNZIQ | | phenylephrine hcl | | prednisoln sp-moxiflox- | |
| pamidronate | | phenyleph-tropicamide in wate | | bromfen | 120 |
| PANCREAZE | | phenytoin | 39 | prednisolone | 82 |
| pantoprazole | 99 | phenytoin sodium extended | | prednisolone acetate | 121 |
| PARAGARD T 380A | 109 | PHESGO | | prednisolone sod ph-bromfenac | |
| paraplatin | 33 | PHEXXI | 111 | prednisolone sodium | |
| paricalcitol | | philith | 116 | phosphate | 82, 121 |
| paroex oral rinse | | phosphate laxative | 97 | prednisone | |
| paroxetine hcl | | PHOSPHOLINE IODIDE | | prednisone intensol | |
| paroxetine mesylate | | PHOTOFRIN | | pregabalin | |
| (menop.sym) | 53 | PIFELTRO | | prenatal | |
| PASER | | pilocarpine hcl | | prenatal complete | |
| PAVBLU | | pimecrolimus | | prenatal multi-dha (algal oil) | |
| <i>PAXLOVID</i> | | pimozide | | prenatal multivitamins | |
| pazopanib | | pimtrea (28) | | prenatal one daily | |
| PEDIARIX (PF) | | pindolol | | prenatal vit no.179-iron-folic | |
| PEDVAX HIB (PF) | | pioglitazone | | prenatal vitamin | |
| peg 3350-electrolytes | | pioglitazone-glimepiride | | prenatal vitamin with minerals | |
| peg3350-sod sul-nacl-kcl-asb- | | pioglitazone-metformin | | prevalite | |
| PEGASYS | | PIQRAY | | PREVNAR 20 (PF) | |
| peg-electrolyte soln | | pirfenidone | | PREVYMIS | |
| PEMAZYRE | | piroxicam | | PREZCOBIX | |
| pemetrexed disodium | | pitavastatin calcium | | PREZISTA | |
| PENBRAYA (PF) | | PLAN B ONE-STEP | | PRIFTIN | |
| penciclovir | | PLEGRIDY | | primaquine | |
| penicillamine | | plerixafor | | PRIMEAIRE | |
| penicillin v potassium | | PNEUMOVAX-23 | | primidone | |
| PENTACEL (PF) | | POCKET CHAMBER | | PRIORIX (PF) | |
| pentamidine | | podofilox | | probenecid | |
| PENTASA | | polycin | | probenecid-colchicine | |
| pentoxifylline | | polyethylene glycol 3350 | | procentra | |
| perampanel | | polymyxin b sulf-trimethoprim | | PROCHAMBER | |
| perindopril erbumine | | POMALYST | | prochlorperazine | |
| periogard | | portia 28 | | prochlorperazine maleate | |
| PERJETA | | posaconazole | | PROCRIT | |
| permethrin | | potassium chloride | | procto-med hc | |
| perphenazine | | potassium citrate | | proctosol hc | |
| perphenazine-amitriptyline | | potassium iodide | | proctozone-hc | |
| PFIZER COVID 2024-25 | | POTELIGEO | | PROFILNINE | |
| (5Y-11Y)PF | 103 | povidone-iodine | | progesterone | |
| PFIZER COVID 2024-25 | 103 | powderlax | | progesterone micronized | |
| (6MO-4Y)PF | 103 | PRALATREXATE | | PROGRAF | |
| PHERURANE | | praminexole | | PROLASTIN-C | |

| prolate | 46 | RELENZA DISKHALER | 17 | rufinamide | 39 |
|------------------------------|---------|--------------------------|-----|-----------------------|-----|
| PROLEUKIN | 99 | RELISTOR | 97 | RUKOBIA | 18 |
| PROMACTA | 65 | RENACIDIN | 129 | RUXIENCE | 34 |
| promethazine | 122 | rena-vite | 131 | RYBELSUS | 92 |
| promethazine-codeine | 123 | renthyroid | 93 | RYDAPT | 34 |
| promethazine-dm | 123 | repaglinide | 91 | RYONCIL | 79 |
| promethazine-phenylephrine | 123 | REPATHA PUSHTRONEX | 67 | S | |
| promethegan | | REPATHA SURECLICK | 67 | SAFYRAL | 117 |
| propafenone | 57 | REPATHA SYRINGE | 67 | sajazir | 126 |
| proparacaine | 120 | RESTASIS MULTIDOSE | 120 | salsalate | 48 |
| propranolol | 60 | <i>RETACRIT</i> | 99 | <i>SANTYL</i> | 77 |
| propranolol-hydrochlorothia | ızid60 | RETROVIR | 17 | sapropterin | 89 |
| propylthiouracil | | REVCOVI | 79 | SAVELLA | |
| PROQUAD (PF) | | REVLIMID | 34 | saxagliptin | 92 |
| protriptyline | | REVUFORJ | 34 | saxagliptin-metformin | |
| prucalopride | | REXTOVY | | scalacort | |
| pruradik | | REXULTI | | SCEMBLIX | |
| pulmosal | | REYATAZ | | scopolamine base | |
| PULMOZYME | | REYVOW | | SECUADO | |
| purelax | | REZDIFFRA | | SELARSDI | |
| PURIXAN | | RIASTAP | | selegiline hcl | - |
| pyrazinamide | | ribavirin | | selenium sulfide | |
| pyridostigmine bromide | | RIDAURA | | SELZENTRY | |
| pyrimethamine | | rifabutin | | SEMGLEE(INSULIN | 10 |
| O | 21 | rifampin | | GLARGINE-YFGN) | 87 |
| QUADRACEL (PF) | 103 104 | riluzole | | SEMGLEE(INSULIN | 0 / |
| quetiapine | | rimantadine | | GLARG-YFGN)PEN | 97 |
| | | | | SEREVENT DISKUS | |
| quinapril | | ringer's | | sertraline | |
| quinapril-hydrochlorothiazid | | RINVOQ | | | |
| quinidine gluconate | | RINVOQ LQ | | setlakin | |
| quinidine sulfate | | risedronate | | sevelamer carbonate | |
| quinine sulfate | | risperidone | | sevelamer hcl | |
| <i>quit 2</i> | | risperidone microspheres | | SEVENFACT | 65 |
| quit 4 | | RITEFLO AEROCHAMBER | | sf 81 | 0.4 |
| QVAR REDIHALER | 125 | ritonavir | | sf 5000 plus | |
| R | | rivaroxaban | | sharobel | |
| RABAVERT (PF) | | rivastigmine | | SHINGRIX (PF) | |
| rabeprazole | | rivastigmine tartrate | | SIGNIFOR | 34 |
| RADICAVA | 43 | rivelsa | | sildenafil | |
| RADICAVA ORS STARTER | | rizatriptan | | (pulm.hypertension) | |
| KIT SUSP | | ROCTAVIAN | | silodosin | |
| raloxifene | 106 | roflumilast | 126 | silver sulfadiazine | 70 |
| ramelteon | 54 | romidepsin | 34 | SIMLANDI(CF) | 108 |
| ramipril | 60 | ropinirole | 41 | SIMLANDI(CF) | |
| ranolazine | 68 | rosadan | 72 | AUTOINJECTOR | 108 |
| rasagiline | 41 | rosula cleansing cloths | 72 | simliya (28) | 117 |
| REBIF (WITH ALBUMIN) | 56 | rosuvastatin | 67 | simpesse | 117 |
| REBIF REBIDOSE | 56 | rosyrah | 117 | <i>SIMPONI</i> | 108 |
| REBIF TITRATION PACK | 56 | ROTARIX | | SIMULECT | 34 |
| reclipsen (28) | 116 | ROTATEQ VACCINE | 104 | simvastatin | 67 |
| RECOMBIVAX HB (PF) | | roweepra | | sirolimus | 34 |
| RECTIV | | ROZLYTREK | | <i>SIRTURO</i> | |
| REGRANEY | 71 | RUCONFST | 126 | SKVI 4 | |

| <i>SKYRIZI</i> 69, 97 | subvenite starter (blue) kit39 | (3 PACK) | 69 |
|------------------------------------|-----------------------------------|------------------------|-----|
| <i>SKYSONA</i> 43 | subvenite starter (green) kit40 | TALTZ SYRINGE | 69 |
| <i>SLYND</i> 117 | subvenite starter (orange) kit40 | TALZENNA | 35 |
| <i>smoothlax</i> 97 | <i>SUCRAID</i> 97 | tamoxifen | 35 |
| sodium chloride79, 126 | sucralfate99 | tamsulosin | 129 |
| sodium chloride 0.9 %79 | sulfacetamide sodium69, 122 | TANDEM MOBI AUTOSOFT | 7 |
| sodium citrate-citric acid129 | sulfacetamide sodium (acne)74 | <i>30 KT 23</i> | 85 |
| sodium fluoride 5000 plus81 | sulfacetamide sodium-sulfur72, 73 | TANDEM MOBI AUTOSOFT | 7 |
| sodium fluoride-pot nitrate81 | sulfacetamide-prednisolone122 | XC KIT 5 | 85 |
| SODIUM OXYBATE54 | <i>sulfacleanse</i> 8-473 | TANDEM MOBI TRUSTEEL | |
| sodium phenylbutyrate79 | sulfadiazine22 | KIT 23 | |
| sodium polystyrene sulfonate 130 | sulfamethoxazole- | tanlor | |
| sodium,potassium,mag sulfates97 | trimethoprim22, 23 | tarina 24 fe | 117 |
| solifenacin128 | <i>SULFAMYLON</i> 74 | tarina fe 1/20 (28) | |
| <i>SOLIRIS</i> 79 | sulfasalazine97 | TASIGNA | |
| soluvita131 | sulfatrim23 | tavaborole | |
| soluvita a,c,d with fluoride131 | sulindac48 | TAVALISSE | |
| SOMATULINE DEPOT34 | sumatriptan42 | TAYTULLA | |
| SOMAVERT89 | sumatriptan succinate42 | tazarotene | |
| sorafenib34 | sunitinib malate34 | TECELRA | |
| sotalol57 | SUNLENCA | TECENTRIQ | |
| sotalol af57 | SUNOSI | TECENTRIQ HYBREZA | |
| SOTYKTU69 | <i>super b-50 complex</i> 131 | telmisartan | |
| <i>SOTYLIZE</i> 57 | <i>super quints</i> 132 | telmisartan-amlodipine | |
| SPACE CHAMBER128 | SUTAB97 | telmisartan- | |
| SPEVIGO69 | syeda | hydrochlorothiazid | 61 |
| SPIKEVAX 2024-2025 | <i>SYLVANT</i> 34 | TEMODAR | |
| | | temozolomide | |
| (12Y UP)(PF)104 | symax fastabs94 | temsirolimus | |
| spinosad | symax-sl94 | | |
| SPINRAZA (PF)43 | symax-sr94 | tencon | |
| SPIRIVA RESPIMAT126 | SYMDEKO126 | TENIVAC (PF) | 104 |
| spironolactone61 | <i>SYMFI</i> | tenofovir disoproxil | 10 |
| spironolacton-hydrochlorothiaz61 | SYMTUZA18 | fumarate | |
| SPRAVATO54 | SYNAGIS | terazosin | |
| sprintec (28) | <i>SYNJARDY</i> 92 | terbinafine hcl | |
| <i>sps (with sorbitol)</i> 130 | <i>SYNJARDY XR</i> 92 | terbutaline | |
| <i>sronyx</i> | T | terconazole | |
| ssd70 | T | teriflunomide | |
| sss 10-572 | <i>FLEX</i> 85 | teriparatide | |
| st joseph aspirin48 | <i>SLIM X2</i> 85 | testosterone | |
| STAMARIL (PF)104 | <i>TABLOID</i> 35 | testosterone cypionate | |
| STELARA69 | <i>TABRECTA</i> 35 | testosterone enanthate | |
| STIOLTO RESPIMAT126 | <i>tacrolimus</i> 35, 71 | tetrabenazine | |
| <i>STIVARGA</i> 34 | tadalafil (pulm. hypertension)126 | tetracaine hcl | |
| stop smoking aid80 | <i>TAFINLAR</i> 35 | tetracycline | 23 |
| <i>STRENSIQ</i> 89 | tafluprost (pf)121 | TEVIMBRA | 35 |
| stress formula with iron131 | <i>TAGRISSO</i> 35 | TEZSPIRE | 126 |
| stress formula with iron(sulf) 131 | <i>TAKE ACTION</i> 117 | THALOMID | 35 |
| <i>STRIBILD</i> 18 | <i>TAKHZYRO</i> 126 | theophylline | 126 |
| STRIVERDI RESPIMAT126 | TALTZ AUTOINJECTOR69 | thioridazine | |
| <i>strong iodine</i> | TALTZ AUTOINJECTOR | thiotepa | |
| <i>SUBLOCADE</i> 46 | (2 PACK)69 | thiothixene | |
| subvenite | TALTZ AUTOINJECTOR | thyroid (pork) | |

| tiadylt er | 61 | tretinoin microspheres | | TYBOST | 18 |
|-------------------------------------|-----|---------------------------------|--------|--------------------------------|--------|
| tiagabine | 40 | TRETTEN | 65 | TYENNE | 108 |
| TIBSOVO | 35 | triamcinolone acetonide | 77, 81 | TYENNE AUTOINJECTOR | 108 |
| ticagrelor | 65 | triamterene | 61 | <i>TYMLOS</i> | 106 |
| TICE BCG | 104 | triamterene-hydrochlorothiazid. | 61 | <i>TYPHIM VI</i> 10 | 4, 105 |
| TICOVAC | 104 | triazolam | 54 | TYSABRI | 43 |
| tilia fe | 117 | tricon | 132 | TYVASO | 127 |
| timolol | | triderm | | TYVASO DPI | |
| timolol maleate | | trientine | | TYVASO REFILL KIT | |
| timolol maleate (pf) | - | tri-estarylla | | TYVASO STARTER KIT | |
| tinidazole | | trifluoperazine | | U | |
| tiopronin | | trifluridine | | unithroid | 93 |
| tiotropium bromide | | trihexyphenidyl | | UNITUXIN | |
| TIVICAY | | TRIJARDY XR | | UPTRAVI | |
| TIVICAY PD | | TRIKAFTA | | uretron d-s | |
| tizanidine | | tri-legest fe | | urimar-t | |
| tobramycin | | tri-linyah | | urogesic-blue | |
| • | | tri-lo-estarylla | | uro-mp | |
| tobramycin in 0.225 % nacl | | • | | * | |
| tobramycin-dexamethasone | | tri-lo-marzia | | uro-sp | |
| tolcapone | | tri-lo-mili | | ursodiol | |
| tolmetin | | tri-lo-sprintec | | uryl | |
| tolterodine | | trimethobenzamide | | USTEKINUMAB-TTWE | 70 |
| tolvaptan | | trimethoprim | | V | |
| tolvaptan (polycys kidney dis, | | tri-mili | | valacyclovir | |
| topiramate | | trimipramine | | VALCHLOR | |
| topotecan | | TRIMO-SAN JELLY | | valganciclovir | |
| toremifene | 35 | TRINTELLIX | 54 | valproic acid | |
| torpenz | | TRIPTODUR | 36 | valproic acid (as sodium salt) | 40 |
| torsemide | 61 | tri-sprintec (28) | 117 | valsartan | 61 |
| TOUJEO MAX U-300 | | TRIUMEQ | 18 | valsartan-hydrochlorothiazide | 61 |
| SOLOSTAR | 88 | TRIUMEQ PD | 18 | valtya | 117 |
| TOUJEO SOLOSTAR U-300 | | tri-vitamin with fluoride | 132 | vancomycin | 24 |
| INSULIN | 88 | tri-vylibra | 117 | vandazole | 111 |
| tovet emollient | 77 | tri-vylibra lo | 117 | VAQTA (PF) | 105 |
| TRACLEER | 127 | TROGARZO | 18 | varenicline tartrate | 80 |
| tramadol | 48 | tropicamide | 119 | VARISOFT INFUSION SET 43 | 86 |
| tramadol-acetaminophen | 48 | trospium | 129 | VARIVAX (PF) | 105 |
| trandolapril | | TRULANCE | | VARUBI | 97 |
| trandolapril-verapamil | | TRULICITY | 92 | VASCEPA | 67 |
| tranexamic acid | | TRUMENBA | | VAXCHORA VACCINE | 105 |
| tranexamic acid in nacl,iso-o | | TRUSTEEL INFUSION SET 32 | | VAXELIS (PF) | |
| tranylcypromine | | TRUSTEX-RIA NON-LUB | | VAXNEUVANCE (PF) | |
| travoprost | | CONDOMS | 109 | VCF CONTRACEPTIVE | |
| TRAZIMERA | | tulana | | FILM | 111 |
| trazodone | | turqoz (28) | | VCF CONTRACEPTIVE | |
| TRELEGY ELLIPTA | | TWIIST REFILL KT(CSST- | 117 | GEL | 112 |
| TREMFYA | | NDL-SYR) | 86 | VECTIBIX | |
| TREMFYA PEN | - | TWIIST RFL(INFUS-CSST- | | VEKLURY | |
| TREMFYA PEN INDUCTION | | NDL-SYR) | 86 | veletri | |
| PK-CROHN | | TWIIST STARTER KIT | | velivet triphasic regimen (28) | |
| | | | | | |
| treprostinil sodium | | TWINRIX (PF) | | VELSIPITY | |
| tretinointretinoin (antineonlastic) | | TWIRLA TYBLUMF | | VEMLIDY VENCLEXTA | |
| n ennom (anuneomasne) | | 1 1 D L U /VI E | 11/ | ν Ε/Νυ LΕΛΙΑ | tn |

| VENCLEXTA STARTING | | water for irrigation, sterile | 79 | ZEPATIER | 19 |
|------------------------------|-----|-------------------------------|-------|---------------------------|-------|
| PACK | 36 | WEGOVY | | ZEPBOUND | |
| venlafaxine | | wera (28) | | ZEPOSIA | |
| venxxiva | | WIDE-SEAL DIAPHRAGM | | ZEPOSIA STARTER KIT | |
| verapamil | | wintergreen oil | | (28-DAY) | 43 |
| VERQUVO | | wixela inhub | | ZEPOSIA STARTER PACK | 13 |
| VERZENIO | | women's gentle laxative | 12/ | (7-DAY) | 43 |
| vestura (28) | | (bisac) | 98 | ZEVALIN (Y-90) | |
| V-GO 20 | | wymzya fe | | zidovudine | |
| V-GO 30 | | X | 110 | ZIEXTENZO | |
| V-GO 40 | | <i>XALKORI</i> 3 | 86 37 | ziprasidone hcl | |
| VIBERZI | | xarah fe | - | ziprasidone mesylate | |
| vienva | | XARELTO | | ZIRABEV | |
| vigabatrin | | XARELTO DVT-PE TREAT | 00 | ZOLADEX | |
| _ | | 30D START | 66 | zoledronic acid | |
| vigadrone VIJOICE | | XDEMVY | | zoledronic acid-mannitol- | 90 |
| vilazodone | | XELJANZ | | | 90.00 |
| VIMIZIM | | | | water | |
| | | XELJANZ XR | | ZOLINZA | |
| VIMKUNYA | | xelria fe | | zolmitriptan | |
| vinblastine | | XEMBIFY | | zolpidem | |
| vincasar pfs | | XENPOZYME | | zonisamide | |
| vincristine | | XERMELO | | zovia 1-35 (28) | |
| vinorelbine | | XGEVA | | ZTALMY | |
| <i>VIOKACE</i> | | XIFAXAN | | ZTLIDO | |
| viorele (28) | | XIGDUO XR | | ZUBSOLV | |
| VIRACEPT | | XIIDRA | | zumandimine (28) | |
| VIREAD | | XOLAIR | | ZURZUVAE | |
| VISCO-3 | | XOSPATA | | <i>ZYDELIG</i> | |
| VISTOGARD | | <i>XTANDI</i> | | ZYKADIA | |
| vitamin b complex-folic acid | | xulane | | ZYMFENTRA | |
| vitamins a,c,d and fluoride | 132 | XURIDEN | 80 | ZYNTEGLO | 99 |
| VITRAKVI | 36 | XYNTHA | | <i>ZYNYZ</i> | 37 |
| VIVITROL | 48 | XYNTHA SOLOFUSE | | | |
| <i>VIVOTIF</i> | | XYWAV | 55 | | |
| VIZIMPRO | | Y | | | |
| volnea (28) | 118 | <i>YASMIN (28)</i> | 118 | | |
| VONJO | 36 | YAZ (28) | 118 | | |
| VONVENDI | 66 | YERVOY | 37 | | |
| VOQUEZNA DUAL PAK | 99 | YESCARTA | 37 | | |
| VOQUEZNA TRIPLE PAK | 99 | <i>YESINTEK</i> | 70 | | |
| voriconazole | 14 | <i>YF-VAX (PF)</i> | 105 | | |
| <i>VORTEX HOLDING</i> | | YONDELIS | 37 | | |
| CHAMBER | 128 | yuvafem | 111 | | |
| VRAYLAR | 55 | ${f Z}$ | | | |
| VUMERITY | 57 | zafemy | 112 | | |
| vyfemla (28) | 118 | zafirlukast | 127 | | |
| vylibra | 118 | zaleplon | 55 | | |
| VYLOY | 36 | zarah | 118 | | |
| VYNDAMAX | 68 | ZEJULA | 37 | | |
| VYNDAQEL | 68 | ZELBORAF | 37 | | |
| VYXEOS | | zenatane | 73 | | |
| \mathbf{W} | | ZENPEP | 98 | | |
| warfarin | 66 | zenzedi | 55 | | |
| - | | | | | |

Express Scripts reserves the right to make changes to the Drug List without notice. Your plan may cover additional medications. Express Scripts does not take responsibility for any medication decisions made by the doctor or pharmacist.

- 1. Prices shown are not guaranteed and coverage is subject to your plan terms and conditions.
- 2. U.S. Food and Drug Administration (FDA) website, "Generic Drug Facts." Last updated 06/01/18.
- 3. Plan coverage details may vary if you do not reside in CA. Please contact us at 855-672-2789